{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 29,
   "id": "67b0f81b-6625-4ce8-a308-8000af9e1ce6",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ TF-IDF index built and saved.\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "from sklearn.feature_extraction.text import TfidfVectorizer\n",
    "import joblib\n",
    "\n",
    "# Custom tokenizer instead of lambda\n",
    "def whitespace_tokenizer(text):\n",
    "    return text.split()\n",
    "\n",
    "# Load preprocessed clinical trials\n",
    "df = pd.read_csv(\"clinical_trials_cleaned.csv\")\n",
    "\n",
    "# Join tokens back into strings\n",
    "df['joined'] = df['tokens'].apply(eval).apply(lambda tokens: ' '.join(tokens))\n",
    "\n",
    "# Initialize TF-IDF vectorizer\n",
    "vectorizer = TfidfVectorizer(\n",
    "    lowercase=False,\n",
    "    tokenizer=whitespace_tokenizer,\n",
    "    preprocessor=None,\n",
    "    token_pattern=None,\n",
    "    max_df=0.85,\n",
    "    min_df=5,\n",
    ")\n",
    "\n",
    "# Fit and transform\n",
    "tfidf_matrix = vectorizer.fit_transform(df['joined'])\n",
    "\n",
    "# Save vectorizer, matrix, and metadata\n",
    "joblib.dump(vectorizer, \"clinical_trials_vectorizer.pkl\")\n",
    "joblib.dump(tfidf_matrix, \"clinical_trials_tfidf_matrix.pkl\")\n",
    "df[['doc_id', 'original_text']].to_csv(\"clinical_trials_metadata.csv\", index=False)\n",
    "\n",
    "print(\"‚úÖ TF-IDF index built and saved.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "203a5ba7-6b19-4a37-a137-00f9d33f531a",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ BM25 index for Clinical Trials built and saved.\n"
     ]
    }
   ],
   "source": [
    "# ‚úÖ build_bm25_clinical_trials.py\n",
    "import pandas as pd\n",
    "import joblib\n",
    "from rank_bm25 import BM25Okapi\n",
    "\n",
    "# Load cleaned clinical trials data\n",
    "df = pd.read_csv(\"clinical_trials_cleaned.csv\")\n",
    "\n",
    "# Prepare corpus: list of token lists\n",
    "corpus = df['tokens'].apply(eval).tolist()\n",
    "\n",
    "# Build BM25 index\n",
    "bm25 = BM25Okapi(corpus)\n",
    "\n",
    "# Save index and metadata\n",
    "joblib.dump(bm25, \"clinical_trials_bm25_model.pkl\")\n",
    "joblib.dump(corpus, \"clinical_trials_bm25_corpus.pkl\")\n",
    "df[['doc_id', 'original_text']].to_csv(\"clinical_trials_metadata.csv\", index=False)\n",
    "\n",
    "print(\"‚úÖ BM25 index for Clinical Trials built and saved.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "id": "0bbaaf5d-767c-4783-b289-50611275a70d",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "==============================\n",
      "üß™ TREATMENT SAFETY\n",
      "==============================\n",
      "\n",
      "üîç Query: What are the side effects of the vaccine?\n",
      "\n",
      "üîπ Doc ID: NCT00359671  (Score: 18.1472)\n",
      "Treatment With MK6592 and an Anti-cancer Drug in Patients With Advanced Solid Tumors (6592-001)\n",
      "A study to evaluate safety and tolerability of MK6592 in combination with an anti-cancer       drug\n",
      "in adult patients with advanced solid tumors.                          Inclusion Criteria:\n",
      "-  Patients with advanced solid tumors (metastatic or local) unresponsive to standard\n",
      "therapy, progressed on standard therapy, or no standard therapy exists. No limit to              the\n",
      "number of prior treatment regimens            -  Patients may be fully active without physical\n",
      "restrictions, ambulatory with              restrictions on strenuous physical activity, or\n",
      "ambulatory and capable of self-care              but not work activities (i.e., Eastern Cooperative\n",
      "Oncology Group performance status              of greater than or equal to 2)            -\n",
      "Demonstrates adequate organ function (liver, kidneys, hematologic)          Exclusion Criteria:\n",
      "-  Chemotherapy or radiation therapy within 2 weeks of dosing; or unresolved side\n",
      "effects(s) from prior treatment regimen            -  Participation in an investigational study\n",
      "within 14 days of dosing            -  Primary central nervous system tumor            -  Active\n",
      "brain or spinal cord metastases. Patients who completed a course of therapy              for CNS\n",
      "metastases may be eligible if considered clinically stable for 3 months prior              to study\n",
      "entry            -  Symptoms from fluid in the abdomen or around the lungs            -  Requires\n",
      "certain drugs or other products known to be metabolized by the liver enzyme              CYP3A4\n",
      "\n",
      "üîπ Doc ID: NCT02201563  (Score: 16.5381)\n",
      "Minocycline Therapy for Management of Adverse Radiation Effects             Stereotactic\n",
      "radiosurgery (SRS) is a well-established treatment for patients with metastatic       brain tumors.\n",
      "Although SRS has a very high tumor growth control these interventions are       associated with\n",
      "adverse radiation effects (ARE) in approximately 15 % of patients. The       traditional approach,\n",
      "and still a mainstay, is the administration of a course of high dose       anti-inflammatory\n",
      "corticosteroids. Currently there are no other effective oral       neuroprotective agents in\n",
      "clinical practice which can improve outcomes of patients with ARE       after radiosurgery for brain\n",
      "metastases.        Minocycline, an antibiotic with a favorable adverse effect profile and\n",
      "pharmacokinetics, has       been shown to have neuroprotective properties in experimental models of\n",
      "a variety of       neurological diseases, as well as in human clinical trials. The investigators\n",
      "propose a       single arm clinical trial, to evaluate the safety and feasibility of minocycline in\n",
      "improving ARE. This study will recruit 15 patients who will be treated with minocycline       (100mg\n",
      "BID) for 3 months. This clinical trial has the potential to prove that minocycline       therapy is\n",
      "safe in this patient population. In addition, positive results will provide       preliminary\n",
      "evidence for its use in an array of radiosurgical indications.                     Although\n",
      "stereotactic radiosurgery (SRS) has proven to be highly effective in the management       of brain\n",
      "metastases, it is not without risk. Despite selective targeting of lesions and the       sharp dose\n",
      "fall-off associated with radiosurgical treatments, adverse radiation effects       (AREs) can occur\n",
      "in 10-15% of patients. Adverse radiation effects (AREs) can be defined as       unexpected or\n",
      "undesirable post-radiosurgery imaging change regardless of whether it is       clinically\n",
      "symptomatic. Patients showing ARE have limited therapeutic options with       corticosteroids being\n",
      "the main treatment modality. This single arm clinical trial, will       evaluate the safety and\n",
      "feasibility of minocycline in improving AREs. Brain metastases       patients with documented AREs\n",
      "will be treated with minocycline (100 mg twice a day) for 3       months in addition to the standard\n",
      "treatment with oral corticosteroids. The investigators       anticipate recruiting a total of 15\n",
      "patients over 12 months.        Primary aim:        The primary aim is of this study to evaluate\n",
      "safety and feasibility of minocycline therapy       in patients with ARE after radiosurgery. The\n",
      "investigators' hypothesis is that minocycline       will be safe in this patient population. Safety\n",
      "will be assessed by monitoring blood levels       of drug, liver enzymes, renal function tests, and\n",
      "monitoring for major and minor       side-effects.        Research Strategy The investigators plan\n",
      "to conduct a single arm observational study to       evaluate safety and feasibility of minocycline\n",
      "in patients diagnosed with radiosurgery       associated adverse radiation effects. In addition to\n",
      "clinical and biochemical monitoring for       safety, the investigators will also employ\n",
      "neuroimaging techniques to investigate whether       minocycline reduces enhancement at lesion in\n",
      "post contrast T1 weighted MRI and reduces hyper       intensity surrounding the tumor as detected by\n",
      "T2 MRI radiosurgery.        Primary Outcomes: 1) The primary clinical outcome will be safety of\n",
      "minocycline use in this       patient population.        Secondary outcomes: 1) The investigators\n",
      "will also review brain images in detail to find any       evidence of benefit from Minocycline\n",
      "therapy such as reduction or resolution of volume of T2       hyper intensity and contrast\n",
      "enhancement at the lesion (radiation necrosis) at 4-6 weeks and       3 month follow-up. 2) Overall\n",
      "neurological status 3) Change in neurocognitive status, 4)       Reduction in the number of patients\n",
      "needing resection 5) Changes in plasma biomarkers, and       plasma drug levels.        Target\n",
      "Population: Recruitment will take place at Center of Image-guided Neurosurgery of       UPMC. All\n",
      "patients with AREs after brain metastases radiosurgery will be potentially       eligible for the\n",
      "study. The investigators anticipate enrolling 15 patients. Patients will be       diagnosed based on\n",
      "MRI findings. The investigators will evaluate T1 pre and post contrast,       T2, FLAIR and\n",
      "Perfusion MR in order to diagnose ARE. MR spectroscopy or CT Pet will be       obtained when\n",
      "clinically indicated. The investigators will use T1/T2 matching and proportion       of edema versus\n",
      "lesion volume as a guide for diagnosing ARE.                         Inclusion Criteria:\n",
      "-  Age range: 18 - 90 years            -  Males and females.            -  Patients must have\n",
      "undergone cranial radiosurgery.            -  MRI evidence supporting the diagnosis of ARE and/or\n",
      "surgical biopsy evidence of              necrosis without tumor at ‚â§2 months before study entry.\n",
      "-  Karnofsky performance status of ‚â•60,            -  With or without evidence of progressive\n",
      "neurologic signs or symptoms appropriate to              the location of the ARE, and no previous\n",
      "bevacizumab therapy.            -  With or without previous chemotherapy for their tumor.\n",
      "-  Routine laboratory study results with bilirubin ‚â§1.5 times the upper limit of normal,\n",
      "aspartate aminotransferase and/or alanine aminotransferase <2.5 times the upper limit\n",
      "of normal, creatinine <2.0 times the upper limit of normal.            -  Patients with a history of\n",
      "seizures will be required to be receiving anticonvulsant              therapy and to be seizure-free\n",
      "for ‚â•1 week before study.          Exclusion Criteria:            -  Significant mass effect\n",
      "requiring resection (as assessed by a clinical neurosurgeon)            -  Known hypersensitivity to\n",
      "tetracyclines            -  Women of childbearing age must be non-lactating and have a negative\n",
      "urine pregnancy              test (adequate birth control includes use of intra uterine device, or a\n",
      "barrier              method, e.g. condom, diaphragm). The results of animal studies indicate that\n",
      "tetracyclines cross the placenta and are found in fetal tissues, having potentially\n",
      "toxic effects on the developing fetus (often related to retardation of skeletal\n",
      "development). Evidence of embryo toxicity has been noted in animals treated early in\n",
      "pregnancy. Therefore pregnant women will not be allowed to participate in this study            -\n",
      "Female subjects on oral contraceptives            -  Contraindication to undergo MRI            -\n",
      "Significant cardiopulmonary, renal or neurological co-morbidities            -  Current diagnosis of\n",
      "major depression, substance abuse, or other psychiatric              disorders;\n",
      "\n",
      "üîπ Doc ID: NCT00528749  (Score: 12.2726)\n",
      "Non-Invasive Measurement of Respiratory Effort             This study is intended to compare\n",
      "intrathoracic pressure and respiratory effort data       obtained by forehead venous pressure and\n",
      "respiratory movement (FVP/RM) with data obtained by       the current gold standard, esophageal\n",
      "manometry. If this feasibility study validates the       ability of FVP/RM data to quantitatively\n",
      "measure respiratory effort non-invasively, further       studies will be performed to validate the\n",
      "utility of the ARES device in diagnosis of the       UARS.                     Sleep apnea is the\n",
      "most common disorder observed in the practice of sleep medicine and is       responsible for more\n",
      "morbidity and mortality than any other sleep disorder.(1) Although       characterized over 40 years\n",
      "ago, sleep apnea has only recently gained recognition as one of       the world's most prevalent\n",
      "undiagnosed disorders. Due to associated morbidity and mortality,       sleep apnea has been\n",
      "identified as a major public health concern. Currently, sleep apnea is       diagnosed by performing\n",
      "a sleep study. This requires a patient staying overnight in a sleep       laboratory while being\n",
      "monitored, which is often inconvenient for patients and is relatively       expensive to perform.\n",
      "The development of a device that allows for simple home monitoring of       patients when assessing\n",
      "for sleep apnea would be a significant development in the field of       sleep medicine.        The\n",
      "differentiation of obstructive sleep apnea (OSA) from central sleep apnea is an       important\n",
      "aspect of diagnosing and treating OSA. In central apneas/hyponeas, the lack of       airflow is due\n",
      "to lack of respiratory effort. In OSA, effort to breathe continues, but       airflow is prevented\n",
      "by an occluded airway. More recently, subtle obstructive events without       a defined\n",
      "desaturation, characterized by increasing respiratory efforts against a partially       closed\n",
      "airway and terminated by an arousal, have been described as Upper Airway Resistance       Syndrome\n",
      "(UARS). UARS can lead to daytime somnolence due to these frequent arousals.       Although nasal\n",
      "pressure signal has been used as a surrogate, by definition, distinguishing       UARS from OSA\n",
      "requires the use of esophageal manometry. This syndrome is characterized by       increased upper\n",
      "airway resistance (IUAR) that was defined by increasingly negative       inspiratory esophageal\n",
      "pressure. (2) To better understand the clinical significance of       esophageal manometry, let us\n",
      "briefly review some basic physiology. Taking a breath requires       that the inspiratory muscles\n",
      "generate sufficient force to overcome the elastic recoil of the       chest wall and lungs,\n",
      "frictional lung and chest wall tissue resistance, and the frictional       resistance of airflow\n",
      "through the airways. At the end of inspiration, the potential energy       stored in the tissues of\n",
      "the lungs and chest wall is available to allow rapid passive       exhalation when the inspiratory\n",
      "muscles cease contraction and the distending force       disappears. All intrathoracic structures\n",
      "are subjected to the pressures generated by       breathing. The esophagus is a thin walled muscular\n",
      "tube that, from the view of pulmonary       physiologists, is ideally placed in the thoracic cavity\n",
      "between the lung surface and the       chest wall. Measurement of differential pressure changes in\n",
      "the lumen of the esophagus       accurately reflect changes in intrathoracic pressure. These changes\n",
      "in intrathoracic       pressure are in turn reflective of inspiratory effort and have become the\n",
      "gold standard for       detecting and quantifying inspiratory effort.        Unfortunately,\n",
      "measurement of esophageal manometry requires the placement of an esophageal       catheter via the\n",
      "nose or mouth. This procedure in invasive, time consuming, and requires       specialized training.\n",
      "For this reason, esophageal manometry is not routinely performed       during sleep studies,\n",
      "although it is performed in patients at the WRAMC sleep lab who are       suspected of having UARS.\n",
      "Instead of esophageal manometry, the most frequently used method       of monitoring respiratory\n",
      "effort is to record thoracic cage expansion. In this procedure,       bands are placed around the\n",
      "rib cage and abdomen. The change in circumference of these two       compartments with breathing is\n",
      "measured. This procedure yields a qualitative change in       inspiratory volume and paradoxical\n",
      "movement of the rib cage or abdomen can indicate effort       against a closed or partially\n",
      "collapsed airway. This device is impractical for       self-application by patients. Given the\n",
      "limitations of the latter procedure and the invasive       nature of esophageal manometry, a non-\n",
      "invasive quantitative method for measuring respiratory       effort would be a significant\n",
      "advancement in sleep medicine.        Over the past five years, investigators from Advanced Brain\n",
      "Monitoring, Inc. developed and       validated the Apnea Risk Evaluation System (ARES). This device\n",
      "was initially developed to       provide a highly accurate method of in-home diagnosis of OSA that\n",
      "maximized patient comfort       and ease of use. The ARES Unicorder was designed as a single site\n",
      "(forehead) system to       acquire oxygen saturation, pulse rate, snoring, airflow (nasal pressure),\n",
      "and head       position/movement. Recently, investigators determined that a number of signals that\n",
      "were       being acquired with the Unicorder could be used to measure respiration.(1) Pulsations\n",
      "observed in the red and infrared optical signals used to compute oxygen saturation and the\n",
      "forehead sensor pressure signal appear to reflect central venous pressure changes. These       data\n",
      "has been termed the Forehead Venous Pressure/Respiratory Movement (FVP/RM) measure. If       FVP/RM\n",
      "data proves to correlate with esophageal manometry data, the long sought after       non-invasive\n",
      "quantitative measurement of intrathoracic pressure and respiratory effort would       be available.\n",
      "This would represent a significant advancement in the diagnostic evaluation of       sleep\n",
      "disordered breathing.        To better illustrate how forehead venous pressure could reflect\n",
      "intrathoracic pressure, let       us again review some physiology. During inspiration, the central\n",
      "venous pressure (CVP)       decreases, aiding the return of blood to the heart. Changes in pleural\n",
      "and intrathoracic       pressure due to respiration are reflected by and can be timed to changes in\n",
      "central venous       pressure. When recumbent, the internal and external jugular veins are open and\n",
      "provide the       primary cerebral and superficial forehead venous return. The communication between\n",
      "the       superior vena cava and the veins of the headallows intrathoracic pressure changes to be\n",
      "reflected by the superficial veins of the head. In a sense, the forehead veins offer a       direct\n",
      "fluid filled catheter into the thoracic cavity, and when the correct compressive       force is\n",
      "applied against the skull, respiratory effort linked venous pressure changes can be       accurately\n",
      "measured.        In summary, current evaluation of UARS requires esophageal manometry testing, an\n",
      "invasive       and time consuming procedure for accurate diagnosis. Currently, no non-invasive\n",
      "quanitative       means of measuring intrathoracic pressure changes linked to respiratory effort\n",
      "exists. This       study is a pilot trial of a new non-invasive method of determining intrathoracic\n",
      "pressures.       If intrathoracic pressure data from this device is found to correlate with\n",
      "esophgeal       manometry data, this could have significant implications on the way in which UARS is\n",
      "diagnosed. This technology also has the potential to develop a non-invasive means of       measuring\n",
      "CVP.                         Inclusion Criteria:            -  Age 18 or older,            -\n",
      "Referred for sleep study at WRAMC for suspected sleep disordered breathing.          Exclusion\n",
      "Criteria:            -  Pregnancy            -  Age <18            -  Nasal defects precluding\n",
      "insertion of esophageal manometer            -  Patients currently on anticoagulation\n",
      "\n",
      "üîπ Doc ID: NCT01084668  (Score: 11.5533)\n",
      "Quality of Life in Adalimumab Treated Psoriasis Patients Failing Other Biologic Disease Modifying\n",
      "Anti-rheumatic Drugs             The aim of this post-marketing observational study (PMOS) was to\n",
      "obtain further data on       long-term safety, efficacy, and quality of life outcomes for adalimumab\n",
      "in routine clinical       use in participants with moderate to severe chronic plaque psoriasis after\n",
      "unsustainable       clinical response to other biologic disease modifying anti-rheumatic drugs\n",
      "(BDMARDs). There       are few data so far showing the effects of switching from other BDMARDs to\n",
      "adalimumab in       patients with moderate to severe chronic plaque psoriasis. This study was\n",
      "designed to       evaluate the long-term effectiveness of adalimumab in participants with moderate\n",
      "to severe       chronic plaque psoriasis using the Psoriasis Area and Severity Index (PASI) in\n",
      "participants       previously treated with efalizumab, infliximab, or etanercept and who either\n",
      "never achieved       satisfactory response, achieved satisfactory response initially but lost it\n",
      "over time, or       discontinued treatment due to intolerance/side effect(s) or other reasons, for\n",
      "example after       regular stop of etanercept.                     This was a non-interventional\n",
      "PMOS conducted in a prospective, single-country, multicenter       format to assess the quality of\n",
      "life of psoriasis patients taking adalimumab as prescribed       by their physician in accordance\n",
      "with the terms of the local marketing authorization with       regard to dose, population, and\n",
      "indication. The prescription of adalimumab was clearly       separated from the decision to include\n",
      "the participant in this study. No procedures other       than standard of care were to have been\n",
      "performed. Visits were non-interventional and timing       of participant appointments was left to\n",
      "each physician. After therapy initiation, visits       occurred over 12 months usually close to\n",
      "Weeks 4, 12, 24, 36, and 52 for a total of 6 visits       (Visits 1 through 6 including Screening).\n",
      "Because participant visits were left to the       physician, participant failure to meet the\n",
      "suggested visit weeks did not constitute a breach       of the protocol.\n",
      "Inclusion Criteria:            -  Patients for whom adalimumab therapy is indicated and has been\n",
      "prescribed according              to the product label            -  Patients aged 18 years and\n",
      "older            -  Unsatisfactory response to prior BDMARDS (efalizumab, infliximab, etanercept) in\n",
      "patients with moderate to severe chronic plaque psoriasis or achievement of\n",
      "satisfactory response initially, but loss over time or discontinuation of treatment              due\n",
      "to intolerance/side effects(s) or other reasons e.g. restart after regular stop              of\n",
      "etanercept            -  Patients must fulfill Austrian Treatment Recommendations for use of BDMARD\n",
      "in              psoriasis (chest X-ray and purified protein derivative [PPD] skin test negative for\n",
      "tuberculosis)            -  Patient is willing to consent to data being collected and provided to\n",
      "Abbott            -  Patient must be able and willing to self-administer Pen injections or have a\n",
      "qualified person available to administer Pen injections          Exclusion Criteria:            -\n",
      "Patients who meet contraindications as outlined in the latest version of the              Humira-Pen\n",
      "Summary of Product Characteristics (SPC)            -  Patients who do not meet the criteria for the\n",
      "use of BDMARDs of the Austrian              Treatment Recommendations            -  Patients\n",
      "participating in another study or clinical trial\n",
      "\n",
      "üîπ Doc ID: NCT02556827  (Score: 11.4334)\n",
      "Demodex Density, Immune Response and Oxidative Stress in Rosacea Patients             Aim of study\n",
      "is to determine reactive oxygen products and antioxidant capacity with rosacea       patients; to\n",
      "measure metalloproteinase level and inflammatory markers of immune response and       investigate\n",
      "their corelation with demodex infestation and also investigate the role of       photoaging and\n",
      "sebum secretion in rosacea.                     Rosacea is a common and chronic inflammatory disease\n",
      "characterized by facial erythema,       papule, pustule and telangiectasia. Ultraviolet, Demodex\n",
      "mite, oxidative stress and       antioxidant system disorders are emphasized in increased\n",
      "inflammation seen in rosacea.        The aim of our study was to evaluate the status of oxidative\n",
      "stress, matrix       metalloproteinase (MMP) and inflammatory markers in systemic circulation, their\n",
      "relationship       with demodex density and investigate the role of photoaging and sebum secretion\n",
      "in rosacea.        Forty patients with rosacea and age, gender and skin phenotype matched 40 healthy\n",
      "volunteers       were enrolled in the study. Reflectance confocal microscopy (RCM) was used to\n",
      "calculate       facial demodex density. The number of demodex, follicle, the number of mite per\n",
      "follicle,       the number of infested follicle and the number of mite per infested follicle were\n",
      "calculated       with RCM.        Photoaging severity and facial sebum levels were also assessed.\n",
      "Total oxidant capacity       (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI),\n",
      "paraoxonase-1       (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-\n",
      "alpha (TNF-Œ±),       interleukin-1beta (IL-1Œ≤), matrix metalloproteinase-1 (MMP-1) and matrix\n",
      "metalloproteinase-9       (MMP-9) levels in venous blood were measured.\n",
      "Inclusion Criteria:            -  Between the ages of 18-70            -  No systemic illness\n",
      "-  No other inflammatory dermatoses except for rosacea            -  No smoking            -  Not\n",
      "using any topical, systemic treatment and sunblock at least a month for rosacea              or\n",
      "other condition          Exclusion Criteria:            -  Systemic illness            -  Other\n",
      "inflammatory dermatoses except for rosacea            -  Smoking            -  Using any topical,\n",
      "systemic treatment and sunblock for rosacea or other condition            -  Type 4 rosacea patient\n",
      "(only ocular involvement)\n",
      "\n",
      "\n",
      "üîç Query: Is the treatment well tolerated by patients?\n",
      "\n",
      "üîπ Doc ID: NCT00221637  (Score: 14.1100)\n",
      "Efficacy of Valproate in Peripheral Neuropathic Pain             The purpose of this study is to\n",
      "determine whether valproate is effective and well tolerated       in the treatment of neuropathic\n",
      "peripheral pain. The drug is administered by intravenous       route followed by oral route during 4\n",
      "weeks.                     Background. Neuropathic peripheral pain is often refractory to usual\n",
      "analgesics. Some       anticonvulsant drugs may be effective, but often partially only, and not\n",
      "always well       tolerated. Valproate is a well-known anticonvulsant drug, with moderate possible\n",
      "adverse       events and for which an intravenous form is available.        Aim. The principal aim\n",
      "is to assess the efficacy and safety of sodium Valproate in       peripheral neuropathic pain.\n",
      "Secondary aims are to asses the effect of IV and oral treatment       on neurophysiologic measures.\n",
      "Design. Randomized, double-blind vs. placebo, parallel groups, monocentric clinical trial.\n",
      "Treatments. Experimental arm: Intravenous eight-hour sodium Valproate infusion, followed by       a\n",
      "four-week oral route sodium Valproate treatment. Control arm: Intravenous eight-hour       placebo\n",
      "infusion, followed by a four-week oral route placebo treatment. Rescue medications       are allowed\n",
      "in both groups.        Eligibility criteria. Peripheral neuropathic pain with pain intensity of at\n",
      "least 40 mm on a       visual analog scale.        Outcomes. Primary outcome is the intensity of\n",
      "pain on a visual analog scale after 4 weeks of       treatment. Secondary outcomes: intensity of\n",
      "pain after IV treatment; neurophysiologic       measures (thermal thresholds, RIII reflex);\n",
      "association of response to IV treatment with       oral treatment efficacy.\n",
      "Inclusion Criteria:            -  peripheral neuropathic pain            -  signed written informed\n",
      "consent          Exclusion Criteria:            -  central neuropathic pain            -  current or\n",
      "past hepatic disease\n",
      "\n",
      "üîπ Doc ID: NCT00428285  (Score: 13.9185)\n",
      "Tolerability, Safety, & Efficacy of Argon Plasma Coagulation to Treat Anal Intraepithelial Neoplasia\n",
      "in HIV-Positive Men             The purpose of this study is to assess if argon plasma coagulation\n",
      "(APC) is a safe and well       tolerated treatment method for anal intraepithelial neoplasia (AIN)\n",
      "grade 2/3 in       HIV-positive men having sex with men (MSM).                     HIV infected men\n",
      "having sex with men (MSM) are at increased risk of developing anal cancer       compared to the\n",
      "general population and the incidence continues to increase despite better       control of HIV\n",
      "infection with HAART (Highly Active Anti-Retroviral Therapy). The causative       agent is known to\n",
      "be Human Papilloma Virus infection which can lead to dysplastic changes in       the anus,\n",
      "detectable by High Resolution Anoscopy with biopsies. The analysis of the abnormal       tissue can\n",
      "then be graded as Anal Intraepithelial Neoplasia 1 to 3, with AIN 2 or 3       considered as high\n",
      "grade dysplasia. These lesions are cancer precursors, but the proportion       of lesions\n",
      "progressing to invasive anal cancer and the time to event are unknown. There is       currently no\n",
      "recognized treatment to offer as standard of care although it is of general       belief that\n",
      "treating these lesions, as it is done for women with CIN 2 and 3 (Cervical       Intraepithelial\n",
      "Neoplasia) could help decrease the number of progressions to invasive anal       cancer in MSM\n",
      "infected with HIV.        By experience at our center and results of this technique for other\n",
      "gastrointestinal       pathologies, we believe Argon Plasma Coagulation (APC) could be a safe, well\n",
      "tolerated and       efficient treatment of high-grade dysplasia (AIN 2/3) in HIV infected MSM.\n",
      "This study will assess the APC treatment in 20 patients, all HIV infected MSM, with\n",
      "established AIN 2/3 (as confirmed with their last two anal biopsies, at least 4 months       apart).\n",
      "Patients will then be followed with regular High Resolution Anoscopies for two       years. The\n",
      "primary objective is to assess if APC is a safe and well tolerated treatment       method for AIN\n",
      "2/3 in HIV-positive MSM. As secondary objectives, the efficacy of APC       treatment on AIN 2/3\n",
      "lesions in HIV-positive MSM, the number of treatments with APC       necessary to obtain regression\n",
      "or resolution of AIN 2/3 over two years and the efficacy of       APC treatment to decrease anal HPV\n",
      "in this population will also be addressed.                         Inclusion Criteria:            -\n",
      "Age 18-65 years            -  The last two High Resolution Anoscopies (HRA) of the patient,\n",
      "occurring at least 4              months apart, revealed histologic diagnoses of AIN 2 or 3\n",
      "-  HIV infected for at least 6 months            -  Patient must be a man having sex with other men\n",
      "(currently or anteriorly).            -  Able to provide a signed and dated Research Ethics Board\n",
      "(REB)-approved informed              consent form (ICF) for the study          Exclusion Criteria:\n",
      "-  History of invasive anal cancer            -  International normalized ratio (INR) > 1.5\n",
      "-  Platelet count < 50,000            -  Previously (or currently) received chemotherapy or\n",
      "radiotherapy for AIN or anal              cancer            -  Currently receiving interferon or\n",
      "cidofovir treatment            -  Diagnosed with circumferential (diffuse) high-grade AIN, or\n",
      "involving > 75% of the              anal canal.\n",
      "\n",
      "üîπ Doc ID: NCT00383799  (Score: 13.9103)\n",
      "Iv Amiodarone Versus Iv Procainamide to Treat Haemodynamically Well Tolerated Ventricular\n",
      "Tachycardia             The purpose of this study is to determine whether intravenous amiodarone has\n",
      "less cardiac       significant adverse events compared to intravenous procainamide in the acute\n",
      "treatment of       haemodynamically well tolerated wide QRS tachycardia, the majority of them of\n",
      "probably       ventricular origen.                     Multicenter, prospective and randomized study\n",
      "in phase IV. A total of 302 patients will be       included in the study within 40-50 institutions\n",
      "in Spain. Patients with regular and       monomorphic tachycardia ‚â• 120 bpm, QRS ‚â• 120 ms and\n",
      "haemodynamically well tolerated will be       randomized to receive iv amiodarone (single dosage: 5\n",
      "mg/kg in 20 minutes) vs iv       procainamide (single dosage: 10 mg/kg in 20 minutes). The study\n",
      "period will be 40 minutes       from infusion initiation. Study variables include the presence of\n",
      "clinically cardiac       significant adverse events: hypotension, syncope, heart failure,\n",
      "symptomatic sinus       bradycardia, AV block, proarrhythmia and tachycardia acceleration (<20\n",
      "lpm)and death. Total       observation period will be 24 hours after the end of the infusion.\n",
      "Inclusion Criteria:            -  Patients with stable tachycardia ‚â•120 lpm, QRS ‚â•120 ms and\n",
      "haemodynamically well              tolerated defined as: 1)Systolic blood pressure ‚â•90 mmHg, 2)\n",
      "absence of dyspnea at              rest, 3)absence of peripheric hypoperfusion signs and 4)no severe\n",
      "angina.            -  Age > 18 years            -  Written inform consent obtained\n",
      "Exclusion Criteria:            -  Treatment with iv amiodarone or iv procainamide during the\n",
      "previous 24 hours            -  QRS tachycardia <120 ms            -  Patients with QRS ‚â•120 ms\n",
      "tachycardia with haemodynamic compromise that requires              urgent cardioversion for\n",
      "termination            -  Irregular tachycardia            -  Tachycardia that is considered as\n",
      "supraventricular due to physician criteria              (adenosine and/or vagal manoeuvres response)\n",
      "-  Patient that do not want to cooperate\n",
      "\n",
      "üîπ Doc ID: NCT02787551  (Score: 13.9054)\n",
      "Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1\n",
      "Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period             Primary\n",
      "Objective:        To demonstrate the superiority of the insulin glargine/lixisenatide fixed ratio\n",
      "combination       (FRC) versus GLP-1 receptor agonist (GLP-1 RA) in hemoglobin A1c (HbA1c) change.\n",
      "Secondary Objectives:        To compare the overall efficacy and safety of the insulin\n",
      "glargine/lixisenatide fixed ratio       combination (FRC) to GLP-1 receptor agonist (GLP-1 RA) on\n",
      "top of metformin (with or without       pioglitazone) in patients with type 2 diabetes.        To\n",
      "evaluate safety, efficacy and other endpoints of FRC up to the end of the extension       period.\n",
      "The maximum duration for GLP1-RA patients will be approximately 29 weeks: an up to 2 week\n",
      "screening period, a 26 week treatment period (either randomized or uncontrolled), and a 3 or       9\n",
      "day post-treatment safety followup period.        Maximum duration for FRC patients will be\n",
      "approximately 55 weeks: an up to 2- week screening       period, a 26-week randomized treatment\n",
      "period, a 26-week extension period and a 3-day       post-treatment safety follow-up period. All\n",
      "primary and secondary efficacy, safety and other       endpoints will be also assessed at the end of\n",
      "the extension period.                         Inclusion criteria :            -  Patients with type\n",
      "2 diabetes mellitus diagnosed at least 1 year prior to screening              visit.            -\n",
      "Patients who have been treated with one of the following glucagon-like peptide 1\n",
      "(GLP-1) receptor agonists for at least 4 months prior to screening visit (V1), and              with\n",
      "stable dose for at least 3 months prior to screening visit (V1):            -  Liraglutide\n",
      "(Victoza¬Æ) 1.8 mg QD or 1.2 mg QD, if the 1.8 mg QD dose is not well              tolerated\n",
      "according to the Investigator's judgment or            -  Exenatide (Byetta¬Æ) 10 ¬µg BID or of 5 ¬µg\n",
      "BID, if 10 ¬µg BID dose is not well tolerated              according to the Investigator's judgment\n",
      "in combination with metformin (daily dose              ‚â•1500 mg/day or maximum tolerated dose\n",
      "[MTD]), with or without pioglitazone, both at              stable dose for at least 3 months prior\n",
      "to screening.          or          Patients who have been treated with stable dose of one of the\n",
      "following GLP-1 receptor         agonists for at least 6 months prior to screening visit (V1):\n",
      "-  Exenatide extended-release (Bydureon¬Æ) 2 mg once weekly (QW), if well tolerated\n",
      "according to Investigator's judgment,            -  Albiglutide (Tanzeum¬Æ) 50 mg QW or 30 mg QW, if\n",
      "50 mg QW is not well tolerated              according to Investigator's judgment,            -\n",
      "Dulaglutide (Trulicity¬Æ) 1.5 mg QW or 0.75 mg QW, if 1.5 mg QW is not well tolerated\n",
      "according to Investigator's judgment in combination with metformin (daily dose ‚â•1500\n",
      "mg/day or MTD), with or without pioglitazone, both at stable dose for at least 3              months\n",
      "prior to screening;            -  Signed written informed consent.          Exclusion criteria:\n",
      "-  At screening visit, age <18.            -  Screening HbA1c <7% and >9%.            -  Pregnancy\n",
      "or lactation, women of childbearing potential with no effective              contraceptive method.\n",
      "-  Any use of antidiabetic drugs within 3 months prior to the screening visit other than\n",
      "those described in the inclusion criteria.            -  Previous treatment with insulin in the year\n",
      "prior to screening visit (note:              short-term treatment with insulin [‚â§10 days] due to\n",
      "intercurrent illness including              gestational diabetes is allowed at the discretion of the\n",
      "study physician).            -  Laboratory findings at the time of screening, including:\n",
      "-  Fasting plasma glucose (FPG) >250 mg/dL (13.9 mmol/L),            -  Amylase and/or lipase >3\n",
      "times the upper limit of the normal laboratory range (ULN),            -  Alanine transaminase or\n",
      "aspartate transaminase >3 ULN,            -  Calcitonin ‚â•20 pg/mL (5.9 pmol/L),            -\n",
      "Positive pregnancy test.            -  Patient who has renal function impairment with estimated\n",
      "glomerular filtration rate              <30 mL/min (using the Modification of Diet in Renal Disease\n",
      "formula) or end-stage              renal disease.            -  Contraindication to use of insulin\n",
      "glargine, or lixisenatide or GLP-1 receptor              agonist (Victoza¬Æ, Byetta¬Æ, Bydureon¬Æ,\n",
      "Tanzeum¬Æ or Trulicity¬Æ) according to local              labeling.            -  Any contraindication\n",
      "to metformin or pioglitazone use, according to local labeling.            -  History of\n",
      "hypersensitivity to insulin glargine, or to any of the excipients.            -  History of allergic\n",
      "reaction to any GLP-1 receptor agonist or to meta-cresol.            -  Personal or immediate family\n",
      "history of medullary thyroid cancer (MTC) or genetic              condition that predisposes to MTC\n",
      "(eg, multiple endocrine neoplasia type 2              syndromes).            -  History of\n",
      "pancreatitis (unless pancreatitis was related to gallstones and              cholecystectomy was\n",
      "already performed), chronic pancreatitis, pancreatitis during a              previous treatment with\n",
      "incretin therapies, pancreatectomy.            -  Body mass index ‚â§20 or >40 kg/m^2\n",
      "Exclusion criteria for the extension period:            -  Patients in the FRC arm with a rescue\n",
      "therapy and HbA1c >8% at week 22.            -  Patients in the FRC arm who discontinued prematurely\n",
      "from FRC treatment before week              26.            -  Patients in the GLP-1RA treatment arm\n",
      "after randomization.          The above information is not intended to contain all considerations\n",
      "relevant to a         patient's potential participation in a clinical trial.\n",
      "\n",
      "üîπ Doc ID: NCT01703078  (Score: 13.8523)\n",
      "Safety and Tolerability of Different Concentrations of an Ingenol Derivative Field Therapy in the\n",
      "Treatment of Actinic Keratosis             The purpose of this study is to determine if the new\n",
      "ingenol derivative gels are as safe as       and as well tolerated as ingenol mebutate gel when\n",
      "applied to AK lesions on the forearm for       two consecutive days.                     Various\n",
      "concentrations of new ingenol derivatives will be applied to AKs on the forearms.       Reactions\n",
      "and safety will be compared to a US registered and marketed ingenol gel to       ascertain if the\n",
      "new ingenol is at least as safe and as well tolerated as the registered       ingenol.\n",
      "Inclusion Criteria:            -  Must be male or female and at least 18 years of age.            -\n",
      "Female patients must be of non-childbearing potential or if of childbearing potential\n",
      "then negative serum and urine pregnancy test and using effective contraception            -  Ability\n",
      "to provide informed consent          Exclusion Criteria:            -  location of the selected\n",
      "treatment area within 5cm of an incompletely healed wound or              within 5cm of a suspected\n",
      "basal cell carcinoma or squamous cell carcinoma            -  undergone Cosmetic or therapeutic\n",
      "procedures within 2cm of the selected treatment              area in the 2 weeks prior to Visit 2\n",
      "-  use of acid-containing therapeutic products within 2cm of the selected treatment area\n",
      "in the 2 weeks prior to Visit 2            -  use of topical moisturisers/creams/lotions, artificial\n",
      "tanners or topical steroids              within 2cm of the selected treatment areas in the 2 weeks\n",
      "prior to visit 2 Treatment              with immunomodulators, or interferon/interferon inducers or\n",
      "systemic medications that              suppress the immune system within 4 weeks of Visit 2\n",
      "-  Treatment with 5-FU, imiquimod, diclofenac, or photodynamic therapy within 2 cm of\n",
      "the treatment area in the 8 weeks prior to visit 2            -  use of systemic retinoids\n",
      "-  those who are currently participating in any other clinical trial            -  females who are\n",
      "pregnant or are breastfeeding            -  those known or suspected of not being able to comply\n",
      "with the requirements of the              protocol or provide consent\n",
      "\n",
      "\n",
      "üîç Query: Any serious adverse events reported during the trial?\n",
      "\n",
      "üîπ Doc ID: NCT02107651  (Score: 12.6241)\n",
      "Reporting of Adverse Events in Patients Treated With New Oral Anticoagulants             Serious\n",
      "adverse events in patients treated with new oral anticoagulants are underreported.\n",
      "The study investigates if serious adverse events in patients treated with NOAC are reported       to\n",
      "the Health and Medicines Authority.                         Inclusion Criteria:            -\n",
      "patients admitted for GI bleeding while in treatment with NOAC          Exclusion Criteria:\n",
      "\n",
      "üîπ Doc ID: NCT02133456  (Score: 11.9107)\n",
      "A Post-marketing Safety Study of Inactivated, Split-virion Influenza Vaccine in Subjects Aged 3\n",
      "Years and Older             To monitor the safety of Shanghai Institute of Biological Products\n",
      "Company's influenza       vaccine in subjects aged 3 years and older through Adverse Events\n",
      "Following Immunization       Surveillance System of China.        The hypothesis is that there is no\n",
      "significant difference in the occurrence of adverse       events among influenza vaccines\n",
      "manufactured by SIBP and other companies.                     Inactivated split-virion vaccines from\n",
      "Shanghai Institute of Biological Products Company       have been used for more than 10 years in\n",
      "Beijing population. Some 160 thousands doses have       been sold to subjects aged 3 years and older\n",
      "in this area. We review and summarize       spontaneously reported adverse events from safety\n",
      "surveillance.        Adverse events were collected through the Adverse Events Following Immunization\n",
      "(AEFI)       Surveillance System. Beijing CDC and local prefectural CDC must organize an expert\n",
      "panel to       investigate adverse events and assess causality, using criteria based on Chinese\n",
      "Standard       Procedures for Vaccination. The panels consist of physicians, epidemiologists,\n",
      "pharmacists,       and other relevant experts. In general, expert panels investigate deaths, life-\n",
      "threatening       illnesses, and permanent disabilities, and immunization-program managers or\n",
      "vaccination       providers investigate common, minor adverse events. Adverse events are classified\n",
      "into one       of five categories: vaccine reactions (common and minor to rare and more serious),\n",
      "program       errors, coincidental illnesses, psychogenic reactions, and unclassifiable events.\n",
      "At the time of vaccination, vaccinees were instructed to report any adverse event to\n",
      "physicians or vaccination providers. The following adverse events were required to be\n",
      "reported: adverse events that were fatal or that resulted in disability and clusters of       events\n",
      "(i.e., notably high numbers of similar adverse events related to a certain vaccine) ;\n",
      "anaphylaxis or other allergic reactions occurring within 24 hours after vaccination; fever\n",
      "(axillary temperature, >37.5¬∞C), angioedema, or a local injection-site reaction (diameter,\n",
      ">2.5 cm) occurring within 5 days after vaccination; purpura, an Arthus reaction, febrile\n",
      "convulsion, seizure, or polyneuritis occurring within 15 days after vaccination; and the\n",
      "Guillain-Barr√© syndrome occurring within 3 months after vaccination. Other reactions that       were\n",
      "common and minor (e.g., mild pain and fatigue) were not required to be reported.\n",
      "Inclusion Criteria:            -  Males and females aged 3 years and above on the day of\n",
      "immunization, who are eligible              for seasonal influenza vaccination.            -\n",
      "Recipients of SIBP's inactivated, split-virion influenza vaccine.          Exclusion Criteria:\n",
      "-  History of any serious reaction to flu vaccine, or any materials in the vaccine, and\n",
      "to eggs (including ovalbumin) and chicken protein.            -  Receipt of a live vaccine within 4\n",
      "weeks prior to Study Day 1.            -  Any condition, which in the opinion of the study doctor,\n",
      "might interfere with the              evaluation of the study objective.\n",
      "\n",
      "üîπ Doc ID: NCT02449174  (Score: 11.8646)\n",
      "Fecal Microbiota Transplantation to Treat Recurrent C. Difficile Associated Diarrhea Via Retention\n",
      "Enema or Oral Route             The objective of the study is to investigate the safety of a frozen\n",
      "or lyophilized inoculum       administered, respectively, by retention enema or capsules in patients\n",
      "with recurrent C.       difficile associated diarrhea (RCDAD).        This is a single center,\n",
      "randomized, parallel assignment, open label safety study conducted       in subjects with RCDAD.\n",
      "Fifty subjects will be enrolled in the study and randomized at 1:1       ratio to receive frozen\n",
      "filtered intestinal bacteria via retention enema or lyophilized       donor intestinal bacteria. All\n",
      "subjects will be followed for a total of 3 years after study       completion.        Donors will be\n",
      "enrolled and screened at the laboratory in the Center for Infectious Diseases       at University of\n",
      "Texas School of Public Health (UT-SPH). The donors will come from a variety       of places,\n",
      "including the UT-SPH. We will screen at least 20 donors to recruit at least 15       qualified\n",
      "donors.        Recipients may self-refer but must have a physician who agrees to accept care of the\n",
      "patient       following fecal microbiota transplantation (FMT). Subjects consenting to treatment at\n",
      "Baylor       St. Luke's Medical Center (BSLMC) and the UT-SPH must be willing to self-pay for the\n",
      "FMT in       the amount of $1,500. There will be no insurance accepted. Subjects undergoing\n",
      "retention       enema will be treated as outpatients at either at BSLMC, Kelsey-Seybold Clinic, or\n",
      "at the       Memorial Hermann in the Texas Medical Center. All subjects taking capsules with\n",
      "lyophilized       intestinal bacteria will be seen at UT-SPH. Once the procedure is completed, the\n",
      "recipient's       care will be returned to their physician. We will screen at least 75 recipients to\n",
      "recruit       50 qualified recipients.        The primary endpoint is to evaluate the safety of FMT\n",
      "by rectal or oral routes with       secondary endpoint related to efficacy prevention of RCDAD. In\n",
      "order to monitor any health       effects for safety, participants will be contacted pre- and 7, 14,\n",
      "30 days, then monthly       basis for the first 90 days after FMT and quarterly till 3 years after\n",
      "FMT. The following       procedures will be completed: review recipient diary with the recipient to\n",
      "ensure that the       following information is recorded correctly and a fresh stool sample will be\n",
      "collected from       recipient, tested for C. difficile toxins and an aliquot (2mL) stored at -80C\n",
      "for microbiome       analysis. Recipients will be contacted by phone for their diarrhea status on\n",
      "monthly basis       till 90 days after FMT, then on quarterly basis till 3 years after FMT.\n",
      "Clinical improvement is monitored by telephone/email and or E-mail up to 3 years after FMT.\n",
      "Minor clinical management of the subject with over the counter medication (e.g. loperamide,\n",
      "acetaminophen and Saccharomyces boulardii [probiotic]) will be performed in the case of mild\n",
      "diarrhea and abdominal pain.        All subjects will be followed up by phone the day after FMT to\n",
      "assess health status during       week one. Study subjects will be monitored on approximately days\n",
      "7, 14 and 30, monthly for       the first 3 month and quarterly for 3 years after FMT, at which time\n",
      "we will review the       recipient diary with the recipient to review any adverse experience or\n",
      "medication taken       since the medical history obtained at FMT.        Investigators should\n",
      "determine if any adverse experience or medication need to be further       studied. Donor will be\n",
      "contacted and tested if it is necessary. All actions will be recorded       on with medical\n",
      "condition, dates of adverse experience and medication taken, indication for       new medication\n",
      "taken, and total daily dose.        Recipients should be instructed at FMT to contact the\n",
      "Investigator if they have any       questions regarding adverse experience or the appropriateness of\n",
      "a medication after FMT.        The following definitions of terms are guided by the International\n",
      "Conference of       Harmonization and US Code of Federal Regulations (21 CFR 312.32).        An\n",
      "adverse experience is any unfavorable or unintended sign, symptom, of disease temporally\n",
      "associated with FMT procedure, whether or not considered related to the procedure,       including,\n",
      "but not limited to:          -  Any symptom not previously reported by the recipients (Recent\n",
      "Medical History)          -  An exacerbation of a pre-existing illness, increases in the frequency\n",
      "and/or severity            of the signs or symptoms of CDAD (defined as positive C. difficile toxin\n",
      "test and            enteric symptoms)          -  A significant increase in frequency or intensity\n",
      "of a pre-existing episodic event or            condition          -  A condition first detected or\n",
      "diagnosed after study drug administration even through            the condition may have been\n",
      "present before the procedure Details of all adverse            experiences that occur after FMT\n",
      "through approximately day 90 visit will be collected            as indicated above. Then the subject\n",
      "will be followed on quarterly basis for 3 years            about their CDAD and other medical\n",
      "concerns        Serious adverse experience is any adverse experience that:          -  Results in\n",
      "death          -  Is life threatening (at immediate risk of death from the procedure as it occurred)\n",
      "-  Requires inpatient hospitalization (overnight stay) or prolongs a current\n",
      "hospitalization          -  Causes a persistent or significant disability/incapacity          -\n",
      "Medical important (any event that requires medical or surgical intervention to prevent\n",
      "one of the outcomes listed above) The investigator will exercise medical and scientific\n",
      "judgment when deciding whether expeditious reporting is appropriate in other situations\n",
      "not strictly meeting the listed criteria above. The investigators will meet/discuss            with\n",
      "experts in the field if there is a question of whether the adverse experience            would be\n",
      "considered serious.        Severity - The adverse experience will be documented on the appropriate\n",
      "page in the Patient       Diary according to the following descriptors:          -  Mild: associated\n",
      "with no limitation of usual activities or only slight discomfort          -  Moderate: associated\n",
      "with limitation of usual activities or significant discomfort          -  Severe: associated with\n",
      "inability to carry out usual activities or very marked            discomfort        Relationship -\n",
      "the relationship of adverse experience to FMT will be assigned by the       Investigator according\n",
      "to the following definitions:          -  Probable: a reaction that follows a reasonable temporal\n",
      "sequence from the procedure            that follows a known or expected response pattern to the\n",
      "suspected procedure and that            could not be reasonably explained by the known\n",
      "characteristics of that patient's            clinical state          -  Possible: a reaction that\n",
      "follows a reasonable temporal sequence from the procedure            that follows a known or\n",
      "expected response pattern to the procedure but could readily            have been produced by a\n",
      "number of other factors          -  Unlikely: a reaction that does not follow a reasonable temporal\n",
      "sequence from the            procedure but for which causality from FMT cannot be ruled out.\n",
      "-  Not related: a reaction for which sufficient data exist to indicate that the etiology\n",
      "is unrelated to the procedure Pre-existing signs and symptoms and medical conditions\n",
      "Medical conditions that are present at or before the procedure that manifest with the\n",
      "same severity or frequency will not be recorded as adverse experience. Similarly, signs\n",
      "or symptoms related to a pre-existing disease will not be recorded as adverse            experience\n",
      "unless there is an increase in the severity or frequency of the signs or            symptoms. These\n",
      "pre-existing conditions, signs, or symptoms will be recorded on the            Recent Medical\n",
      "History Form.        Progression of underlying conditions as an adverse experience        If the\n",
      "progression of the underlying condition might be reasonably anticipated given the       nature and\n",
      "severity of the underlying condition, then the progression of the underlying       condition per se\n",
      "will not constitute an adverse experience. However, if the progression of       the underlying\n",
      "condition is fatal, then the progression of the underlying condition should       be reported as an\n",
      "adverse experience.        Recording and documenting adverse experience        The Investigator must\n",
      "completely and promptly record each new adverse experience and serious       adverse experience,\n",
      "even if the relationship of adverse experience to the procedure is       assessed by the\n",
      "Investigator to be \"unlikely\" or \"not related\". In addition, the       investigator must document\n",
      "and follow serious adverse experiences that occur from the       procedure through 3 years after the\n",
      "FMT. The Investigator should attempt, if possible, to       establish a diagnosis based on the\n",
      "presenting signs and symptoms. If an adverse experience       meets the definition of a serious\n",
      "adverse experience then the Investigator must also       complete the serious adverse experience,\n",
      "and also send any supporting source documents       directly to the University of Texas Health\n",
      "Science Center IRB as soon as the event is       discovered. At each visit, after the patient has\n",
      "had an opportunity to mention any problems       spontaneously, the Investigator (or designee) will\n",
      "inquire about adverse experience by       asking the standard questions listed in, such as:\n",
      "-  Have you had any medical problems since your last visit?          -  Have any medical problems\n",
      "present at your last visit changed, i.e., stopped, worsened,            or improved?          -\n",
      "Have you taken any new medicines, other than study drug, since your last visit? Any\n",
      "spontaneous adverse experience information provided by the patient will be reported. If\n",
      "an adverse experience has not resolved at the time of the Final Visit, the Investigator\n",
      "should evaluate the status of the adverse experience at the Follow-Up telephone/email\n",
      "contact (day 60) and update to reflect the status of the adverse experience (e.g.            ongoing\n",
      "or resolved).        Investigator reporting of serious adverse experience All serious adverse\n",
      "experience must be       reported to the University of Texas Health Science IRB using the serious\n",
      "adverse experience       facsimile or email or by telephone/email as soon as the serious adverse\n",
      "experience is       discovered, and within 24 hours after the Investigator recognizes or classifies\n",
      "the event as       a serious adverse experience. A brief description of the event must be provided\n",
      "at the time       of the initial serious adverse experience report. The initial serious adverse\n",
      "experience       report should be followed up by additional information using the serious adverse\n",
      "experience       within 48 hours. The reports should identify the patient by their unique patient\n",
      "number       instead of names. The completed serious adverse experience Form will be used by the\n",
      "investigators in regulatory filings. The investigator is responsible for continuing to       report\n",
      "to the University of Texas Health Science IRB any new or relevant follow-up       information\n",
      "obtained concerning the serious adverse experience. The results of any       additional assessments\n",
      "conducted must be also reported to the University of Texas Health       Science IRB.\n",
      "Notification of post-study serious adverse experience Investigators are not obligated to\n",
      "actively seek follow-up information for patients with adverse experience after the       conclusion\n",
      "of the study (i.e., > 3 years after the FMT procedure). However, if the       investigator becomes\n",
      "aware of an adverse experience that occurs after the patient completes       and the adverse\n",
      "experience is considered by the Investigator to be at least possibly related       to study\n",
      "procedure, the investigator must notify the University of Texas Health Science       Center IRB.\n",
      "Inclusion Criteria:            1. Male and female subjects 18 years of age or older            2.\n",
      "Sexually active female subjects of child-bearing potential must agree to use an\n",
      "effective method of birth control during the treatment and follow-up period            3. Required\n",
      "to sign an informed consent form            4. Subject‚Äüs attending physician agrees to provide care\n",
      "following FMT            5. Able to follow study procedures and follow-ups.            6. Diagnosed\n",
      "by medical history of ‚â• 3 RCDAD bouts in outpatients or ‚â• 2 bouts of RCDAD              in an\n",
      "inpatient with ‚â• 2 positive fecal tests for C. difficile toxin            7. Received at least one\n",
      "course of adequate antibiotic therapy for CDAD (‚â• 10 days of              vancomycin, metronidazole\n",
      "or fidaxomicin) after the subjects last bout of CDAD          Exclusion Criteria:            1.\n",
      "Subjects with known neutropenia with absolute neutrophil count <0.5 x 109/L            2. Evidence\n",
      "of toxic megacolon, fulminant colitis, gastrointestinal perforation, ileus,              abdominal\n",
      "distension, lack of bowel sounds, fever, or hypotension            3. Known peripheral white blood\n",
      "cell count > 15.0 x 109/L or temperature > 38.0 ¬∞C            4. Diarrhea due to definable non-CDAD\n",
      "pathogen            5. Post total colectomy or presence of a colostomy            6. Unable to\n",
      "tolerate FMT via enema for any reason            7. Requiring systemic non-C. difficile antibiotic\n",
      "therapy at the time of FMT            8. Actively taking Saccharomyces boulardii or other probiotic\n",
      "at the time of FMT            9. Need for continuing use of oral vancomycin, oral or IV\n",
      "metronidazole, fidaxomicin,              rifaximin or nitazoxanide at the time of FMT           10.\n",
      "Renal failure requiring dialysis           11. Severe underlying disease such that the patient is\n",
      "not expected to survive for one or              more years or unstable medical condition requiring\n",
      "daily change in treatments\n",
      "\n",
      "üîπ Doc ID: NCT01906593  (Score: 11.5611)\n",
      "A Post-marketing Safety Study of Beijing Tiantan Biological's Influenza Virus Vaccine in Elderly\n",
      "To monitor the safety of Beijing Tiantan Biological's influenza vaccine in elderly through\n",
      "Adverse Events Following Immunization Surveillance System of China.        The hypothesis is that\n",
      "there is no significant difference in the occurrence of adverse       events among influenza\n",
      "vaccines manufactured by independent companies.                     In 2011 and 2012, Beijing\n",
      "Municipal Health Bureau launched the free influenza vaccination       campaign among children aged\n",
      "6-18 years old and the elderly aged 60 years old and above.       Inactivated split-virion vaccines\n",
      "from Beijing Tiantan Biological Products Company were used       for the elderly in the campaign.\n",
      "All vaccine recipients provided written informed consent, containing information about the\n",
      "vaccine, possible adverse effects, and medical care.        Adverse events were collected through\n",
      "the National Immunization Information System's       National Adverse Events Following Immunization\n",
      "(AEFI) Surveillance System, which was       established in 2005 on the basis of World Health\n",
      "Organization (WHO) guidelines. According to       the Guideline for the Identification of Adverse\n",
      "Reaction after Immunization issued by the       Chinese Ministry of Health in 2008, Beijing CDC and\n",
      "local prefectural CDC must organize an       expert panel to investigate adverse events and assess\n",
      "causality, using criteria based on       Chinese Standard Procedures for Vaccination. The panels\n",
      "consist of physicians,       epidemiologists, pharmacists, and other relevant experts. In general,\n",
      "expert panels       investigate deaths, life-threatening illnesses, and permanent disabilities, and\n",
      "immunization-program managers or vaccination providers investigate common, minor adverse\n",
      "events. Adverse events are classified into one of five categories: vaccine reactions (common\n",
      "and minor to rare and more serious), program errors, coincidental illnesses, psychogenic\n",
      "reactions, and unclassifiable events.        At the time of vaccination, vaccinees were instructed\n",
      "to report any adverse event to       physicians or vaccination providers. Adverse events that were\n",
      "fatal or that resulted in       disability and clusters of events (i.e., notably high numbers of\n",
      "similar adverse events       related to a certain vaccine) were required to be reported within 2\n",
      "hours after their       occurrence. The following adverse events were required to be reported within\n",
      "2 days after       their occurrence: anaphylaxis or other allergic reactions occurring within 24\n",
      "hours after       vaccination; fever (axillary temperature, >37.5¬∞C), angioedema, or a local\n",
      "injection-site       reaction (diameter, >2.5 cm) occurring within 5 days after vaccination;\n",
      "purpura, an Arthus       reaction, febrile convulsion, seizure, or polyneuritis occurring within 15\n",
      "days after       vaccination; and the Guillain-Barr√© syndrome occurring within 3 months after\n",
      "vaccination.       Other reactions that were common and minor (e.g., mild pain and fatigue) were not\n",
      "required       to be reported.                         Inclusion Criteria:            1. Males and\n",
      "females aged 60 years and above on the day of immunization, who are              eligible for\n",
      "seasonal influenza vaccination.            2. In the judgement of the study doctor are determined to\n",
      "be in reasonable health              considering their age and able to comply with all study\n",
      "procedure.          Exclusion Criteria:            1. History of any serious reaction to flu\n",
      "vaccine, or any materials in the vaccine, and              to eggs (including ovalbumin) and chicken\n",
      "protein.            2. Receipt of a live vaccine within 4 weeks prior to Study Day 1.            3.\n",
      "Any condition, which in the opinion of the study doctor, might interfere with the\n",
      "evaluation of the study objective.\n",
      "\n",
      "üîπ Doc ID: NCT02318992  (Score: 11.4983)\n",
      "Fresh, Frozen or Lyophilized Fecal Microbiota Transplantation for Multiple Recurrent C. Difficile\n",
      "Associated Diarrhea             The objective of the study is to investigate the efficacy of fresh,\n",
      "frozen or lyophilized       fecal microbiota transplantation (FMT) via colonoscopy in patients with\n",
      "recurrent C.       difficile associated diarrhea (RCDAD). We will generate a frozen, lyophilized or\n",
      "fresh fecal       microbiota transplantation (FMT) inoculum from well-screened healthy volunteer\n",
      "donors of       ‚â•150 gram/sample. Delivery of FMT will be performed colonoscopically. Fecal samples\n",
      "from       donors and recipients will be saved for later metagenomic studies to characterize the\n",
      "microbiome of the gut in patients before and after FMT.        Donors will be enrolled and screened\n",
      "at the Center for Infectious Disease laboratory for       enteric pathogens at University of Texas\n",
      "School of Public Health (EPDL-UT-SPH) which is       College American Pathologist and Clinical\n",
      "Laboratory Improvement Amendments certified       laboratory. The donors will come from a variety of\n",
      "places, including the University of Texas       School of Public Health. We will screen at least 70\n",
      "donors to recruit at least 20 qualified       donors.        Recipients All patients to be treated\n",
      "must have a physician who is willing to care from them       after discharge from our facility.\n",
      "Recipients will need to have insurance or be willing to       self-pay for this therapy. Attending\n",
      "physician of recipients/patients will order the FMT and       make clinical decisions related to\n",
      "overall health for his/her patients. All patients       undergoing therapy will be handled as\n",
      "outpatients at either Baylor St. Luke's Medical Center       in the Texas Medical Center, the\n",
      "Digestive Disease Center at Memorial Hermann in the Texas       Medical Center, or Kelsey-Seybold\n",
      "Clinic - Main Campus on Holcombe Blvd. Once the procedure       is completed, the recipient will be\n",
      "transferred back to their original medical treatment       facility or be released to home care\n",
      "under the care of their physician. A gastroenterologist       with privileges at Endoscopy procedure\n",
      "site will perform the FMT via colonoscopy. The Center       for Infectious Disease enteric pathogens\n",
      "laboratory at the University of Texas School of       Public Health will prepare donor stool for\n",
      "administration via a colonoscope. We will screen       at least 120 recipients to recruit 100\n",
      "qualified recipients.        Evaluation of the safety of FMT and recurrence of clinical symptoms of\n",
      "CDAD will be       performed by the primary physicians and research coordinators from the EPDL-UT-\n",
      "SPH. The       primary endpoint is to evaluate the safety of the FMT (fresh or frozen or lyophilized\n",
      "health       donor feces) for the treatment of patients with 3 or more episodes of RCDAD. A second\n",
      "efficacy endpoint is to evaluate the recurrence of clinical symptoms and CDAD after initial\n",
      "therapy. In order to monitor any health effects for safety, participants will be contacted\n",
      "quarterly for three years following study completion. The recipient will be contacted by the\n",
      "investigator pre- and approximately 7, 14 and 30 days after the procedure is performed. The\n",
      "following procedures will be completed: review recipient diary with the recipient to ensure\n",
      "that the following information is recorded correctly and a fresh stool sample will be\n",
      "collected from recipient, tested for C. difficile toxins and an aliquot (2 mL) stored at       -80C\n",
      "for future analysis (e.g. microbiome). The recipients will be contacted by phone for       their\n",
      "diarrhea status.                     The following safety endpoints will be evaluated in this study.\n",
      "Medical conditions        Clinical improvement is monitored by telephone/email and or E-mail during\n",
      "90 days after FMT.       Minor clinical management of the subject with over the counter medication\n",
      "(e.g. loperamide,       acetaminophen and Saccharomyces boulardii [probiotic]) will be performed in\n",
      "the case of mild       diarrhea and abdominal pain.        All subjects will be followed up by phone\n",
      "the day after FMT to assess health status during       week one. Study subjects will be monitored on\n",
      "approximately days 7, 14 and 30 after FMT, at       which time we will review the recipient diary\n",
      "with the recipient to review any adverse       experience or medication taken since the medical\n",
      "history obtained at FMT.        Investigators should determine if any adverse experience or\n",
      "medication need to be further       studied. Donor will be contacted and tested if it is necessary.\n",
      "All actions will be recorded       on with medical condition, dates of adverse experience and\n",
      "medication taken, indication for       new medication taken, and total daily dose (Patient Data\n",
      "Collection Form).        Recipients should be instructed at FMT to contact the Investigator if they\n",
      "have any       questions regarding adverse experience or the appropriateness of a medication after\n",
      "FMT.        Monitoring for safety        The following definitions of terms are guided by the\n",
      "International Conference of       Harmonization and US Code of Federal Regulations (21 CFR 312.32).\n",
      "An adverse experience is any unfavorable or unintended sign, symptom, of disease temporally\n",
      "associated with FMT procedure, whether or not considered related to the procedure,       including,\n",
      "but not limited to:          -  Any symptom not previously reported by the recipients (Recent\n",
      "Medical History)          -  An exacerbation of a pre-existing illness, increases in the frequency\n",
      "and/or severity            of the signs or symptoms of CDAD (defined as positive C. difficile toxin\n",
      "test and            enteric symptoms)          -  A significant increase in frequency or intensity\n",
      "of a pre-existing episodic event or            condition          -  A condition first detected or\n",
      "diagnosed after study drug administration even through            the condition may have been\n",
      "present before the procedure        Details of all adverse experiences that occur after FMT through\n",
      "approximately day 90 visit       will be collected as indicated above.        Serious adverse\n",
      "experience is any adverse experience that:          -  Results in death          -  Is life\n",
      "threatening (at immediate risk of death from the procedure as it occurred)          -  Requires\n",
      "inpatient hospitalization (overnight stay) or prolongs a current            hospitalization\n",
      "-  Causes a persistent or significant disability/incapacity          -  Medical important (any event\n",
      "that requires medical or surgical intervention to prevent            one of the outcomes listed\n",
      "above)        The investigator will exercise medical and scientific judgment when deciding whether\n",
      "expeditious reporting is appropriate in other situations not strictly meeting the listed\n",
      "criteria above. The investigators will meet/discuss with experts in the field if there is a\n",
      "question of whether the adverse experience would be considered serious.        Severity - The\n",
      "adverse experience will be documented on the appropriate page in the Patient       Diary according\n",
      "to the following descriptors:          -  Mild: associated with no limitation of usual activities or\n",
      "only slight discomfort          -  Moderate: associated with limitation of usual activities or\n",
      "significant discomfort          -  Severe: associated with inability to carry out usual activities\n",
      "or very marked            discomfort        Relationship - the relationship of adverse experience to\n",
      "FMT will be assigned by the       Investigator according to the following definitions:          -\n",
      "Probable: a reaction that follows a reasonable temporal sequence from the procedure            that\n",
      "follows a known or expected response pattern to the suspected procedure and that            could\n",
      "not be reasonably explained by the known characteristics of that patient's            clinical state\n",
      "-  Possible: a reaction that follows a reasonable temporal sequence from the procedure\n",
      "that follows a known or expected response pattern to the procedure but could readily            have\n",
      "been produced by a number of other factors          -  Unlikely: a reaction that does not follow a\n",
      "reasonable temporal sequence from the            procedure but for which causality from FMT cannot\n",
      "be ruled out.          -  Not related: a reaction for which sufficient data exist to indicate that\n",
      "the etiology            is unrelated to the procedure        Pre-existing signs and symptoms and\n",
      "medical conditions        Medical conditions that are present at or before the procedure that\n",
      "manifest with the same       severity or frequency will not be recorded as adverse experience.\n",
      "Similarly, signs or       symptoms related to a pre-existing disease will not be recorded as adverse\n",
      "experience unless       there is an increase in the severity or frequency of the signs or symptoms.\n",
      "These       pre-existing conditions, signs, or symptoms will be recorded on the Recent Medical\n",
      "History       Form.        Progression of underlying conditions as an adverse experience        If\n",
      "the progression of the underlying condition might be reasonably anticipated given the       nature\n",
      "and severity of the underlying condition, then the progression of the underlying       condition per\n",
      "se will not constitute an adverse experience. However, if the progression of       the underlying\n",
      "condition is fatal, then the progression of the underlying condition should       be reported as an\n",
      "adverse experience.        Recording and documenting adverse experience        The Investigator must\n",
      "completely and promptly record each new adverse experience and serious       adverse experience,\n",
      "even if the relationship of adverse experience to the procedure is       assessed by the\n",
      "Investigator to be \"unlikely\" or \"not related\". In addition, the       investigator must document\n",
      "and follow serious adverse experiences that occur from the       procedure through 90 days after the\n",
      "FMT. The Investigator should attempt, if possible, to       establish a diagnosis based on the\n",
      "presenting signs and symptoms. If an adverse experience       meets the definition of a serious\n",
      "adverse experience then the Investigator must also       complete the serious adverse experience,\n",
      "and also send any supporting source documents       directly to the University of Texas Health\n",
      "Science Center IRB as soon as the event is       discovered. At each visit, after the patient has\n",
      "had an opportunity to mention any problems       spontaneously, the Investigator (or designee) will\n",
      "inquire about adverse experience by       asking the standard questions listed in, such as:\n",
      "-  Have you had any medical problems since your last visit?          -  Have any medical problems\n",
      "present at your last visit changed, i.e., stopped, worsened,            or improved?          -\n",
      "Have you taken any new medicines, other than study drug, since your last visit?        Any\n",
      "spontaneous adverse experience information provided by the patient will be reported. If       an\n",
      "adverse experience has not resolved at the time of the Final Visit, the Investigator       should\n",
      "evaluate the status of the adverse experience at the Follow-Up telephone/email       contact (day\n",
      "60) and update to reflect the status of the adverse experience (e.g. ongoing or       resolved).\n",
      "Investigator reporting of serious adverse experience        All serious adverse experience must be\n",
      "reported to the University of Texas Health Science       IRB using the serious adverse experience\n",
      "facsimile or email or by telephone/email as soon as       the serious adverse experience is\n",
      "discovered, and within 24 hours after the Investigator       recognizes or classifies the event as a\n",
      "serious adverse experience. A brief description of       the event must be provided at the time of\n",
      "the initial serious adverse experience report. The       initial serious adverse experience report\n",
      "should be followed up by additional information       using the serious adverse experience within 48\n",
      "hours. The reports should identify the       patient by their unique patient number instead of\n",
      "names. The completed serious adverse       experience Form will be used by the investigators in\n",
      "regulatory filings. The investigator is       responsible for continuing to report to the University\n",
      "of Texas Health Science IRB any new       or relevant follow-up information obtained concerning the\n",
      "serious adverse experience. The       results of any additional assessments conducted must be also\n",
      "reported to the University of       Texas Health Science IRB.        Notification of post-study\n",
      "serious adverse experience        Investigators are not obligated to actively seek follow-up\n",
      "information for patients with       adverse experience after the conclusion of the study (i.e., > 90\n",
      "days after the FMT       procedure). However, if the investigator becomes aware of an adverse\n",
      "experience that occurs       after the patient completes and the adverse experience is considered by\n",
      "the Investigator to       be at least possibly related to study procedure, the investigator must\n",
      "notify the University       of Texas Health Science Center IRB.                         Inclusion\n",
      "Criteria:          Recipients            1. Male and female patients ‚â• 18 years of age            2.\n",
      "Sexually active male and female patients of child-bearing potential must agree to use\n",
      "an effective method of birth control during the treatment and follow-up period            3. Female\n",
      "patients of child-bearing potential must have a negative pregnancy test in the              72 hours\n",
      "before the procedure            4. Required to sign an informed consent form            5. Deemed\n",
      "likely to survive for ‚â• 3 months after enrolment            6. Diagnosis of ‚â• 3 recurrent CDAD\n",
      "(RCDAD) bouts in outpatients or ‚â• 2 bouts of CDAD in              an inpatient without other\n",
      "explanation for diarrhea and with ‚â• 2 positive fecal tests              for C. difficile toxin\n",
      "7. Referred by subjects attending physician who will provide non-transplant care for the\n",
      "subject and follow up at 1, 7, 14, 30 days after FMT            8. Received at least one course of\n",
      "adequate antibiotic therapy for CDAD (‚â• 10 days of              vancomycin at a dose of ‚â•125 mg four\n",
      "times per day, ‚â• 10 days of metronidazole at a              dose of 500mg three times per day or\n",
      "fidaxomixin 200mg twice a day for 10 days            9. Anti-CDI antibiotic treatment stopped 2-4\n",
      "days before the transplantation          Donors            1. Able to provide and sign informed\n",
      "consent            2. Able to complete and sign the donor questionnaire            3. Able to adhere\n",
      "to fecal transplantation stool collection requirements          Exclusion Criteria:\n",
      "Recipients            1. Patients with neutropenia with absolute neutrophil count <0.5 x 109/L\n",
      "2. Evidence of toxic megacolon or gastrointestinal perforation on abdominal x-ray            3.\n",
      "Peripheral white blood cell count > 15.0 x 109/L AND temperature > 38.0 ¬∞C            4. Active\n",
      "gastroenteritis due to Salmonella, Shigella, E. coli 0157:H7, Yersinia or\n",
      "Campylobacter, and Norovirus            5. Presence of colostomy            6. Unable to tolerate\n",
      "HBT for any reason            7. Requiring systemic antibiotic therapy for more than 7 days\n",
      "8. Actively taking Saccharomyces boulardii or other probiotic            9. Severe underlying\n",
      "disease such that the patient is not expected to survive for one or              more years or\n",
      "unstable medical condition requiring daily change in treatments           10. Prolonged compromised\n",
      "immunity due to cytotoxic chemotherapy or HIV infection          Donors            1. Test positive\n",
      "for any of variables            2. History of any type of active cancer or autoimmune disease\n",
      "3. History of risk factors for acquisition of HIV, syphilis, Hepatitis B, Hepatitis C,\n",
      "prion or any neurological disease as determined by the donor questionnaire            4. History of\n",
      "gastrointestinal disorder, e.g., inflammatory bowel disease, irritable              bowel syndrome,\n",
      "chronic constipation or diarrhea            5. Antibiotic use or any systemic immunosuppressive\n",
      "agents in the 3 months prior to              stool donation            6. Receipt of any type of\n",
      "live vaccine within 3 months prior to stool donation            7. Current or previous medical or\n",
      "psychosocial condition            8. Body mass index over 30\n",
      "\n",
      "==============================\n",
      "üß™ PATIENT ELIGIBILITY\n",
      "==============================\n",
      "\n",
      "üîç Query: Who can participate in the trial?\n",
      "\n",
      "üîπ Doc ID: NCT02818738  (Score: 18.7375)\n",
      "Efficiency of Levamisole for Maintaining Remission After the First Flare of Steroid Sensitive\n",
      "Nephrotic Syndrome in Children             Idiopathic Nephrotic Syndrome is sensitive to steroid in\n",
      "90% of children. However, most       patients relapse and become steroid-dependant, with a long\n",
      "lasting relapsing course. The aim       of this study is to assess the efficiency of a 6-months\n",
      "levamisole course, given early after       first remission, on maintaining a relapse-free course at\n",
      "12 months.                     Introduction (INS) is likely a primal immune disorder. Initial\n",
      "treatment relies on steroid       therapy. NS is sensitive to steroid in more than 90% of cases,\n",
      "with an excellent renal       prognosis. Nevertheless, 80% of patients with steroid sensitive NS do\n",
      "relapse, 60% within       the first year. 2/3 of them will experience steroid dependency, with a\n",
      "long lasting       relapsing course. These patients require further immunosuppressive drugs as\n",
      "steroid sparing       agents, such as mycophenolate, cyclophosphamide, calcineurin inhibitors or\n",
      "rituximab.       Morbidity is high and related both to the duration of the disease, sometimes until\n",
      "adulthood, and to treatments side effects.        Levamisole is an immunomodulator that has been\n",
      "used for more than thirty years in the       treatment of steroid-dependent or frequently relapsing\n",
      "NS. Its major advantages are its       immunomodulatory action and lower and reversible toxicity.\n",
      "Exact physiopathology of both INS and levamisole action remain unknown. Nevertheless, we       make\n",
      "the hypothesis that very early treatment with levamisole may enhance its efficiency and       modify\n",
      "the disease's course.        This is the first trial to assess the efficiency of levamisole in\n",
      "increasing duration of       remission after the first manifestation of INS.        Design :\n",
      "-  A multicenter, double-blind, placebo-controlled, randomised clinical trial.          -  38\n",
      "centers participate to the recruitment : 3 Pediatric Nephrology units and 35 General\n",
      "Pediatric units.          -  20 centers participate to the randomized phase.        Sample size :\n",
      "156 patients, 78 in each group        Treatment groups :          1. Levamisole Hydrochloride Dosage\n",
      ": 5, 10, 25 et 50mg. Dosage form : oral tablets            Posology : 2.5 mg/kg on alternate days\n",
      "maximum 150mg. Treatment duration : 6 months          2. placebo : matching verum        Assessment\n",
      ":        Study visits at inclusion, M1 (randomisation), M3, M6, M9, M12. Supplementary visit if\n",
      "relapse occurs.        Statistical procedure Analysis of efficiency will be performed on intention\n",
      "to treat       population. Analysis of tolerance will be performed on randomized patients who have\n",
      "received       at least one dose of treatment.        No intermediary analysis is planned.\n",
      "Inclusion Criteria:            -  Age 12 months < age < 16 years            -  Child's weight ‚â• 7 Kg\n",
      "-  Diagnosis of first manifestation of INS defined by:            -  hypoalbuminemia < 25g/l,\n",
      "proteinuria > 0.20 g/mmol of urinary creatinine            -  normal C3 fraction of complement\n",
      "-  Written informed consent from both parents          Exclusion Criteria:            -  Anteriority\n",
      "of INS            -  Pregnancy, breast feeding or planned pregnancy during the study            -\n",
      "Patients with neutropenia, convulsions or hepatic disease            -  Diabetes or malignancy\n",
      "\n",
      "üîπ Doc ID: NCT01346007  (Score: 17.9416)\n",
      "Study of 7-valent Pneumococcal Conjugate Vaccine in Children With Idiopathic Nephrotic Syndrome\n",
      "The purpose of this study is to determine whether 7-valent pneumococcal conjugate vaccine\n",
      "safely induces immune responses and immunological memory in children with idiopathic       nephrotic\n",
      "syndrome in remission.                     Idiopathic nephrotic syndrome (INS) is the most frequent\n",
      "glomerular disease in children       under 16 years old with incidence rate 2-7/100,000\n",
      "patients/year depending on ethnicity.       Those patients are susceptible to invasive pneumococcal\n",
      "disease (IPD) including peritonitis,       pneumonia with or without pleural effusion and\n",
      "meningitis. Due to increased mortality and       risk of relapses associated with IPD, it has been\n",
      "recommended that children with INS should       be immunized with pneumococcal conjugate vaccine\n",
      "[1]. However, concerns on vaccine safety       and impaired immunogenicity due to INS pathogenesis\n",
      "and immunosuppressive treatment are a       hurdle for universal implementation of existing\n",
      "guidelines.        To thoroughly evaluate safety of 7-valent pneumococcal conjugate vaccine (PCV7)\n",
      "in children       with INS in remission, we will investigate a possible association of vaccination\n",
      "with       increased risk for recurrences of INS. We will also study immunogenicity and kinetics of\n",
      "immune response in INS patients and healthy subjects and the effect of different types of\n",
      "treatment on primary immune response and antibody persistence at 12-14 months following\n",
      "vaccination with PCV7.                         Inclusion Criteria:            -  Male or Female\n",
      "-  Between 2-20 years of age          Exclusion Criteria:            -  serious allergic reaction to\n",
      "previous vaccination            -  history of invasive pneumococcal disease            -\n",
      "vaccination with pneumococcal conjugate vaccine            -  vaccination with pneumococcal\n",
      "polysaccharide vaccine            -  administration of intravenous immunoglobulin or other blood\n",
      "products during the last              3 months\n",
      "\n",
      "üîπ Doc ID: NCT01847131  (Score: 16.9778)\n",
      "Effectiveness of Oxymetazoline Added on Nasal Steroid in Rhinitis With Persistent Nasal Obstruction\n",
      "Background Allergic rhinitis is a common health problem with a worldwide prevalence is       10-25%,\n",
      "and poses significant impact on the quality of life of the patients. In Thailand,       the\n",
      "prevalence of allergic rhinitis in the general population is 13.5%, of which the       frequency of\n",
      "allergic rhinitis increased from 23% to 38% in the children, and 61.9% in the       graduate\n",
      "students. Despite intranasal steroid being the current first-line treatment of       patients with\n",
      "allergic rhinitis, only 60% of patients achieve excellent control. Persistent       nasal congestion\n",
      "is the major symptom which is difficult to control in these patients. Data       are limited about\n",
      "efficacy and safety of the additional use of 0.05% intranasal       oxymetazoline hydrochloride\n",
      "(OXY) for persistent nasal congestion that does not adequately       respond to recommended doses of\n",
      "intranasal steroid (INS) and oral antihistamine(OAH).        Objective To determine the efficacy and\n",
      "safety of the additional use of OXY for persistent       nasal congestion in allergic rhinitis or\n",
      "non-allergic rhinitis patients inadequately       controlled by combination treatment with INS and\n",
      "OAH.        Methods The investigators performed a 6-week, randomized, double blind, placebo\n",
      "controlled,       clinical trial in 50 patients with allergic rhinitis or non-allergic rhinitis whom\n",
      "inadequately controlled by combination treatment with INS and oral antihistamine (OAH).       After\n",
      "an initial screening, qualified individuals were randomized into 2 groups including       the\n",
      "treatment group and the control group. The treatment group received the INS (2 puffs in       each\n",
      "nostril twice daily) and OAH (1 tablet once daily) plus OXY (2 puffs in each nostril       twice\n",
      "daily) The control group received INS (2 puffs in each nostril twice daily) and OAH (1       tablet\n",
      "once daily) plus placebo (2 puffs in each nostril twice daily).                     All participants\n",
      "will continue medications for 4 weeks, then stop using interventional       medication and still\n",
      "take INS (2 puffs in each nostril twice daily) and OAH (1 tablet once       daily) for 2 more weeks.\n",
      "Then, all participants will come for the last visit to see whether       rebound nasal symptoms\n",
      "occur. Participants will be asked to record nasal symptom diary card,       and nasal peak\n",
      "inspiratory flow. Rhinoconjunctivitis Quality of life Questionnaire (Rcq)       will be recorded\n",
      "during visit.                         Inclusion Criteria:            -  Patient 18 years of age or\n",
      "greater            -  Diagnosis with allergic or nonallergic rhinitis with persistent nasal\n",
      "obstruction            -  Being treated with intranasal steroid and oral antihistamine\n",
      "Exclusion Criteria:            -  Underlying disease of hypertension            -  Use oral or nasal\n",
      "decongestant 7 days prior to entering the study            -  Nasal polyp or significant deviated\n",
      "nasal septum            -  Respiratory tract infection 14 days prior to entering the study\n",
      "\n",
      "üîπ Doc ID: NCT01077609  (Score: 16.2099)\n",
      "Flixonase Safety in Patients With Allergic Rhinitis (AR)             This is an inception cohort\n",
      "study that analyses data from an administrative medical records       database. The two inception\n",
      "cohorts are: 1) patients initiated on intranasal FP and 2)       patients initiated on another INS\n",
      "(not FP). The candidates for the inception cohorts did not       use any intranasal steroid in the\n",
      "year prior to initiation.                          Inclusion Criteria:            -  Patient records\n",
      "dated between January 1990 - January 2002 were used to develop the              overall study\n",
      "cohort. The cohort was composed of the following patients:                 1. All patients with at\n",
      "least one prescription for Flixonase                 2. A random sample of patients having at least\n",
      "one prescription for an INS other                   than Flixonase          Exclusion Criteria:\n",
      "Patient-level exclusion            -  Patients with less than 180 days of continuous eligibility\n",
      "before index date            -  Patients who are under four years of age at index date            -\n",
      "Patients who are older than 85 years of age at index date          Episode-level exclusion\n",
      "-When patient history was divided into Flixonase or other INS use episodes, patients with\n",
      "less than 120 days of eligibility after the last prescription in the episode Patients with\n",
      "an event of interest 180 days prior to patients' entry into the cohort or anytime prior to\n",
      "an episode index date were automatically excluded from the analysis of that event. This\n",
      "exclusion criterion was applied to rule out prevalent conditions.\n",
      "\n",
      "üîπ Doc ID: NCT00398476  (Score: 15.7611)\n",
      "Fluticasone Nasal Spray Patient Preference Study             The objectives of this study are to\n",
      "evaluate and compare patient preference for FF       (Fluticasone Furoate) and FP (Fluticasone\n",
      "Propionate Aqueous)nasal sprays in the treatment       of allergic rhinitis following single-dose\n",
      "administration.                          Inclusion Criteria:            -  allergic rhinitis\n",
      "-  literate          Exclusion Criteria:            -  clinical significant uncontrolled disease\n",
      "-  Use of intranasal corticosteroids (<4 weeks of FP [branded or generic],<4 week\n",
      "exposure to FF, <4 weeks use of other INS)            -  Use of intranasal medications <1 week\n",
      "-  Use of meds that significantly inhibit CYP4503A4            -  Use of perfume or oral rinse on\n",
      "study day            -  Allergy/intolerance to INS, antihistamines, or excipients            -\n",
      "Positive pregnancy test or female who is breastfeeding            -  Affiliation with\n",
      "investigational site\n",
      "\n",
      "\n",
      "üîç Query: Eligibility criteria for patients with lung cancer\n",
      "\n",
      "üîπ Doc ID: NCT00047385  (Score: 12.9058)\n",
      "National Lung Screening Trial (NLST) Screening             RATIONALE: Effective screening tests\n",
      "should help doctors detect lung cancer early and plan       curative treatment. It is not yet known\n",
      "whether low-dose helical computed tomography (LDCT)       screening is more effective than chest\n",
      "radiography (CXR) screening in reducing death from       lung cancer.        PURPOSE: Randomized\n",
      "clinical trial to compare the effectiveness of LDCT scan with that of       CXR in screening\n",
      "individuals who are at high risk for developing lung cancer.                     OBJECTIVES:\n",
      "-  Compare whether screening with low-dose helical CT scan vs chest x-ray reduces lung\n",
      "cancer-specific mortality in participants who are at high risk for developing lung\n",
      "cancer.        OUTLINE:        NLST participants were randomized to either low-dose helical CT or\n",
      "chest x-ray in equal       proportions. A total of 53,454 participants were enrolled (26,722 in low-\n",
      "dose CT and 26,732       in chest radiography) at 33 screening centers across the United States.\n",
      "Screening was       offered three times (at baseline and two annual follow-up examinations). The\n",
      "primary       endpoint of the study was lung cancer mortality. The study arms were compared with\n",
      "regard to       overall mortality, lung cancer incidence, and screening-related complications.\n",
      "All low-dose scanners and chest x-ray machines were certified for use and met NLST protocol\n",
      "requirements and American College of Radiology guidelines. Low-dose CT acquisitions and       chest\n",
      "radiographs were interpreted by trained radiologists. Participants and their health       care\n",
      "provider were informed of study examination results. Participants with abnormalities\n",
      "suspicious for lung cancer were contacted for information regarding diagnostic evaluation.\n",
      "Medical records were collected on diagnostic evaluation, medical complications, and initial\n",
      "treatment.        Participants were then contacted at least annually by mail or telephone.\n",
      "The National Lung Screening Trial (NLST) represents the union of two NCI-sponsored efforts,\n",
      "the NCI Lung Screening Study and the American College of Radiology Imaging Network (ACRIN).\n",
      "Inclusion Criteria:            -  Age 55-74 years (pack-years = packs per day * years smoked)\n",
      "-  30 or more pack-years of cigarette smoking history            -  Former smokers: quit smoking\n",
      "within the previous 15 years            -  Ability to lie on the back with arms raised over the head\n",
      "-  Signed informed consent form          Exclusion Criteria:            -  Metallic implants or\n",
      "devices in the chest or back, such as pacemakers or Harrington              fixation rods\n",
      "-  Treatment for, or evidence of, any cancer other than nonmelanoma skin cancer or\n",
      "carcinoma in situ (with the exception of transitional cell carcinoma in situ or              bladder\n",
      "carcinoma in situ) in the 5 years prior to eligibility assessment            -  History of lung\n",
      "cancer            -  History of removal of any portion of the lung, excluding needle biopsy\n",
      "-  Requirement for home oxygen supplementation            -  Participation in another cancer\n",
      "screening trial            -  Participation in a cancer prevention study, other than a smoking\n",
      "cessation study            -  Unexplained weight loss of more than 15 pounds in the 12 months prior\n",
      "to eligibility              assessment            -  Recent hemoptysis            -  Pneumonia or\n",
      "acute respiratory infection treated with antibiotics in the 12 weeks              prior to\n",
      "eligibility assessment            -  Chest CT examination in the 18 months prior to eligibility\n",
      "assessment\n",
      "\n",
      "üîπ Doc ID: NCT03084692  (Score: 12.8268)\n",
      "Therapeutic Yoga and Resistance Exercise for Lung Cancer             The purpose of the study is to\n",
      "determine the feasibility and preliminary efficacy of a       combined therapeutic yoga and\n",
      "resistance exercise intervention for individuals with lung       cancer and their caregivers. The\n",
      "investigators aim is to help reduce the fear of exercise by       tailoring the program to meet the\n",
      "specific needs of the survivor with lung cancer. The       investigators want to see whether\n",
      "individuals with lung cancer and their caregivers are       interested in participating in this type\n",
      "of program, and if they are able to attend the       intervention sessions and complete the program.\n",
      "The investigators also plan to study the       preliminary effects of therapeutic yoga and\n",
      "resistance exercise on fitness outcomes for both       individuals with lung cancer and their\n",
      "caregivers.                     To determine the feasibility of a combined therapeutic yoga and\n",
      "resistance exercise       intervention for lung cancer survivors and their caregivers. A single\n",
      "group before and after       intervention study design will be used for this pilot feasibility\n",
      "trial. Brochures and       information about the study will be distributed at the Cross Cancer\n",
      "Institute, and       interested individuals will be screened for eligibility. A convenient sampling\n",
      "technique       will be used to recruit individuals with lung cancer and their caregiver.\n",
      "Participants       deemed eligible to take part in the study will provide written informed consent\n",
      "to       participate in the study and will undergo baseline testing. The intervention will be\n",
      "carried       out over a period of 8 weeks. The feasibility outcomes will include eligibility rate,\n",
      "completion rate, adherence rate and adverse events. Dyspnea will be the primary       self-reported\n",
      "outcome to be measured for individuals with lung cancer. The secondary       outcomes will include\n",
      "fatigue, shoulder range of motion, chest expansion, and muscular       strength. The outcome\n",
      "measures for the caregivers will include quality of life (QoL) and       muscular strength.\n",
      "Inclusion Criteria:            1. Diagnosis of Primary Lung Cancer Stage I-III            2. Any\n",
      "form of Lung cancer included: Small Cell Lung Cancer and Non-Small Cell Lung              Cancer\n",
      "3. Age: 18 years or above            4. Patients at any time point during treatment: ongoing\n",
      "treatment, completed treatment              or recently diagnosed and about to start treatment\n",
      "5. Karnofsky Performance Status ‚â• 50 (Appendix A)            6. Life expectancy at least one year -\n",
      "Exclusion Criteria:            1. Metastatic lung disease            2. Secondary Lung cancer due to\n",
      "metastasis from other parts of body            3. Co-morbid conditions such as diabetes, congestive\n",
      "heart failure, dementia,              cerebrovascular diseases.            4. Individuals who would\n",
      "be unsafe to participate in an intervention program.            5. Unable to provide consent in\n",
      "English            6. Unable to complete either testing or intervention components (e.g. extended\n",
      "holiday)          Caregiver eligibility: Caregivers will be screened using the PAR-Q + questionnaire\n",
      "and         will be required to obtain approval from a family physician should any safety concerns\n",
      "be         identified.\n",
      "\n",
      "üîπ Doc ID: NCT01752647  (Score: 12.7963)\n",
      "CT Screening For Lung Cancer in High Risk Patients: the Russian Study.             This prospective\n",
      "cohort trial was planned to assess the feasibility of establishing a lung       cancer screening\n",
      "program in Russian Federation using low-dose CT scanning in asymptomatic       patients with at\n",
      "least a 30 pack-year history of cigarette smoking.                     Low dose computer tomography\n",
      "(LDCT) showed promising results in recently published studied.       Lung cancer screening programs\n",
      "with fluorography introduced in USSR in 70s-80s showed shift       to earlier stages with no data on\n",
      "mortality. No other studies or programs on lung cancer       screening were introduced in Russia\n",
      "since then.        The purpose of this study is to assess the feasibility of establishing a lung\n",
      "cancer       screening program in Russian Federation using LDCT scanning in asymptomatic patients\n",
      "with at       least a 30 pack-year history of cigarette smoking. This cohort prospective study is\n",
      "planned       to enroll at least 500 current or former smokers.        Patients will be screened by\n",
      "LDCT scan at baseline with recommendation to perform follow-up       in case of any positive result.\n",
      "For nodes more than 10 mm full clinical examination is       recommended. For nodes 3-9.9 mm follow-\n",
      "up scans in 1, 3 or 6 months is recommended. For       nodes smaller than 3 mm and negative results\n",
      "annual LDCT is recommended. Patient with       positive results will be followed until final\n",
      "clinical diagnosis.        Secondary outcomes include:          -  Lung cancer diagnoses          -\n",
      "Lung cancer and overall mortality          -  Quality of life assessment          -  Complications\n",
      "of diagnostic and surgical procedures following a positive result.          -  Comparison of\n",
      "independent radiological evaluation of scans.                         Inclusion Criteria:\n",
      "-  Age 50-75 years            -  30 or more pack-years of cigarette smoking history            -\n",
      "Former smokers: quit smoking within the previous 10 years            -  Ability to tolerate CT\n",
      "procedure            -  Signed informed consent          Exclusion Criteria:            -  Any\n",
      "cancer other than nonmelanoma skin cancer or carcinoma in situ in the 5 years              prior to\n",
      "eligibility assessment            -  Severe uncontrolled heart, vascular, respiratory or endocrine\n",
      "pathology.            -  Life-expectancy less than 1 year            -  History of lung cancer\n",
      "-  History of lung surgery.            -  Acute respiratory disease            -  Hemoptysis.\n",
      "-  Weight loss more than 10 kg in the 12 months prior to eligibility assessment            -\n",
      "Participation in other cancer clinical trial            -  Chest CT examination in the 12 months\n",
      "prior to eligibility assessment.\n",
      "\n",
      "üîπ Doc ID: NCT02500693  (Score: 12.0606)\n",
      "Circulating Tumor Cells in Lung Cancer Screening             This trial is intended to evaluate the\n",
      "value of circulating tumor cells (CTC), in       combination with unenhanced (without injection of\n",
      "contrast media) low dose (to limit the       effective radiation dose below 1,5 mSv) chest computed\n",
      "tomography (LDCT) in the screening of       Lung cancer (LC).        LDCT screening was shown to\n",
      "reduce LC mortality in smokers and ex-smokers, older than 55       years, with a history of more\n",
      "than 30 pack-years. LDCT however shows a close to 30% rate of       false positive that require\n",
      "repeat follow-up and also invasive investigations, but also       false negatives with metastatic LC\n",
      "being discovered between screening rounds.        Migration of circulating tumor cells (CTC) is an\n",
      "early event of carcinogenesis and       characterizes aggressive cancers. We recently showed that\n",
      "CTC can be detected with the ISET       technique in a population at high risk for LC, i.e. COPD\n",
      "patients before LC was detectable       on LDCT.        The study will focus on patients at very\n",
      "high risk for lung cancer i.e. smokers and       ex-smokers suffering Chronic Obstructive Pulmonary\n",
      "Disease (COPD).        The study will enroll 600 participants who will undergo three rounds of\n",
      "screening at one       year intervals, each round combining search for CTC on a blood sample and\n",
      "LDCT. Each       participant will be followed for at least one year after the last screening round\n",
      "Inclusion Criteria:            -  Age 55 years or more            -  30 or more pack-years of\n",
      "cigarette smoking history            -  Former smokers: quit smoking within the previous 15 years\n",
      "-  Signed informed consent form            -  Presence of COPD            -  Affiliation to the\n",
      "French social security system          Exclusion Criteria:            -  Chest CT examination in the\n",
      "12 months prior to eligibility assessment(1)            -  Treatment for, or evidence of, any cancer\n",
      "other than skin basocellular carcinoma in              the 5 years prior to eligibility assessment\n",
      "-  Pneumonia or acute respiratory infection treated with antibiotics in the 12 weeks\n",
      "prior to eligibility assessment            -  Unexplained weight loss of more than 15 10%pounds in\n",
      "the 12 months prior to              eligibility assessment            -  Recent hemoptysis\n",
      "-  History of lung volume reduction with coils, glue or valves¬∞            -  Metallic implants or\n",
      "devices in the chest or back, such as pacemakers or Harrington              fixation rods\n",
      "-  Participation in another cancer screening trial            -  Participation in a cancer\n",
      "prevention study, other than a smoking cessation study            -  Vulnerable persons: adults\n",
      "under guardianship, adults under trusteeship or persons              deprived of their liberty,\n",
      "patients under 18 years old            -  Medical and/or psychiatric problems of sufficient severity\n",
      "to limit full compliance              with the study or expose patients to undue risk\n",
      "1. Many COPD patients will have had a previous chest CT examination. This has\n",
      "become common in medical practice, especially in patients with chronic lung\n",
      "diseases such as COPD patients. Including such patients would introduce huge                   bias\n",
      "in the study by artificially focusing on rapidly growing cancers. Redoing a                   CT in\n",
      "a screening intend in a patient who recently underwent this investigation                   would\n",
      "also unnecessarily enhance irradiation in these patients. It should be                   note that\n",
      "in the NLST trial \"previous chest CT (‚â§ 18 months)\" was a key                   exclusion criterion\n",
      "[NLST Radiology 2011].\n",
      "\n",
      "üîπ Doc ID: NCT02194738  (Score: 12.0440)\n",
      "Genetic Testing in Screening Patients With Stage IB-IIIA Non-Small Cell Lung Cancer That Has Been or\n",
      "Will Be Removed by Surgery (The ALCHEMIST Screening Trial)             This research trial studies\n",
      "genetic testing in screening patients with stage IB-IIIA       non-small cell lung cancer that has\n",
      "been or will be removed by surgery. Studying the genes       in a patient's tumor cells may help\n",
      "doctors select the best treatment for patients that have       certain genetic changes.\n",
      "PRIMARY OBJECTIVES:        I. To centrally test resected non-small cell lung cancer (NSCLC) for\n",
      "genetic mutations to       facilitate accrual to randomized adjuvant studies.        II. To obtain\n",
      "clinically annotated tumor tissue and patient-matched non-malignant       deoxyribonucleic acid\n",
      "(DNA) from peripheral blood, as well as detailed epidemiologic and       clinical follow-up data, to\n",
      "allow clinically annotated advanced genomic analyses in concert       with the National Cancer\n",
      "Institute (NCI) Center for Cancer Genomics (CCG).        SECONDARY OBJECTIVES:        I. To\n",
      "characterize the natural history of molecularly characterized NSCLC to allow       subsequent\n",
      "development of targeted therapies against genotype-defined subpopulations in the       adjuvant and\n",
      "recurrent settings.        II. To cross-validate local genotyping assays for epidermal growth factor\n",
      "receptor (EGFR)       and anaplastic lymphoma receptor tyrosine kinase (ALK) with a central\n",
      "reference standard.        TERTIARY OBJECTIVES:        I. To study the genomic evolution of lung\n",
      "cancers by comparing genomic characteristics at       resection and at recurrence.        II. To\n",
      "understand reasons behind lack of enrollment to adjuvant targeted therapy studies for\n",
      "potentially eligible patients.        OUTLINE:        Patients undergo collection of blood and\n",
      "tissue samples for EGFR, ALK, and programmed cell       death protein 1 (PD-1)/programmed cell death\n",
      "ligand 1 (PD-L1)/cytotoxic       t-lymphocyte-associated protein 4 (CTLA-4) testing via direct\n",
      "sequencing, fluorescence in       situ hybridization (FISH) and immunohistochemistry (IHC). Patients\n",
      "that have had surgery       prior to pre-registration will submit samples from the previous surgery\n",
      "for testing.        After completion of study, patients that are not enrolled on either A081105,\n",
      "E4512, or       EA5142 are followed up every 6 months for 5 years.                         Inclusion\n",
      "Criteria:            -  PATIENT PRE-REGISTRATION ELIGIBILITY CRITERIA:            -  For pre-\n",
      "surgical patients                 -  Suspected diagnosis of resectable non-small cell lung cancer;\n",
      "patients with                   squamous cell carcinoma are eligible only if the registering site\n",
      "has EA5142                   institutional review board (IRB) approved                 -  Suspected\n",
      "clinical stage of IIIA, II or large IB (defined as size >= 4cm)            -  For post-surgical\n",
      "patients                 -  Completely resected non-small cell lung cancer; patients with squamous\n",
      "cell                   carcinoma are eligible only if the registering site has EA5142 IRB approved\n",
      "-  Pathologic stage IIIA, II or IB (defined as size >= 4 cm)            -  Eastern Cooperative\n",
      "Oncology Group (ECOG) performance status 0-1            -  No patients who have received neoadjuvant\n",
      "therapy (chemo- or radio-therapy) for this              lung cancer            -  No prior or\n",
      "concurrent malignancies within 5 years, except non-melanoma skin              carcinoma or in situ\n",
      "carcinomas; a secondary primary lung cancer is considered a              concurrent malignancy and\n",
      "would make a patient ineligible for A151216            -  No prior treatment with agents targeting\n",
      "EGFR mutation, ALK rearrangement, and              PD-1/PD-L1/CTLA-4            -  No patients known\n",
      "to be pregnant or lactating            -  Patients who have had local genotyping are eligible,\n",
      "regardless of the local result            -  No patients with recurrence of lung cancer after prior\n",
      "resection            -  Note: Post-surgical patients should proceed to registration immediately\n",
      "following              preregistration            -  PATIENT REGISTRATION ELIGIBILITY CRITERIA:\n",
      "-  Completely resected NSCLC; patients with squamous cell carcinoma are eligible only if\n",
      "the registering site has EA5142 IRB approved            -  Pathologic stage IIIA, II, or large IB\n",
      "(defined as size >= 4 cm)            -  Tissue available for the required analyses            -  In\n",
      "order to allow for time for central genotyping and eligibility for the ALCHEMIST\n",
      "treatment trial, patients must register within the following eligibility windows,\n",
      "depending on the adjuvant treatment approach:                 -  If no adjuvant therapy, register\n",
      "patient within 75 days following surgery                 -  If adjuvant chemotherapy only, register\n",
      "patient within 225 days following                   surgery                 -  If adjuvant\n",
      "chemotherapy and radiation, register patient within 285 days                   following surgery\n",
      "\n",
      "\n",
      "üîç Query: Am I eligible for this study?\n",
      "\n",
      "üîπ Doc ID: NCT02244437  (Score: 18.2703)\n",
      "Ibuprofen vs Acetaminophen for AMS Prevention             AMS (acute mountain sickness) affects\n",
      "those who ascend too high (>2000m) too fast.       Acetazolamide is an effective drug for the\n",
      "prevention of AMS where proper acclimatization       with gradual ascent may not be an option. AMS\n",
      "presents with headache and other non-specific       symptoms such as nausea, tiredness, and\n",
      "dizziness. Because of the side effects of       acetazolamide such as a tingling sensation, other\n",
      "drugs have been investigated to see if       they will prevent AMS. Ibuprofen has recently been\n",
      "shown to prevent AMS. In this present       study the investigators want to see if acetaminophen can\n",
      "also prevent AMS as acetaminophen       unlike ibuprofen does not have gastric side effects. Second,\n",
      "because acetaminophen has much       less anti-inflammatory component than ibuprofen, it may also\n",
      "provide some insight into the       pathophysiology of AMS if acetaminophen were found to be\n",
      "effective in the prevention of AMS.                     Acute mountain sickness (AMS) is a well-\n",
      "known disorder in sojourners to high altitude       (>2000m) characterized by headache, nausea and\n",
      "tiredness, akin to hangover-like symptoms.       The Lake Louise criteria for AMS was primarily\n",
      "developed to allow uniformity in comparing       the prevalence of AMS in different high altitude\n",
      "regions.        Proper acclimatization by gradual ascent to high altitude is the best means of\n",
      "prevention of       AMS. However there may be instances when rapid ascents may be necessary.\n",
      "Acetazolamide is       the best known drug for the prevention of AMS. Because of its well-known side\n",
      "effects like       tingling sensation in the fingers and toes and its potential sulpha allergy\n",
      "(acetazolamide       is a sulpha-based drug) problems, alternative drugs in the prevention of AMS\n",
      "have been       sought. Recently two randomized controlled trials have shown the usefulness of\n",
      "ibuprofen 600       mg tid orally in the prevention of AMS.        The exact mechanism causing AMS\n",
      "is unknown although evidence points to a process in the       central nervous system. The mechanism\n",
      "of headache, the main feature in most AMS patients, is       probably multifactorial with various\n",
      "chemical and mechanical factors activating a final       common pathway, the trigeminovascular\n",
      "system. Triggering factors associated with high       altitude hypoxia leading to AMS may include\n",
      "arachidonic acid metabolites amongst others such       as serotonin, histamine, and nitric oxide.\n",
      "The response in AMS prevention to non-steroidal       anti-inflammatory drugs (NSAIDs) and steroids\n",
      "provides indirect evidence of arachidonic acid       pathway and inflammation in the genesis of AMS.\n",
      "But in contrast, the role of drugs such as acetaminophen which primarily provide analgesia       by\n",
      "blunting the meningovascular receptors known to mediate nociception is unknown in the\n",
      "prevention of AMS. Crucially if acetaminophen can prevent AMS the gastric irritation and\n",
      "possible gastrointestinal bleeding which are well known side effects of ibuprofen would not       be\n",
      "encountered. In addition acetaminophen like ibuprofen and (unlike acetazolamide) is       easily\n",
      "available over the counter.        Therefore, the investigators hypothesize that acetaminophen in\n",
      "adequate dosage ( 1 g tid)       will be as effective as ibuprofen ( 600 mg tid) in the prevention\n",
      "of AMS.        Western trekkers will be randomly administered either acetaminophen or ibuprofen in a\n",
      "double       blind fashion at 4300m where the investigators will enroll the participants. Then, at\n",
      "5000 m       at Lobuje after 48 to 96 hours the investigators will re-examine with the Lake Louise\n",
      "Questionnaire (LLQ) to see their AMS status. The investigators will also check the pulse\n",
      "oximeter.        Sample Size:        With a variable alpha 5%, power 80%, control 34% (based on\n",
      "previous studies) and       experimental group 18%, the sample size arrived at (using\n",
      "http://www.sealedenvelope.com/power/binary-superiority/ ) was 115 per arm, a total of 230\n",
      "participants. With a 20 % drop out the final number the investigators require is 288\n",
      "participants.                         Inclusion Criteria:            -  Healthy subjects between the\n",
      "ages of 18 and 65, male or female, non-Nepali, without              AMS or any concurrent illness,\n",
      "and not already taking NSAIDs and acetazolamide or any              other drug for the prevention of\n",
      "altitude illness. Subjects will be enrolled by study              administrators en route directly\n",
      "to Everest Base Camp or Kala Patthar between the              villages of Pheriche/Dingboche and\n",
      "Lobuche.          Exclusion Criteria:            -  Individuals not meeting inclusion criteria,\n",
      "including mild AMS (more than one mild              symptom on the Lake Louise Questionnaire) or\n",
      "significantly depressed oxygen              saturation (<75%); females known to be pregnant, cannot\n",
      "exclude the possibility of              being pregnant, or have missed menses by over 7 days;\n",
      "individuals who have spent 24              hours at an altitude of 4500 meters/14,000 feet within\n",
      "the last 9 days; anyone known              to have taken any of the following in the last 2 days:\n",
      "acetazolamide (Diamox¬Æ),              steroids (dexamethasone, prednisone), theophylline, or\n",
      "diuretics (Lasix¬Æ);              individuals who have a known intracranial space occupying lesion or\n",
      "a history of              elevated intracranial pressure, (i.e. tumors, hydrocephalus, etc).\n",
      "\n",
      "üîπ Doc ID: NCT01522326  (Score: 18.1279)\n",
      "Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness\n",
      "The objective of this study is to determine the efficacy of metoclopramide in relieving the\n",
      "symptoms of Acute Mountain Sickness (AMS).        It is our hypothesis that the combined antiemetic\n",
      "and analgesic effects of metoclopramide       (which has been study-proven to be effective in\n",
      "relieving symptoms of migraine headache)       will prove to be more efficacious in relieving\n",
      "symptoms of acute mountain sickness than the       standard, previously-studied analgesic\n",
      "medication, ibuprofen.                     Acute Mountain Sickness (AMS) is a well described disease\n",
      "process that occurs as a result of       rapid exposure to high altitude. High altitude headache\n",
      "(HAH) is defined as the presence of       headache in the setting of a recent increase in altitude.\n",
      "When HAH is associated with       nausea, vomiting, fatigue, weakness, dizziness, lightheadedness or\n",
      "poor sleeping, AMS is       diagnosed. While benign, AMS is very common, afflicting up to 80 % of\n",
      "travelers who ascend       rapidly to 14,000 ft, and can be debilitating. AMS is thought to occur\n",
      "secondary to       hypoxia-induced cerebral vasodilation. The antiemetic metoclopramide has been\n",
      "well studied       and is commonly administered for treatment of migraine headaches in emergency\n",
      "departments       across the U.S. The symptoms of migraine headaches are often similar to those of\n",
      "AMS. The       mechanism of metoclopramide‚Äüs beneficial effect in this indication appear to be a\n",
      "result of       its antagonism of central and peripheral dopamine receptors,most notably by blocking\n",
      "stimulation of the medullary chemoreceptor trigger zone. No studies have yet evaluated the\n",
      "potential benefits of metoclopramide for the relief of AMS. In contrast, ibuprofen has been\n",
      "well studied and found to be an effective treatment for the relief of symptoms of high\n",
      "altitude headache and AMS.        The study will be a convenience sample of trekkers traveling\n",
      "through the Annapurna Circuit       in Nepal during the 3 month time period of March-May, 2012.\n",
      "Subjects will be recruited from       visitors to Manang, Nepal staying in local hostels, those\n",
      "visiting the Himalayan Rescue       Association clinic in Manang, and those responding to locally\n",
      "posted signage regarding study       enrollment.        Eligible patients will be consented and\n",
      "enrolled in the study. Patients will be randomized       to receive either Ibuprofen 400mg or\n",
      "Metoclopramide 10mg by mouth. Investigators will be       blinded as to which arm of the study the\n",
      "patient is enrolled. Participants will be assessed       by Lake Louise Score and Visual Analog\n",
      "Scale for headache and nausea severity immediately       prior to ingestion of study medication, and\n",
      "then serially at 30, 60, and 120 minutes       following medication ingestion. Standard statistical\n",
      "analysis of the Lake Louise AMS scores       and visual analog scales will be used to determine\n",
      "which medication is more effective in       treating acute mountain sickness.\n",
      "Inclusion Criteria:            -  Presence at Manang recruitment center (at approximately 11,500 ft)\n",
      "during the dates              March through May, 2012.            -  Recent increase in altitude of\n",
      "> 1000 ft vertical in last 24 hours            -  Presence of headache and at least one other\n",
      "symptom required for diagnosis of acute              mountain sickness (including nausea, vomiting,\n",
      "fatigue, weakness, dizziness,              lightheadedness or poor sleeping.)          Exclusion\n",
      "Criteria:            -  Age less than 19 years old            -  Known allergy or contraindication\n",
      "to either ibuprofen or metoclopramide            -  Evidence of severe high altitude illness (e.g.\n",
      "High altitude pulmonary edema (HAPE)              as evidenced by dyspnea at rest -- or of High\n",
      "Altitude Cerebral Edema (HACE) as              evidenced by altered mental status or ataxia)\n",
      "-  Known or suspected pregnancy            -  Use of other analgesic or antiemetic within 8 hours of\n",
      "study enrollment            -  History of migraines or other chronic headache disorders            -\n",
      "Inability to provide informed consent\n",
      "\n",
      "üîπ Doc ID: NCT00388947  (Score: 16.9371)\n",
      "Observational Data Collection of Surgical Outcomes in the Treatment of Vaginal Prolapse With AMS\n",
      "Products             This registry was observational (only collected information typically noted by\n",
      "the surgeon       when their patients were routinely seen); there was no change to the care the\n",
      "patient       received as a result of being part of the registry). Data collection focused on the\n",
      "surgical       outcomes of AMS prolapse products.                     The Prolapse Registry was an\n",
      "observational study of patients who were implanted with AMS       devices for the surgical repair of\n",
      "female pelvic prolapse. The registry followed patients       post-operatively for up to 2 years and\n",
      "collected demographic, clinical, surgical, safety,       and patient outcomes data.        The\n",
      "registry was a web-based system in which surgeons entered patient information with       regard to\n",
      "their prolapse surgery. All information entered was de-identified (no names, no       date of birth,\n",
      "no date of surgery, etc).                         Inclusion Criteria:            -  Female at least\n",
      "21 years old            -  Has pelvic organ prolapse requiring surgical repair            -\n",
      "Receives at least one of the AMS Prolapse Repair devices in the treatment of their\n",
      "pelvic organ prolapse          Exclusion Criteria:            -  Is contraindicated for an AMS\n",
      "Prolapse Repair per the product's Instruction for Use.\n",
      "\n",
      "üîπ Doc ID: NCT01671475  (Score: 16.8164)\n",
      "Putting Electroencephalography (EEG) in the Emergency Department             The proposed study aims\n",
      "to test the impact of microEEG on clinical management (diagnosis and       treatment) of emergency\n",
      "department patients with Altered Mental Status (AMS). The study will       utilize a portable,\n",
      "wireless, FDA-approved device (microEEG) as the intervention. Patients       will be randomized to\n",
      "routine care plus microEEG (experimental arm) or routine care alone       (control arm). The\n",
      "investigators hypothesize that incorporating microEEG in the work up of       patients with AMS will\n",
      "impact the clinical management of these patients.                     Approximately, 4% and 10% of\n",
      "emergency department (ED) patients in the United States present       with altered mental status\n",
      "(AMS). According to previous studies, close to 30% of AMS cases       occur due to neurological\n",
      "etiologies. Among these pathologies are non-convulsive seizures       (NCS) and non-convulsive\n",
      "status epilepticus (NCSE). In our previous study, the investigators       established that\n",
      "approximately 4% (95% confidence interval, 2-8%) of ED patients with AMS       suffer from NCS and\n",
      "NCSE. Our study also revealed that 78% of the ED patient with AMS have       some form of EEG\n",
      "abnormality.        NCS and NCSE are difficult to diagnose especially in AMS patients because\n",
      "performing a       thorough physical examination or obtaining medical history is often impossible in\n",
      "altered       patients. Definitive diagnosis of NCS/NCSE requires electroencephalography (EEG), a\n",
      "test       that records brain electrical activity and provides information about the brain function.\n",
      "Unfortunately, obtaining an EEG in the ED can be challenging. This requires transporting an\n",
      "EEG machine to patient's bedside, where space limitations and presence of variety of       monitors\n",
      "and devices, especially in over-crowded EDs render this practice difficult. In many\n",
      "institutions an EEG service is not offered after work hours due to the unavailability of       24/7\n",
      "EEG technologist coverage and real-time electroencephalographer interpretation. As a       result of\n",
      "the aforementioned limitations, ED physicians may refrain from ordering EEG.        The wireless\n",
      "portable EEG device (microEEG) designed by the Bio-Signal Group was designed to       address these\n",
      "limitations. With minimal training, ED personnel could use this small,       microEEG device to\n",
      "obtain an EEG. The recording then can be wirelessly transmitted to a host       computer via a\n",
      "secure network connection to the neurology experts who could interpret the       EEG. Incorporating\n",
      "microEEG in the initial workup of patients with AMS could help the ED       attending rule out\n",
      "NCS/NCSE and focus on other diagnoses. Alternatively, if the presence of       NCS is confirmed by\n",
      "EEG, the treatment could be initiated early and potentially reduce       morbidity or mortality.\n",
      "The investigators hypothesize that incorporating EEG in the work of ED patients with AMS       could\n",
      "impact the management(diagnosis and treatment)of these patients and influence their       clinical\n",
      "outcome.        Sample size: Our sample size analysis using data one published related study reveled\n",
      "that       the study would need 65 patients in each group (total n:130). However, the investigators\n",
      "plan to perform an interim analysis after enrolling half of this target sample and adjust       the\n",
      "sample size calculation based on the collected data if necessary.                         Inclusion\n",
      "Criteria:          ED patients ‚â• 18 years old with AMS.          Exclusion Criteria:            1.\n",
      "Patients with apparent and immediately correctable cause of AMS (determined by ED\n",
      "attending during initial evaluation) that include:                 -  Fingerstick or serum glucose\n",
      "less than 60mg/dl                 -  Hypothermia (Hypothermia is defined as any body temperature\n",
      "below 35.0 C [95.0                   F]).                 -  Hyperthermia, heat exhaustion or heat\n",
      "stroke                 -  Opioid overdose responding to Narcan.            2. Patients who cannot\n",
      "undergo EEG recordings for any reason (e.g. severe scalp injury).            3. Hemodynamically\n",
      "unstable patients(SBP <90mm Hg)            4. Patients who are uncooperative or combative.\n",
      "5. Patients transferred out of ED before enrollment.            6. Patients with obvious tonic-\n",
      "clonic or focal seizures in the ED.          Note: Patients with hypoglycemia who do not return to\n",
      "their baseline level of mental         status within 30 minutes of correcting their blood glucose\n",
      "level, will be enrolled.         Similarly, patients who had an obvious seizure in the ED but do not\n",
      "return to their         baseline mental status within 15 minutes will also be enrolled.\n",
      "\n",
      "üîπ Doc ID: NCT02596347  (Score: 16.7821)\n",
      "The Role of JAK2 in Alveolar Macrophages (AM's) in Chronic Beryllium Disease (CBD)\n",
      "Current studies suggest that alveolar macrophages (AM) act as silencers of most immune\n",
      "responses in the lung. However, in pathological conditions, such as asthma, hypersensitivity\n",
      "pneumonitis, and sarcoidosis, AMs become involved in the maintenance and further expansion       of\n",
      "the immune response in the target organ. The Investigator has preliminary data       demonstrating\n",
      "that CBD AMs at the site of disease involvement (bronchoalveolar lavage, BAL)       display an\n",
      "activated cell surface phenotype compared to AMs from healthy controls.       Furthermore, exciting\n",
      "data from our group demonstrates significant differences in gene       expression profiles between\n",
      "CBD and Beryllium Sensitivity (BeS) bronchial alveolar lavage       (BAL) cells, in pivotal immune\n",
      "response genes and networks. Specifically, the Investigator       has found the JAK/STAT pathway and\n",
      "the JAK2 gene was dramatically overexpressed in CBD BAL       cells. In addition, constitutively\n",
      "phosphorylated JAK2 (pJAK2) was found in AMs from Chronic       Beryllium Disease (CBD) patients by\n",
      "Westernblot and was increased after beryllium (Be)       stimulation for 30 min. Moreover, the JAK2\n",
      "inhibitor TG101348 significantly inhibited       Be-induced CBD AMs TNFa and IFNy production.\n",
      "Meanwhile, overexpression of the JAK2 inhibitor       SOCS 1 (suppressors of cytokine signaling)\n",
      "protein decreased Be-induced TNFa production from       AMs. Based on this information, the\n",
      "Investigator hypothesizes that CBD AMs overexpress JAK2,       which augments the immune response to\n",
      "Be and development of CBD but not BeS.        The investigators believe that these studies are\n",
      "highly innovative since they will       undoubtedly shed light on exposure-mediated immune\n",
      "dysregulation in Alveolar Macrophages       (AMs) that lead to disease development and likely\n",
      "progression and with additional study of       this pathway will reveal potential biomarkers for\n",
      "clinical prognosis and diagnosis. The       results obtained from this study will improve the\n",
      "investigators understanding of factors       involved in the development of Chronic Beryllium\n",
      "disease (CBD), as well as define targets       for therapy, and will serve as a model of other\n",
      "exposure-related immune responses and       environmentally-induced chronic diseases. Most\n",
      "importantly, these studies will provide the       investigator with preliminary data to submit a\n",
      "high quality R01, allowing the Investigator       to apply similar approaches to other genes, define\n",
      "a potential target for this and other       similar immune-mediated diseases and continue research\n",
      "efforts at National Jewish Health       (NJH.)                          Inclusion Criteria:\n",
      "-  Chronic Beryllium Disease - These individuals will meet the following inclusion\n",
      "criteria:          Inclusion Criteria:            1. History of beryllium exposure;            2.\n",
      "Positive blood and/or bronchoalveolar lavage (BAL) Beryllium Lymphocyte Proliferation\n",
      "Tests (BeLPT);            3. Biopsy-proven pathologic changes consistent with CBD, specifically non-\n",
      "caseating              granulomas and/or mononuclear cell interstitial infiltrates .\n",
      "Beryllium Sensitization - These individuals will meet the following inclusion criteria:\n",
      "Inclusion Criteria:            1. History of beryllium exposure;            2. Two or more positive\n",
      "blood beryllium lymphocyte proliferation tests (BeLPT) or              positive bronchoalveolar\n",
      "lavage (BAL) BeLPT;            3. Normal lung tissue (no histology suggestive of CBD).\n",
      "Exclusion Criteria:\n",
      "\n",
      "==============================\n",
      "üß™ TRIAL DESIGN\n",
      "==============================\n",
      "\n",
      "üîç Query: How is the study structured?\n",
      "\n",
      "üîπ Doc ID: NCT01797965  (Score: 6.8391)\n",
      "Long-Term Extension Study in Participants With Multiple Sclerosis Who Have Completed Study 205MS301\n",
      "(NCT01064401) to Evaluate the Safety and Efficacy of BIIB019             The primary objective of\n",
      "the study is to assess the safety and tolerability of long-term       treatment with BIIB019\n",
      "(Daclizumab High Yield Process; DAC HYP) monotherapy in participants       with relapsing remitting\n",
      "multiple sclerosis (RRMS) who completed Study 205MS301       (NCT01064401), Study 205MS203\n",
      "(NCT01051349) or Study 205MS302 (NCT01462318).        Secondary objectives of this study in this\n",
      "study population are as follows:        To describe MS-related outcomes, including MS relapse,\n",
      "disability progression, MS lesion       formation, and participant-reported impact of MS, following\n",
      "long-term treatment with DAC HYP       To assess the long-term immunogenicity of DAC HYP\n",
      "administered by prefilled syringe (PFS) To       assess the safety, tolerability, and efficacy of\n",
      "switching to DAC HYP in participants       previously on long-term treatment with interferon Œ≤-1a\n",
      "(Avonex) in Study       205MS301(NCT01064401).                     Enrollment will include up to\n",
      "1600 Participants, this includes approximately 1200       Participants who completed Study 205MS301\n",
      "(NCT01064401). Additionally, approximately 400       Participants from the other BIIB019 extension\n",
      "studies 205MS203 (NCT01051349) and 205MS302       (NCT01462318) will be eligible to enter Study\n",
      "205MS303 at Week 144 of Study 205MS303 [Study       205MS301 (NCT01064401), study 205MS203\n",
      "(NCT01051349) and study 205MS302 (NCT01462318) have       been referred to as parent studies in the\n",
      "protocol]. All Participants will receive the same       dose of DAC HYP as received in the parent\n",
      "studies; i.e., 150 mg by an SC injection every 4       weeks. The duration of DAC HYP treatment is\n",
      "up to approximately 5 years, or until       availability of commercial product (whichever is\n",
      "sooner).                         Key Inclusion Criteria:            -  Must be a subject currently\n",
      "participating in Study 205MS301 (NCT01064401), or subject              currently participating in\n",
      "Study 205MS203 (NCT01051349) or Study 205MS302              (NCT01462318) who has completed End of\n",
      "Study Visit (Week 96 or later).            -  Women of childbearing potential must practice\n",
      "effective contraception during the              study and be willing and able to continue\n",
      "contraception for 4 months after their last              dose of study treatment.          Key\n",
      "Exclusion Criteria:            -  Any subject who permanently discontinued study treatment in Study\n",
      "205MS301              (NCT01064401), Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318)\n",
      "prior to              the end of the study treatment period, or had an Early Termination visit in\n",
      "Study              205MS301, Study 205MS203 (NCT01051349) or Study 205MS302 (NCT01462318).\n",
      "-  Any significant change in the subject's medical history that would preclude\n",
      "administration of BIIB019, including laboratory tests or a current clinically\n",
      "significant condition that, in the opinion of the Investigator, would have excluded              the\n",
      "subject's participation in Study 205MS301 (NCT01064401), Study 205MS203              (NCT01051349)\n",
      "or Study 205MS302 (NCT01462318).          The Investigator must re review the subject's medical\n",
      "fitness for participation and         consider any factors that would preclude treatment in this\n",
      "Study 205MS303.          NOTE: Other protocol-defined inclusion/exclusion criteria may apply.\n",
      "\n",
      "üîπ Doc ID: NCT00586495  (Score: 6.8201)\n",
      "Long-term Extension From RCC Phase II (11515)             Extension to study 11515 (NCT00661375)\n",
      "which was a multicenter study of sorafenib in       patients with renal cell carcinoma (RCC).\n",
      "Inclusion Criteria:          Patients are classified into two groups as below at transition date\n",
      "from Study 11515 to         this study.          Population I: Patients who are willing to continue\n",
      "the study drug, for whom the         investigator consider continuation of the study drug is\n",
      "appropriate, and who do not meet         the criteria of removal from the study in Study 11515 at\n",
      "the end of Study 11515.          Population II: Patients who have been monitored only for survival\n",
      "status at the end of         Study 11515.          Population 1            1. Patients who are\n",
      "willing to continue the study drug,            2. Patients for whom the investigator consider\n",
      "continuation of the study drug is              appropriate            3. Patients who do not meet\n",
      "the criteria of removal from the study in Study 11515 at the              end of Study 11515.\n",
      "4. Patients who give written informed consent prior to any study specific screening\n",
      "procedures with the understanding that the patient has the right to withdraw from the\n",
      "study at any time, without prejudice.          Population 2          1. Patients who give written\n",
      "informed consent prior to any study specific screening         procedures with the understanding\n",
      "that the patient has the right to withdraw from the         study at any time, without prejudice.\n",
      "Exclusion Criteria:            1. Substance abuse, medical, psychological or social conditions that\n",
      "may interfere with              the patient's participation in the study or evaluation of the study\n",
      "results            2. Any condition that could jeopardize the safety of the patient or that affect\n",
      "his/her              compliance in the study            3. Pregnant or breast-feeding patients. Both\n",
      "men and women enrolled in this trial must              use adequate birth control.\n",
      "\n",
      "üîπ Doc ID: NCT01634282  (Score: 6.8107)\n",
      "Along-term Study of OPC-262 in Patients With Type 2 Diabetes             The purpose of this\n",
      "clinical study is to evaluate the safety of OPC-262 (2.5 mg and 5 mg) in       patients with type 2\n",
      "diabetes by long-term administration orally for 52 weeks and to       evaluate the efficacy of\n",
      "OPC-262                          Inclusion Criteria:            -  Patients who completed Study\n",
      "262-09-001 (namely, patients who visited the hospital at              visit Week 24Ôºâ            -\n",
      "Patients who are capable of giving informed consent prior to participating in this\n",
      "clinical study            -  Patients who are able to take contraceptive measures to avoid pregnancy\n",
      "of the              patient or the patient's partner for the entire study period and for 4 weeks\n",
      "after              the study (end of the post-observation period)          Exclusion Criteria:\n",
      "-  Patients who withdrew from Study 262-09-001            -  Patients who experienced serious\n",
      "adverse events that the relationship with the study              drug was not denied in Study\n",
      "262-09-001            -  Patients who experienced serious adverse events that the relationship with\n",
      "the study              drug are denied in Study 262-09-001 and whose symptoms are still emerged at\n",
      "the time              of initiation of this study            -  Patients who met the exclusion\n",
      "criteria of Study 262-09-001 during the study period              of Study 262-09-001            -\n",
      "Female patients who wish to become pregnant during the study period of Study              262-09-002\n",
      "or within 4 weeks after the study            -  Patients otherwise judged by the investigator or\n",
      "subinvestigator to be inappropriate              for inclusion in the study\n",
      "\n",
      "üîπ Doc ID: NCT00142298  (Score: 6.8053)\n",
      "Telbivudine in Adults Previously Treated in Idenix-Sponsored Telbivudine Studies             This\n",
      "trial is being conducted as an open-label, extended-term study for patients with       chronic\n",
      "hepatitis B who have previously completed an Idenix-sponsored trial with       telbivudine.\n",
      "Patients from 6 feeder trials could be eligible to enter current study CLDT600A2303 (\n",
      "NCT00142298) if they met inclusion/exclusion criteria. The feeder studies were as follows:\n",
      "-  CLDT600A2302 (NV-02B-007)(NCT00057265), the GLOBE study, was a Phase III, randomized,\n",
      "doubleblind,multi-center, 104-week, pivotal study of telbivudine vs. lamivudine in\n",
      "treatment of na√Øve patients with compensated chronic hepatitis B.            CLDT600A2302/NV-02B-007\n",
      "(NCT00057265) is hereafter referred to as study 2302.          -  NV-02B-015 (NCT00131742) was a\n",
      "Phase III, randomized, double-blind, 104-week study            comparing the efficacy and safety of\n",
      "telbivudine (600 mg/day) to lamivudine (100            mg/day) in treatment of na√Øve Chinese\n",
      "patients with compensated chronic hepatitis B.            NV-02B-015 (NCT00131742) is hereafter\n",
      "referred to as study 015.          -  CLDT600A2301 (NV-02B-011)(NCT00076336) was a Phase III,\n",
      "randomized double-blind,            multi-center, 104-week, pivotal study of telbivudine (600\n",
      "mg/day) vs. lamivudine (100            mg/day) in treatment-na√Øve adults with decompensated chronic\n",
      "hepatitis B.            CLDT600A2301/NV-02B-011 (NCT00076336) is hereafter referred to as study\n",
      "2301.          -  NV-02B-010 (NCT00124241) was a Phase IIb, 104-week extension study of telbivudine,\n",
      "lamivudine or the combination of both agents in patients with chronic hepatitis B who            had\n",
      "completed the core study NV-02B-003 (NCT00124241). NV-02B-010 (NCT00124241) is            hereafter\n",
      "referred to as study 010.        NV-02B-003 (NCT00124241) was a Phase IIa, 52-week study of\n",
      "telbivudine, lamivudine or the       combination of both agents in patients with HBeAg-positive\n",
      "chronic hepatitis B.          -  CLDT600A2401 (NV-02B-018) (NCT00115245) was a Phase IIIb,\n",
      "randomized, open-label,            multi-center,52-week study of telbivudine vs. adefovir dipivoxil\n",
      "for 24 weeks then a            switch to telbivudine for another 28 weeks in treatment-na√Øve\n",
      "patients with compensated            chronic hepatitis B. CLDT600A2401/NV-02B-018 (NCT00115245) is\n",
      "hereafter referred to as            study 2401.          -  CLDT600A2402 (NV-02B-019) (NCT00132652)\n",
      "was a Phase IIIb, randomized, open-label,            multi-center, 52-week study of switching\n",
      "lamivudine to telbivudine vs. continued on            lamivudine treatment in adults with\n",
      "compensated chronic hepatitis B who were previously            treated with lamivudine for 3-12\n",
      "months. CLDT600A2402/NV-02-019 (NCT00132652) is            hereafter referred to as study 2402.\n",
      "PATIENT GROUPS:        GROUP A: Patients with HBeAg (+) or HBeAg (-) compensated chronic hepatitis B\n",
      "who did not       discontinue treatment in their previous study due to an efficacy response and\n",
      "required       further treatment or who had met the criteria for discontinuation of treatment in\n",
      "their       previous study due to efficacy, but were being maintained on study drug by the principal\n",
      "investigator. For patients treated with telbivudine who enrolled into Group A from studies\n",
      "2302 and 015, the total telbivudine treatment time (starting from feeder study baseline to       the\n",
      "end of the on-treatment period in study 2303) was 208 weeks. For patients treated with\n",
      "lamivudine in studies 2302/015 and enrolled into group A and for all patients in group A       from\n",
      "studies 2401/2402/010, the total telbivudine treatment time was 104 weeks.        GROUP B: Patients\n",
      "with HBeAg (+) or HBeAg (-) decompensated chronic hepatitis B who did not       discontinue\n",
      "treatment in their previous study due to an efficacy response and required       further treatment.\n",
      "Patients treated with telbivudine in study 2301 were enrolled to group B       and the total\n",
      "telbivudine treatment time (starting from feeder study baseline to the end of       the on-treatment\n",
      "period in study 2303) was 208 weeks. For patients treated with lamivudine       in study 2301 and\n",
      "enrolled into group B, the total telbivudine treatment time was 104 weeks.        GROUP C: Patients\n",
      "with either compensated or decompensated chronic hepatitis B, who had       discontinued study drug\n",
      "treatment in their previous Idenix-sponsored study due to an       efficacy response as recommended\n",
      "by protocol. Patients who were eligible for treatment       discontinuation in their previous study\n",
      "but who were, at the principal investigators       discretion, continued on study therapy, were\n",
      "eligible to enter this study in Group C       provided their treatment was discontinued at their\n",
      "last visit of the previous study. The       feeder studies for group C of current study were study\n",
      "2302/015, 2401, 2402, and 010. For       patients who enrolled into group C, total telbivudine\n",
      "treatment time was 104 weeks starting       from the baseline of the feeder studies to their last\n",
      "visit of the feeder studies. Patients       were enrolled to current study (study 2303) for off-\n",
      "treatment follow-up after the treatment       discontinuation due to efficacy. Hence, patients did\n",
      "not receive any study drug except in       case of patients who relapsed and reinitiated treatment.\n",
      "Inclusion Criteria:            -  Patient completed a previous qualifying Idenix-Sponsored trial\n",
      "with telbivudine            -  Patient was not discontinued from previous Idenix-Sponsored study\n",
      "Other protocol-defined inclusion criteria may apply          Exclusion Criteria:            -\n",
      "Patient is pregnant or breastfeeding            -  Patient is co-infected with hepatitis C,\n",
      "hepatitis D or HIV          Other protocol-defined exclusion criteria may apply\n",
      "\n",
      "üîπ Doc ID: NCT01724346  (Score: 6.8026)\n",
      "Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small\n",
      "Lymphocytic Lymphoma             An Open-label Extension Study in Patients 65 Years or Older with\n",
      "Chronic Lymphocytic       Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Who Participated in\n",
      "Study PCYC-1115-CA       (PCI-32765 versus Chlorambucil)                     Study PCYC-1116-CA is\n",
      "an open-label, multicenter extension of Study PCYC 1115-CA       (RESONATE‚Ñ¢-2, the parent study),\n",
      "and it will run concurrently with the parent study. A       patient will be transferred to\n",
      "PCYC-1116-CA after Independent Review Committee (IRC)       confirmation of disease progression (PD)\n",
      "in the parent study or at closure of the parent       study by the sponsor, whichever comes first.\n",
      "After PD, selection of second-line therapy, when clinically indicated, is at the discretion       of\n",
      "the investigator and can include second-line PCI-32765 (for patients randomized to\n",
      "chlorambucil in the parent study who also meet the criteria for second-line PCI-32765\n",
      "therapy), second-line chlorambucil (for patients randomized to PCI-32765 in the parent       study),\n",
      "or other therapies.        Assessments in the extension study vary depending on the treatment to\n",
      "which the patient was       randomized in the parent study, the disease-progression status at\n",
      "transfer to the extension       study, and the planned treatment in the extension study.\n",
      "Inclusion Criteria:            1. Randomized in the parent study, PCYC-1115-CA            2.\n",
      "Informed consent for Study PCYC-1116-CA            3. IRC-confirmed PD in the parent study\n",
      "PCYC-1115-CA or closure of the parent study          Exclusion Criteria:\n",
      "\n",
      "\n",
      "üîç Query: What is the primary endpoint of the trial?\n",
      "\n",
      "üîπ Doc ID: NCT01795729  (Score: 7.9812)\n",
      "Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a\n",
      "Clinical Event Reduction             The aim of the study is to compare optimal medical therapy\n",
      "alone versus percutaneous       coronary intervention on top of medical therapy in the setting of\n",
      "heart transplant recipient       coronary artery disease in a randomized trial.The primary endpoint\n",
      "assessed at 1 year is the       composite of death, myocardial infarction, need for transitory or\n",
      "permanent ventricular       assist device implantation, myocardial revascularization, occurrence or\n",
      "worsening of heart       failure, any graft dysfunction and/or a decrease of left ventricular\n",
      "ejection fraction of at       least 25% compared to baseline. The hypothesis of the study is the\n",
      "superiority of the       interventional management over medical therapy alone in preventing the\n",
      "occurrence of the       primary endpoint of the study.                     The hypothesis of the\n",
      "study is the superiority of the interventional management over medical       therapy alone in\n",
      "preventing the occurrence of the primary endpoint of the study assessed 1       year after\n",
      "randomization.        Objectives: To demonstrate the superiority of the interventional management on\n",
      "top of       optimal medical therapy over optimal medical therapy alone in preventing the occurrence\n",
      "of       the primary endpoint of the study assessed 1 year after randomization        Design :\n",
      "Multicenter, prospective randomized 1 :1, open-label blinded endpoint study        Target population\n",
      ": Heart transplant recipients, aged ‚â•18 years, without coronary artery       disease-related\n",
      "symptoms, with angiographically significant coronary artery stenoses (‚â•50%       anatomically\n",
      "adequate for a revascularization by coronary angioplasty with stent       implantation, with no\n",
      "contraindication to dual antiplatelet therapy associating aspirin and       a P2Y12 inhibitorfor a\n",
      "duration of 12 monthsand with ni grade IA ACC/AHA indication for       revascularization\n",
      "Inclusion period: 12 months (may be extended based on the inclusion rythme)        Maximum duration\n",
      "of participation for patients : 13 months        Total duration of the study : 37 months\n",
      "Primary endpoint : The composit of death, myocardial infarction, retransplantation,\n",
      "implantation of transitory or definitve ventricular assist devices, new or worsening heart\n",
      "failure, graft failure and/or a decrease of left ventricular ejection fraction of at least       25%\n",
      "compared to baseline.The occurrence of any event qualifying for the primary endpoint       will be\n",
      "assessed by a Cox survival analysis stratified on center.The primary endpoint will       be assessed\n",
      "12 months after randomization.        Secondary endpoints : Any of the individual events defining\n",
      "the primary outcome at 1 year        Number of patients to be included and power calculation : 80\n",
      "patients per group. A 1 year       primary endpoint rate of 30% in the active and 50% in with an\n",
      "inclusion period of 24 months       and alpha=5% warants a 90% power using a cox model.\n",
      "Inclusion Criteria:            -  Patients ‚â• 18 years old            -  Heart transplant recipient\n",
      "-  Stable clinical situation            -  One or several non-critical coronary stenoses (‚â• 50% et ‚â§\n",
      "75% visually or              QCA-assessed diameter stenosis) considered as adequate for coronary\n",
      "stenting by the              operator            -  Left ventricular ejection fraction ‚â• 40%\n",
      "-  Informed consentement signed by the patient          Exclusion Criteria:            -  Acute\n",
      "coronary syndrome            -  In-stent restenosis            -  Proof of an extensive myocardial\n",
      "ischemia (‚â• 7/17 segments ASE model)            -  Coronary stenosis considered as critical by the\n",
      "operators with slow flow            -  ACC/AHA Class IA indication for revascularization :\n",
      "-  vessel disease with left ventricular dysfunction                 -  Left main stenosis\n",
      "-  Severe proximal LAD stenosis            -  Contra-indication to dual antiplatelet therapy\n",
      "-  Decompensated heart failure at the time of randomization            -  Pregnant or breast-feeding\n",
      "women- Patients participating to another clinical research              within 30 days before\n",
      "randomization- life expectancy < 1 y            -  Patients unable to observe strict medical therapy\n",
      "and follow-up within 1 year after              randomization\n",
      "\n",
      "üîπ Doc ID: NCT00320008  (Score: 7.8705)\n",
      "Intensified Multifactorial Intervention in Patients With Type 2 Diabetes and Microalbuminuria\n",
      "The purpose of this study is to determine whether intensified multifactorial intervention\n",
      "comprising both behaviour modification and polypharmacy can reduce the risk for late       diabetic\n",
      "complications compared to standard treatment in patients with type 2 diabetes and\n",
      "microalbuminuria.                     The overall description of the Steno-2 Study is stated in four\n",
      "protocols approved by the       regulatory authorities in Denmark. The protocol identification\n",
      "numbers are KA 92071gm (4       years intervention ), KA-99035g (8 years intervention ), KA-99035-GS\n",
      "(13 years follow-up       since intervention start) and H-KA-99035-GS (21 year follow-up since\n",
      "intervention start).        The aim of the study was to determine whether intensified multifactorial\n",
      "intervention       comprising both behaviour modification and polypharmacy can reduce the risk for\n",
      "late       diabetic complications compared to standard treatment in patients with type 2 diabetes\n",
      "and       microalbuminuria. The primary end point after four years of intervention was to\n",
      "progression       to diabetic nephropathy with other microvascular complications as secondary end\n",
      "points. The       primary end point after eight years of intervention was a composite CVD endpoint\n",
      "with       microvascular complications as secondary end points.        The interventional part of\n",
      "the study was ended in December 2001 after a total of eight years       of intervention. From that\n",
      "time on, all patients were followed in a post-trial study. Also,       during post-trial period all\n",
      "patients in both original treatment arms received similar       treatment resembling the treatment\n",
      "given in the original intensive arm of the study. The aim       of the post-trial follow-up was to\n",
      "investigate the effect of intensified multifactorial       intervention on i) mortality and ii)\n",
      "years of life gained, respectively, with such an       interventional approach.        Endpoints in\n",
      "the two parts of the post-trial follow-up:        Part one at 13 years since start of intervention:\n",
      "Primary endpoint: Total mortality. Secondary endpoints: Cardiovascular endpoints as defined\n",
      "previously; Microvascular disease.        Part two at 21 years since start of intervention:\n",
      "Primary endpoint: Difference in median time to 50% mortality in each of the two original\n",
      "treatment groups Secondary endpoints: Cardiovascular endpoints as defined previously;\n",
      "Recurrent cardiovascular events; Microvascular disease.                         Inclusion Criteria:\n",
      "-  Type 2 diabetes            -  Microalbuminuria          Exclusion Criteria:            -\n",
      "Stimulated serum C-peptide concentration less than 600 pmol/L            -  Pancreatic insufficiency\n",
      "or diabetes secondary to pancreatitis            -  Alcohol abuse            -  Non-diabetic kidney\n",
      "disease            -  Life-threatening disease with death probable within 4 years of study start\n",
      "\n",
      "üîπ Doc ID: NCT00543348  (Score: 7.8238)\n",
      "RCT of the Cutting Balloon Versus a High Pressure Balloon for the Treatment of Arteriovenous Fistula\n",
      "Stenoses             The proposed study will investigate the efficacy of the peripheral cutting\n",
      "balloon (PBC)       compared to the high pressure balloon in dilating venous stenosis in\n",
      "hemodialysis fistulas.        2. SPECIFIC AIMS        Study endpoints will be:        Primary\n",
      "Endpoint        1. Primary and assisted patency at 6 months        Secondary Endpoints:          1.\n",
      "Procedure effectiveness/residual stenosis          2. Procedure-related complications          3.\n",
      "Primary patency and primary assisted patency 12 months          4. Secondary patency at 6 and 12\n",
      "months          5. Number/type of secondary interventions.                          Inclusion\n",
      "Criteria:            -  Dysfunctional fistulas will be recruited based on the presence of clinical\n",
      "and              hemodialysis parameters          Exclusion Criteria:            -  Arteriovenous\n",
      "prosthetic grafts\n",
      "\n",
      "üîπ Doc ID: NCT00541268  (Score: 7.7959)\n",
      "Efficacy of Implantable Cardioverter Defibrillator in Patients With Non-ischemic Systolic Heart\n",
      "Failure on Mortality             Primary objective: The primary objective of this study is to\n",
      "determine the efficacy of ICD       therapy compared with control on the endpoint of death from any\n",
      "cause.        Secondary objective: The secondary objectives of the study are to determine if ICD\n",
      "therapy       reduces sudden death.        Study design: Randomized, unblinded, controlled, parallel\n",
      "two group trial.        Primary endpoint: Time to death from any cause.        Sample size: In\n",
      "total, 1000 patients with 500 receiving ICD and 500 patients constituting       the control group.\n",
      "Summary of Subject Eligibility Criteria: Patients with clinical heart failure, left\n",
      "ventricular ejection fraction (LVEF) ‚â§ 35%, non-ischemic etiology and NT-proBNP above 200\n",
      "pg/ml. Patients in NYHA class IV will only be randomised if also fulfilling criteria for a\n",
      "biventricular pacemaker.        Control group: Patients receiving standard therapy for heart failure\n",
      "including       ACE-inhibitor/Angiotensin-Receptor-Blocker and Betablocker unless not tolerated.\n",
      "Aldosterone       antagonism is optional.        Study Duration: The study comprises a screening\n",
      "period of up to 2 years, followed by a       treatment phase of a minimum of 36 months.\n",
      "Randomisation: After fulfilling all eligibility criteria, subjects will be randomized 1:1 to\n",
      "receive ICD implantation or continue usual control. Randomisation will be stratified       according\n",
      "to treatment with a biventricular pacemaker.        Treatment: After randomisation patients\n",
      "allocated to ICD treatment should receive this as       fast as possible and preferably within 2\n",
      "weeks (latest 4 weeks). The ICD will be programmed       with anti-tachycardia pacing and shock\n",
      "therapy.        Assessments: Deaths and hospitalisations for heart failure, stroke or arrhythmias\n",
      "will be       recorded throughout the study duration.        Statistical Considerations: Median\n",
      "lifetime in the control group is expected to be 5 years.       A p-value of 5% (2-sided) is required\n",
      "for significance together with a power of at least       80%. With a relative risk reduction of 25%\n",
      "a sample size of 812 patients in total is       required. In order to allow for cross-over a sample\n",
      "size of 1000 is planned.        Primary Endpoint Analysis: The principal analysis for the primary\n",
      "endpoint (time to death       from any cause) will employ the intent-to-treat principle and use a\n",
      "survival analysis.        Secondary Endpoint Analysis: All time-to-event secondary endpoints will be\n",
      "analyzed       similarly to the primary endpoint.                     Title: A DANish randomized,\n",
      "controlled, multicenter study to assess the efficacy of       Implantable cardioverter defibrillator\n",
      "in patients with non-ischemic Systolic Heart failure       on mortality.        Indication:\n",
      "Prevention of mortality in patients at risk of sudden death.        Primary objective: The primary\n",
      "objective of this study is to determine the efficacy of ICD       therapy compared with control on\n",
      "the endpoint of death from any cause.        Secondary objective: The secondary objectives of the\n",
      "study are to determine if ICD therapy       reduces cardiovascular death as well as sudden death.\n",
      "Study design: Randomized, unblinded, controlled, parallel two group trial.        Primary endpoint:\n",
      "Time to death from any cause.        Sample size: In total, 1000 patients with 500 receiving ICD and\n",
      "500 patients constituting       the control group.        Summary of Subject Eligibility Criteria:\n",
      "Patients with clinical heart failure, left       ventricular ejection fraction (LVEF) ‚â§ 35%, non-\n",
      "ischemic etiology and NT-proBNP above 200       pg/ml. Patients in NYHA class IV will only be\n",
      "randomised if also fulfilling criteria for a       biventricular pacemaker.        Control group:\n",
      "Patients receiving standard therapy for heart failure including       ACE-inhibitor/Angiotensin-\n",
      "Receptor-Blocker and Betablocker unless not tolerated. Aldosterone       antagonism is optional.\n",
      "Study Duration: The study comprises a screening period of up to 2 years, followed by a\n",
      "treatment phase of a minimum of 36 months.        Screening and Randomisation: After the signing of\n",
      "informed consent, screening will include       medical history, vital signs, physical exam, blood\n",
      "chemistry, haematology, and NT-proBNP.       After fulfilling all eligibility criteria, subjects\n",
      "will be randomized 1:1 to receive ICD       implantation or continue usual control. Randomisation\n",
      "will be stratified according to       treatment with a biventricular pacemaker.        Treatment:\n",
      "After randomisation patients allocated to ICD treatment should receive this as       fast as\n",
      "possible and preferably within 2 weeks (latest 4 weeks). The ICD will be programmed       with anti-\n",
      "tachycardia pacing and shock therapy.        Assessments: Deaths and hospitalisations for heart\n",
      "failure, stroke or arrhythmias will be       recorded throughout the study duration. An Endpoint\n",
      "Classification Committee will adjudicate       hospitalizations and deaths for causality.        An\n",
      "independent Data Monitoring Committee will periodically review mortality data throughout       the\n",
      "study.        Statistical Considerations: Median lifetime in the control group is expected to be 5\n",
      "years.       A p-value of 5% (2-sided) is required for significance together with a power of at\n",
      "least       80%. With a relative risk reduction of 25% a sample size of 812 patients in total is\n",
      "required. In order to allow for cross-over a sample size of 1000 is planned.        As event rate\n",
      "was lower than expected the steering committee decided to prolong follow-up       and increase\n",
      "sample size slightly to 1150 patients. Secondly, the steering comittee decided       to add\n",
      "cardiovascular death as a secondary outcome.        Primary Endpoint Analysis: The principal\n",
      "analysis for the primary endpoint (time to death       from any cause) will employ the intent-to-\n",
      "treat principle and use a survival analysis. For       each treatment group, Kaplan-Meier curves\n",
      "will be estimated, graphically displayed, and       compared using a logrank test. A covariate-\n",
      "adjusted analysis of the primary endpoint using a       Cox proportional hazards model will be\n",
      "performed as a supportive analysis. The hazard ratio       and its corresponding 95% confidence\n",
      "interval will be estimated. Subjects withdrawing from       the study early (other than for\n",
      "withdrawal of consent) will be followed for potential       development of the primary endpoint.\n",
      "Subjects completing the study and not experiencing the       composite event will be censored.\n",
      "Secondary Endpoint Analysis: All time-to-event secondary endpoints will be analyzed       similarly\n",
      "to the primary endpoint.        Sample Size: Hazard rates have been estimated for the placebo and\n",
      "ICD groups using subjects       from a variety of databases (including the Echos database and the\n",
      "publication of Definite).       Assuming a 24-month enrollment period and a 36 month follow-up\n",
      "period (resulting in a 5-year       study with a minimum treatment period of 3 years and\n",
      "approximately a median survival time of       60 months), a total of 812 subjects will provide a 80%\n",
      "power with a 2-sided significance       level of 5% for detecting a reduction in hazard of 25%.\n",
      "Safety Summary: The subject incidence of adverse events will be tabulated for each group.\n",
      "Adverse events related to ICD implantation will be summarized. During the trial       inappropriate\n",
      "shocks will be summarized.        Data Monitoring Committee: An independent Data Monitoring\n",
      "Committee consisting of members       with relevant expertise will be assembled prior to study\n",
      "commencement. This committee will       periodically review safety data.        Endpoint\n",
      "Classification Committee: An external Endpoint Classification Committee will       adjudicate death\n",
      "as sudden or non-sudden throughout the study.                         Inclusion Criteria:\n",
      "-  ‚â• 18 years of age at the time of screening.            -  Documented non-ischemic HF with an LVEF\n",
      "‚â§ 35%.            -  NYHA class II-III. If patients are planned for an implantation with a\n",
      "biventricular              pacemaker NYHA class IV patients will be accepted for the trial.\n",
      "-  Before any study-specific procedure, including assessments for screening, the\n",
      "appropriate written informed consent must be obtained (see section 12.1).            -  NT-proBNP\n",
      "above 200 pg/ml (see appendix D).          Exclusion Criteria:          To be eligible for this\n",
      "study, subjects must not meet any of the following criteria:            -  Uncorrected congenital\n",
      "heart disease or valve obstruction, obstructive              cardiomyopathy, active myocarditis,\n",
      "constrictive pericarditis, untreated              hypothyroidism or hyperthyroidism, adrenal\n",
      "insufficiency, active vasculitis due to              collagen vascular disease.            -  On the\n",
      "urgent waiting list for a heart transplant (UNOS category 1A or 1B, or              equivalent).\n",
      "Patients on the non-urgent waiting list for a heart transplant (UNOS              category 2 or 7,\n",
      "or equivalent) are eligible for inclusion in the study.            -  Recipient of any major organ\n",
      "transplant (eg, lung, liver, heart or kidney).            -  Receiving or has received cytotoxic or\n",
      "cytostatic chemotherapy and/or radiation              therapy for treatment of a malignancy within 6\n",
      "month before randomisation or clinical              evidence of current malignancy, with the\n",
      "following exceptions: basal or squamous cell              carcinoma of the skin, cervical\n",
      "intraepithelial neoplasia, prostate cancer (if stable              localized disease, with a life\n",
      "expectancy of > 2.5 years in the opinion of the              investigator).            -  Known to\n",
      "be human immunodeficiency virus positive with an expected survival of less              than 5 years\n",
      "due to HIV.            -  Renal failure treated with dialysis.            -  Recent (within 3\n",
      "months) history of alcohol or illicit drug abuse disorder, based on              self-report\n",
      "-  Any condition (eg, psychiatric illness) or situation that, in the investigator's\n",
      "opinion, could put the subject at significant risk, confound the study results, or\n",
      "interfere significantly with the subject's participation in the study.            -  Unwilling to\n",
      "participate.\n",
      "\n",
      "üîπ Doc ID: NCT02241382  (Score: 7.7934)\n",
      "Cologne Cardioversion Study             Implantation of internal defibrillators, capable of\n",
      "monitoring the heart and shocking life       threatening arrhythmias back to normal rhythm, for\n",
      "patients with severe heart failure       increases the probability of survival. Arrhythmias of the\n",
      "atria of the heart are common in       these patients. Administering a direct current electrical\n",
      "shock under anesthesia       (cardioversion) is the method of choice to reestablish normal sinus\n",
      "rhythm in this instance.       Safety and efficacy of external electrical cardioversion (CV) in\n",
      "patients with ICDs was       demonstrated in several studies. Safety of internal cardioversion\n",
      "(shocking the heart back       into normal rhythm via the implanted defibrillator) was described in\n",
      "several smaller trials.        Performing external instead of internal cardioversion in patients\n",
      "with implanted ICDs is       more feasible for most hospitals, as CV can be performed without a\n",
      "programming computer and       an additional specialist present, e.g. on the intensive care ward,\n",
      "and device interrogation       can be done after CV at the remote ICD/pacemaker clinic.        No\n",
      "scientific data on safety and efficacy endpoints comparing internal vs external CV is\n",
      "currently available. The aim of the study is to compare external vs internal electrical\n",
      "cardioversion for atrial arrhythmias and establish a safety and efficacy profile for       external\n",
      "and internal cardioversion in large cohort of ICD patients.                     Introduction A\n",
      "mortality benefit of implanted cardiac defibrillators in patients (pts) with       severely impaired\n",
      "LV function has been established in multiple large trials. Atrial       fibrillation, -flutter and\n",
      "-tachycardia are a common comorbidity in this patient population.       Cardioversion is the method\n",
      "of choice to reestablish normal sinus rhythm in this instance.       Safety and efficacy of external\n",
      "electrical cardioversion (CV) in patients with pacemakers       and ICDs could be shown in several\n",
      "smaller single center trials. Safety of internal       cardioversion was described in several\n",
      "smaller trials. Reports on efficacy of internal CV       vary between 33% and 83% .\n",
      "Performing external instead of internal cardioversion in pts with implanted ICDs is more\n",
      "feasible for most hospitals, as CV can be performed without a programmer present, e.g. on       the\n",
      "ICU ward, and device interrogation can be done after CV at the remote ICD/pacemaker       clinic. A\n",
      "working group of the German cardiac society recommends internal CV for patients       carrying an\n",
      "ICD, suggesting a superior safety profile for internal CV, despite conflicting       data and a lack\n",
      "of evidence and on this issue. Thus, posing a problem in logistics for many       hospitals.\n",
      "No scientific data on safety and efficacy endpoints comparing internal vs external CV is\n",
      "currently available.        Aim of the study To compare external vs internal electrical\n",
      "cardioversion for atrial       arrhythmias and establish a safety and efficacy profile for external\n",
      "and internal       cardioversion in large cohort of ICD patients. This study will provide vital\n",
      "evidence for       future recommendations regarding cardioversion in the growing population of\n",
      "patients       carrying implanted ICD and pacemakers. The main purpose will be to establish non-\n",
      "inferiority       of external electrical cardioversion to internal electrical cardioversion. This\n",
      "would impact       day to day practice in many arrhythmia centers and smaller hospitals around the\n",
      "world.        Trial populations and choice of primary analysis set The full-analysis set (FAS) is\n",
      "derived       from the intention-to-treat (ITT) principle. This dataset includes all trial subjects\n",
      "randomized, with any valid data on the primary target variables \"occurrence of severe lead       and\n",
      "device impairment\" and \"restoration of normal sinus rhythm\".        The per-protocol set includes\n",
      "all trial subjects who were essentially treated according to       protocol (i.e. who have been\n",
      "cardioverted as assigned) and for whom the primary target       variables \"occurrence of severe lead\n",
      "and device impairment\" and \"restoration of normal sinus       rhythm\" could be determined based on\n",
      "complete and meaningful documentation.        In a non-inferiority trial there are special issues in\n",
      "the choice of primary analysis set.       Conservatism or anticonversatism of the ITT or PP analysis\n",
      "depends on various factors as       type of protocol deviation and missingness, and the method of\n",
      "handling missing data in ITT       population (see Sanchez MM, Chen X. Choosing the analysis\n",
      "population in non-inferiority       studies: per protocol or intent-to-treat. Stat Med. 25,\n",
      "1169-81;2006). Due to our setting       (randomization immediately before intervention, allowance\n",
      "for cross-over from internal to       external CV, intervention in hospital setting) we do not\n",
      "expect a relevant amount of       protocol violations. As the follow-up period of 2 weeks is short,\n",
      "we expect <1% losses to       follow-up. So we assume only minor discrepancies between ITT and PP\n",
      "population.        We do not expect any missing data for the primary efficacy endpoint, as it is\n",
      "measured       immediately after CV. The primary safety endpoint is measured within two weeks after\n",
      "CV, and       we do not expect non-trivial missingness such as dropout due to lack of efficacy. As\n",
      "the       expected number of events for the primary safety endpoint is low, especially for internal\n",
      "CV       patients, any method of handling of missing data in ITT analysis may cause relevant bias.\n",
      "Thus, the per-protocol set is considered the primary analysis population; the ITT analysis       is\n",
      "treated secondary/supportive and should lead to similar conclusions. Patients without any\n",
      "valid data on the primary target variables will be excluded from the FAS (modified ITT), in\n",
      "case of missing data on safety endpoint the valid value will be used. In a sensitivity\n",
      "analysis a conservative scenario will be performed treating missing values as event in\n",
      "external CV group and as no event in internal CV group. Any relevant discrepancies in       drop-out\n",
      "rates between CV groups will be discussed.        Outcome data and data analysis In case of cross-\n",
      "over from internal to external CV the       primary endpoints will be assessed after internal shock.\n",
      "Patient's death during intervention       or within the follow-up period is unlikely and not to be\n",
      "expected. In the case of patient       death during intervention, after the shock, the primary\n",
      "efficacy endpoint will be treated as       failure. In the case of a patient death during\n",
      "intervention, after the shock or during       follow up, the primary safety value will be counted as\n",
      "failure/severe device or lead       impairment. This may be revised after the cause of death was\n",
      "proven not to be lead or device       associated by interrogation and analysis by the manufacturer.\n",
      "Stratification by study center is not feasible due to the low number of expected events, and\n",
      "subgroup analyses by study center will be done for descriptive reasons only.        Duration and\n",
      "study size This study is a multicenter trial. Additional local ethics       application is required\n",
      "at each center.        For the primary safety endpoint \"severe lead and device impairment\" we expect\n",
      "an incidence       of 10% in the external CV group and of 5% in the internal CV group. Thus, for\n",
      "one-sided       alpha 5%, non-inferiority margin of 15%, and power 80%, a sample size of 103\n",
      "patients per       arm, i.e. 206 in total, is required. To account for loss to follow-up (<1% within\n",
      "2 weeks       after CV) and heterogeneity between centers, 230 patients (‚âà206/(1-0.05)^2) (see\n",
      "Donner, A.       Approaches to sample size estimation in the design of clinical trials--a review.\n",
      "Stat Med 3,       199-214;1984) will be randomized. A non-inferiority margin of 15% is large,\n",
      "however, we       chose several endpoints acting as sensitive surrogates of possible or temporary\n",
      "lead       affectation, rather than relying solely on hard endpoints such as permanent lead or\n",
      "device       failure with necessity of surgical revision.        As no data on placebo-controlled\n",
      "trials exists in the setting of ICD trials to determine the       non-inferiority margin on\n",
      "statistical grounds, the margin was chosen on clinically as well       as practicality grounds. A\n",
      "relevantly smaller alpha or tighter margin would lead to an       unachievable sample size and\n",
      "render the trial unfeasible (see D'Agostino, R. B., Massaro, J.       M. & Sullivan, L. M. Non-\n",
      "inferiority trials: design concepts and issues - the encounters of       academic consultants in\n",
      "statistics. Stat Med 22, 169-186;2003).        Of note, to detect an absolute risk reduction of 20%\n",
      "in the primary efficacy endpoint       \"restoration of normal sinus rhythm\", assuming an incidence\n",
      "of 90% in the external CV group       and 70% in the internal CV group, a sample size of 72 patients\n",
      "per arm, i.e. 144 in total,       is required (two-sided alpha 5%, power 80%, continuity corrected\n",
      "chi-squared test). Sample       size determination was performed with ADDPLAN‚Ñ¢ 6.0.\n",
      "Description of trial subject groups At baseline (i.e. before CV) treatment groups will be\n",
      "described and compared using mean, standard deviation and percentiles (0, 25, 50, 75, 100)       for\n",
      "continuous variables, count and percentage for categorical variables. Variables to be\n",
      "summarized include among other sex, age, BMI, comorbidities, type of device, site of\n",
      "implantation, LV ejection fraction, type of anticoagulation, duration of arrhythmia, left\n",
      "atrial diameter, pacing threshold, lead impedance, shock impedance, ventricular and\n",
      "biventricular pacing percentage, battery voltage.        Primary safety endpoint The primary\n",
      "hypothesis \"non-inferiority of external CV to internal       CV\" regarding the primary safety\n",
      "endpoint \"severe lead and device impairment\" will be       evaluated using the confidence interval\n",
      "(CI) approach. A one-sided 95% CI for the difference       \"observed proportion in external group -\n",
      "observed proportion in internal group\" will be       calculated by Newcombe's method 10 and non-\n",
      "inferiority is declared to be shown at one-sided       level 5% if its upper bound lies below the\n",
      "non-inferiority bound of 15%.        Primary efficacy endpoint If non-inferiority regarding the\n",
      "primary safety endpoint \"severe       lead and device impairment\" could be demonstrated, the\n",
      "hypothesis \"superiority of external       CV to internal CV\" regarding the primary efficacy endpoint\n",
      "\"restoration of normal sinus       rhythm\" will be tested in a confirmatory way at two-sided level\n",
      "5%. Due to the fixed       sequence of these two hypotheses, the type I error is not inflated. The\n",
      "proportion of the       primary efficacy endpoint will be compared between treatment groups by\n",
      "Fisher's exact test       with two-sided 95% CI calculated by Newcombe's method 10.        Secondary\n",
      "endpoints The components of the primary safety endpoint (i.e. a rise in threshold       (at constant\n",
      "duration) of >0.5V, exit block, loss of programming, rise in shock impedance by       50%, rise in\n",
      "charge time by 50%, drop in battery voltage of ‚â•0.2V within 2 weeks) will be       analyzed along\n",
      "the same line as the composite.        Moreover, recurrence of atrial arrhythmia at FU, lead\n",
      "impedance and sensing changes,       inadvertent induction of VF during CV, high-sensitive Troponin\n",
      "T level 3h after CV will be       summarized by treatment group and compared by statistical\n",
      "hypothesis tests as applicable;       confidence intervals for treatment differences/effect sizes\n",
      "will be calculated to aid       interpretation.        Subgroup analysis        A subanalysis of\n",
      "predefined subgroups will be performed for:          -  CRT-D patients to assess safety of external\n",
      "CV in pts with LV leads.          -  CRT-D patients with quadripolar leads (including thresholds for\n",
      "all 16 pacing vectors)          -  CRT-D patients with AV-VV optimization algorithms        Safety\n",
      "and suspension/termination criteria Based on published data and own previous work 10       an\n",
      "interim safety analysis will be performed after 50% of target sample size, i.e. 115 pts,       have\n",
      "been included. A statistically significant difference in the primary safety endpoint       between\n",
      "the groups at interim analysis will lead to a subsequent early termination of the       trial (using\n",
      "Fisher's exact test, two-sided level 5%).        Specific termination criteria:          -\n",
      "Significant difference in primary safety endpoint at interim analysis          -  Induction of VF in\n",
      "internal CV group n > 3                         Inclusion Criteria:            -  Age ‚â• 18 years\n",
      "-  Informed, written consent            -  Atrial arrhythmia with indication for CV            -\n",
      "Status post ICD implantation, including CRT-D          Exclusion Criteria:            -  Age < 18\n",
      "years            -  Patients under guardianship or with mental disorders / disabilities            -\n",
      "ICD implantation < 4 weeks prior to CV            -  ICD lead implantation < 4 weeks prior to CV\n",
      "-  Battery in EOL, ERM or ERI, ERT            -  Indications of compromised leads (Impedance <200 or\n",
      ">2000 Ohm, Pacing threshold              >5V/0.4ms), RV Sensing <4mV or RA sensing <0,1mV)\n",
      "\n",
      "\n",
      "üîç Query: How long does the clinical trial last?\n",
      "\n",
      "üîπ Doc ID: NCT00936455  (Score: 6.2612)\n",
      "Stroke Team Remote Evaluation Using a Digital Observation Camera- Long Term Outcomes(STRokE DOC-LTO)\n",
      "SPECIFIC AIM: The specific aims of this study are to evaluate the long term outcomes of\n",
      "patients previously enrolled in the STRokE DOC (\"STRokE DOC Trial (NCT00283868)\")       telemedicine\n",
      "clinical trial.        AIM 1: Aim 1 is a non- randomized, retrospective, data collection study\n",
      "assessing long term       patient outcomes of patients previously enrolled in a telemedicine vs.\n",
      "telephone clinical       trial (STRokE DOC Trial (\"STRokE DOC Trial (NCT00283868)\"); now completed).\n",
      "STRokE DOC-LTO       will evaluate, (only for those patients previously enrolled in the original\n",
      "telemedicine vs.       telephone clinical research trial), the long term patient outcomes; comparing\n",
      "telemedicine       versus telephone-only consultations.                     SPECIFIC AIM: The\n",
      "specific aims of this study are to evaluate the long term outcomes of       patients previously\n",
      "enrolled in the STRokE DOC (\"STRokE DOC Trial (NCT00283868)\")       telemedicine clinical trial.\n",
      "AIM 1: Aim 1 is a non- randomized, retrospective, data collection study assessing long term\n",
      "patient outcomes of patients previously enrolled in a telemedicine vs. telephone clinical\n",
      "trial (STRokE DOC Trial (\"STRokE DOC Trial (NCT00283868)\"); now completed). STRokE DOC-LTO\n",
      "will evaluate, (only for those patients previously enrolled in the original telemedicine vs.\n",
      "telephone clinical research trial), the long term patient outcomes; comparing telemedicine\n",
      "versus telephone-only consultations.        Specific Protocol Information: The protocol will contact\n",
      "these patients by telephone. One of       5 Stroke Center team members will contact the patient,\n",
      "using strict telephone scripted       language (approved by the IRB) and ask questions regarding\n",
      "1. current functional status          2. death          3. Hemorrhage          4. Recurrent Stroke\n",
      "5. Disposition for 3 time periods (6 months after index event, 12 months after index\n",
      "event, and \"current\" time of contact.                         Inclusion Criteria are:            1.\n",
      "Male or female subjects, age > 18 years.            2. Prior enrollment into the STRokE DOC (\"STRokE\n",
      "DOC Trial (NCT00283868)\") clinical              research trial.          Exclusion criteria are:\n",
      "1. Male or female subjects, age < 18 years.            2. Patients not previously enrolled into the\n",
      "STRokE DOC (\"STRokE DOC Trial              (NCT00283868)\") clinical research trial.\n",
      "\n",
      "üîπ Doc ID: NCT01301573  (Score: 6.0500)\n",
      "Long Term Follow-Up Study for rAAV-GAD Treated Subjects             The purpose of this\n",
      "observational study is the long term follow-up of Parkinson's patients       who participated in a\n",
      "clinical trial in which they received AAV-GAD gene transfer into the       subthalamic nucleus (STN)\n",
      "region of the brain. Patients will be followed once a year for up       to five (5) years. The study\n",
      "will monitor and evaluate the long term effects of AAV-GAD and       provide long term safety\n",
      "information.                          Inclusion Criteria:            -  Participated in a clinical\n",
      "trial where they received AAV-GAD            -  Able to give informed consent to participate in the\n",
      "study          Exclusion Criteria:            -  Received Deep Brain Stimulation after receiving\n",
      "AAV-GAD            -  Received any experimental device in the brain after receiving AAV-GAD\n",
      "-  Had any type of brain surgery after receiving AAV-GAD            -  Received any experimental\n",
      "therapy (drug or biologic) for Parkinson's disease or any              other indication after\n",
      "receiving AAV-GAD\n",
      "\n",
      "üîπ Doc ID: NCT01610102  (Score: 5.9083)\n",
      "PROGRESS-AMS 1.0 Clinical Long Term Follow-Up             The primary objective of this study is to\n",
      "collect long term clinical follow-up data on all       patients enrolled in the PROGRESS AMS-1.0\n",
      "study to assess long term safety of the AMS-1.0                     The first clinical experience\n",
      "with AMS was in infrapopliteal arteries and demonstrated       safety and acceptable patency rates\n",
      "up to 12 months post implantation. These encouraging       results led to the initiation of the\n",
      "first trial to treat human coronary lesions with AMS       named Clinical Performance and\n",
      "angiographic Results of Coronary Stenting with Absorbable       Metal Stents (PROGRESS AMS-1).\n",
      "Although an ischemic driven target lesion revascularization       rate of 26.7% (16/60) was observed\n",
      "during the PROGRESS AMS-1 study, it demonstrated that       biodegradable magnesium stents can be\n",
      "implanted safely in coronary arteries, and the stents       degraded as intended without causing\n",
      "stent thrombosis, myocardial infarction or death at one       year. No adverse device effects from\n",
      "the absorbable nature of the stents or its constituents       were detected. The continued clinical\n",
      "follow-up and retrospective evaluation of all       angiographies and IVUS films on all eligible\n",
      "patients enrolled in the PROGRESS-AMS 1.0 will       give important information on the long term\n",
      "safety of absorbable metal scaffolds and thus       can support improvement of the device.\n",
      "Inclusion Criteria:            -  Signed informed consent form available prior to clinical long term\n",
      "follow-up          Exclusion Criteria:            -  Patent did not sign the informed consent form\n",
      "prior to clinical long term follow-up\n",
      "\n",
      "üîπ Doc ID: NCT01286545  (Score: 5.8877)\n",
      "European Ankylosing Spondylitis Infliximab Cohort (EASIC) Follow up Registration Study\n",
      "Long term data on efficacy and safety of anti-TNF treatment with infliximab in patients with\n",
      "ankylosing spondylitis (AS) beyond 5 years is lacking. These data are important because\n",
      "patients with AS usually are younger and withdrawal of anti-TNF therapy in these patients\n",
      "almost always leads to a disease relapse. Furthermore it is still unclear whether long term\n",
      "anti-TNF treatment in AS patients can inhibit radiographic progression. Patients who\n",
      "participated in the EASIC and the DIKAS trial respectively who were treated with infliximab\n",
      "within these studies for 7 and 10 years respectively are followed up by using clinical       outcome\n",
      "parameters every 6 months assessing efficacy and safety of long term treatment.       Furthermore\n",
      "radiographs of the spine, if done for clinical indication, are analyzed. It is       hypothesized\n",
      "that anti-TNF treatment with infliximab is effective and safe over a time       period of 9 and 12\n",
      "years respectively and that long term anti-TNF therapy may inhibit       radiographic progression of\n",
      "the spine.                     Ankylosing spondylitis (AS) is the most frequent subtype of\n",
      "spondyloarthritides (SpA)(Braun       et al.Lancet 2007, 369:1379-90). Treatment with nonsteroidal\n",
      "anti-inflammatory drugs       (NSAIDs) is the cornerstone of the treatment of the disease and is\n",
      "widely used to suppress       inflammation and ameliorate spinal pain (Zochling et al.:Ann Rheum Dis\n",
      "2006, 65:442-52).       There is evidence that antitumour necrosis factor (TNF) therapy is highly\n",
      "effective in SpA,       especially in AS and psoriatic arthritis. Thus, TNF blockers may even be\n",
      "considered as first       line treatment in a patient with active AS whose condition is not\n",
      "sufficiently controlled       with NSAIDs in the case of axial disease, and sulfasalazine or\n",
      "methotrexate in the case of       peripheral arthritis (Zochling et al.:Ann Rheum Dis 2006,\n",
      "65:442-52). Long-term data on       anti-TNF therapy in patients with AS are rather limited.\n",
      "Infliximab in a dosage of 5mg/kg       was shown to be efficacious over 5 years, including a short\n",
      "period of withdrawal and       readministration (Baraliakos et al.:Arthritis Res Ther 2005, 7:\n",
      "R439-44; Baraliakos et al.:J       Rheumatol 2007, 34: 510-5; Braun J et al: Ann Rheum Dis 2008, 67:\n",
      "340-5). In our EASIC study       the investigators have also shown the efficacy and safety of\n",
      "infliximab treatment in       patients with AS over 5 years. Long term data for the treatment of AS\n",
      "with etanercept has       proven the efficacy as well (Dijkmans B et al.:J Rheumatol 2009, 36:\n",
      "1256-64). But long term       data for efficacy and safety of treatment with anti-TNF therapy beyond\n",
      "a time period of 5       years is lacking. These data on long term treatment are essential for\n",
      "several reasons. At       first patients with AS are predominantly of younger age. When taking into\n",
      "account that       withdrawal of anti-TNF therapy leads to disease relapse in a very high proportion\n",
      "of       patients , anti-TNF therapy in AS patients is most often designed as a continuous therapy\n",
      "on       a long term basis. The second reason for the need of long term data beyond 5 years is the\n",
      "ongoing debate whether anti-TNF agents have the potential to inhibit radiographic       progression\n",
      "(Baraliakos X et al.:Ann Rheum Dis 2005, 64:1462-6; van der heijde D et       al:Arthritis Rheum\n",
      "2008, 58: 3063-70). Radiographic data on a larger cohort of patients       treated with infliximab\n",
      "or other anti-TNF blockers for a long time period could contribute       to answer this important\n",
      "question.                         Inclusion Criteria:            -  Established diagnosis of\n",
      "ankylosing spondylitis according to the modified New York              criteria            -\n",
      "Participation in the EASIC trial or participation in the DIKAS/TNF bei AS-trial            -\n",
      "Completion of the EASIC extension or the DIKAS trial            -  Presence of written informed\n",
      "consent from the patient          Exclusion Criteria:\n",
      "\n",
      "üîπ Doc ID: NCT01177059  (Score: 5.8534)\n",
      "Long Term Follow-Up Study of Human Immunodeficiency Virus Type 1 (HIV-1) Positive Patients Who Have\n",
      "Received OZ1 Gene Therapy as Part of a Clinical Trial             The purpose of this Observational\n",
      "Study is long term follow-up of the Human Immunodeficiency       Virus -1 (HIV-1) infected patients\n",
      "who have received a gene therapy product (anti-HIV-1       Ribozyme [OZ1]) as part of an earlier\n",
      "phase 2 trial. Patients are seen twice yearly until 5       years from initial infusion of study\n",
      "drug has elapsed and then yearly for the rest of their       lives. The study will monitor for and\n",
      "record any ill effects from the gene therapy product       to provide long term safety information.\n",
      "During an earlier phase 2 base trial (study # NCT00074997), HIV-1 infected patients received       a\n",
      "gene therapy product (anti-HIV-1 Ribozyme [OZ1]). Gene therapy is an investigational       treatment\n",
      "where genes are inserted into an individual's cells and tissues to treat a       disease. The gene\n",
      "therapy OZ1 is thought to have anti-HIV-1 actions. This is an       Observational Study to provide\n",
      "long term follow-up of those HIV-1 infected patients who       received the gene therapy product\n",
      "(anti-HIV-1 Ribozyme [OZ1]) as part of the earlier study.       Patients are seen twice yearly until\n",
      "5 years from initial infusion of study drug has elapsed       and then yearly for the rest of their\n",
      "lives. The study will monitor for and record any ill       effects from the gene therapy product to\n",
      "provide long term safety information. Observational       study - no investigational drug\n",
      "administered.                         Inclusion Criteria:            -  Patients must have received\n",
      "the Final Cell Product infusion in base study            -  Have signed Informed Consent Form\n",
      "Exclusion Criteria:            -  Any patient from the base study that was assigned to the placebo\n",
      "arm\n",
      "\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import joblib\n",
    "from rank_bm25 import BM25Okapi\n",
    "import textwrap\n",
    "\n",
    "# Load data\n",
    "with open(\"clinical_trials_bm25_corpus.pkl\", \"rb\") as f:\n",
    "    corpus = joblib.load(f)\n",
    "with open(\"clinical_trials_bm25_model.pkl\", \"rb\") as f:\n",
    "    bm25 = joblib.load(f)\n",
    "df_meta = pd.read_csv(\"clinical_trials_metadata.csv\")\n",
    "\n",
    "# Helper to show results\n",
    "def run_query(query, top_k=5):\n",
    "    tokens = query.lower().split()\n",
    "    scores = bm25.get_scores(tokens)\n",
    "    top_idx = sorted(range(len(scores)), key=lambda i: scores[i], reverse=True)[:top_k]\n",
    "    results = []\n",
    "    for i in top_idx:\n",
    "        doc_id = df_meta.iloc[i]['doc_id']\n",
    "        text = df_meta.iloc[i]['original_text']\n",
    "        results.append((doc_id, scores[i], text))\n",
    "    return results\n",
    "\n",
    "# Define test queries\n",
    "queries = {\n",
    "    \"TREATMENT SAFETY\": [\n",
    "        \"What are the side effects of the vaccine?\",\n",
    "        \"Is the treatment well tolerated by patients?\",\n",
    "        \"Any serious adverse events reported during the trial?\"\n",
    "    ],\n",
    "    \"PATIENT ELIGIBILITY\": [\n",
    "        \"Who can participate in the trial?\",\n",
    "        \"Eligibility criteria for patients with lung cancer\",\n",
    "        \"Am I eligible for this study?\"\n",
    "    ],\n",
    "    \"TRIAL DESIGN\": [\n",
    "        \"How is the study structured?\",\n",
    "        \"What is the primary endpoint of the trial?\",\n",
    "        \"How long does the clinical trial last?\"\n",
    "    ]\n",
    "}\n",
    "\n",
    "# Run and print results\n",
    "for section, qs in queries.items():\n",
    "    print(\"=\"*30)\n",
    "    print(f\"üß™ {section}\")\n",
    "    print(\"=\"*30)\n",
    "    for query in qs:\n",
    "        print(f\"\\nüîç Query: {query}\\n\")\n",
    "        results = run_query(query)\n",
    "        for doc_id, score, text in results:\n",
    "            print(f\"üîπ Doc ID: {doc_id}  (Score: {score:.4f})\")\n",
    "            print(textwrap.fill(text, width=100))\n",
    "            print()fana"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 14,
   "id": "9425f6e6-085d-4768-81cc-01c60cde25a5",
   "metadata": {},
   "outputs": [
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "100%|‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà‚ñà| 942/942 [3:59:35<00:00, 15.26s/it]\n"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ BERT embeddings for Clinical Trials built and saved.\n"
     ]
    }
   ],
   "source": [
    "# build_bert_embeddings_clinical.py\n",
    "\n",
    "import pandas as pd\n",
    "import joblib\n",
    "from sentence_transformers import SentenceTransformer\n",
    "from tqdm import tqdm\n",
    "import numpy as np\n",
    "\n",
    "# Load preprocessed data\n",
    "df = pd.read_csv(\"clinical_trials_cleaned.csv\")\n",
    "df['joined'] = df['tokens'].apply(eval).apply(lambda tokens: ' '.join(tokens))\n",
    "\n",
    "# Load a compact, efficient BERT model\n",
    "model = SentenceTransformer(\"all-MiniLM-L6-v2\")  # ~384D embeddings\n",
    "\n",
    "# Encode documents in batches\n",
    "batch_size = 256\n",
    "all_embeddings = []\n",
    "for i in tqdm(range(0, len(df), batch_size)):\n",
    "    batch_texts = df['joined'].iloc[i:i+batch_size].tolist()\n",
    "    embeddings = model.encode(batch_texts, show_progress_bar=False, convert_to_numpy=True)\n",
    "    all_embeddings.append(embeddings)\n",
    "\n",
    "# Stack all batches into one array\n",
    "all_embeddings = np.vstack(all_embeddings)\n",
    "\n",
    "# Save embeddings and doc IDs\n",
    "joblib.dump(all_embeddings, \"clinical_trials_bert_embeddings.pkl\")\n",
    "df[['doc_id', 'original_text']].to_csv(\"clinical_trials_metadata.csv\", index=False)\n",
    "\n",
    "print(\"‚úÖ BERT embeddings for Clinical Trials built and saved.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 15,
   "id": "55ff64b0-24b2-4cd6-b2e7-3edb9f29b235",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "============================================================\n",
      "üîç Query: What are the side effects of the vaccine?\n",
      "\n",
      "üîπ Doc ID: NCT02117570  (Score: 0.4750)\n",
      "A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who\n",
      "Will Each Receive 3 Doses Of Vaccine.             This study will investigate a Clostridium\n",
      "difficile vaccine in healthy adults aged 50 to 85       years, who will each receive 3 doses of\n",
      "vaccine. The study will assess the safety and       tolerability of the vaccine, and also look at\n",
      "the subjects' immune response to the vaccine.                          Inclusion Criteria:\n",
      "Healthy male and female subjects aged 50 to 85 years          Exclusion Criteria:          Proven or\n",
      "suspected prior episode of Clostridium difficile associated diarrhea.          Unstable chronic\n",
      "medical condition or disease requiring significant change in therapy or         hospitalization for\n",
      "worsening disease within 8 weeks before receipt of study vaccine.          Any contraindication to\n",
      "vaccination or vaccine components, including previous anaphylactic         reaction to any vaccine\n",
      "or vaccine-related components.\n",
      "\n",
      "üîπ Doc ID: NCT02052726  (Score: 0.4740)\n",
      "A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who\n",
      "Will Each Receive 3 Doses Of Vaccine.             This study will investigate a clostridium\n",
      "difficile vaccine in healthy adults aged 50 to 85       years, who will each receive 3 doses of\n",
      "vaccine. Subjects will receive their vaccine doses       at either months 0, 1, and 3 or days 1, 8,\n",
      "and 30. Subjects will be divided into 2 age       groups (50-64 and 65-85 years of age). The study\n",
      "will assess how safe and tolerable the       vaccine is, and also look at subjects' immune response\n",
      "to the vaccine.                          Inclusion Criteria:            -  Healthy male and female\n",
      "adults aged 50 to 85 years at enrollment          Exclusion Criteria:            -  Proven or\n",
      "suspected prior episode of Clostridium difficile associated diarrhea.            -  Unstable chronic\n",
      "medical condition or disease requiring significant change in therapy              or hospitalization\n",
      "for worsening disease within 8 weeks before receipt of study              vaccine.            -  Any\n",
      "contraindication to vaccination or vaccine components, including previous              anaphylactic\n",
      "reaction to any vaccine or vaccine-related components\n",
      "\n",
      "üîπ Doc ID: NCT00708630  (Score: 0.4651)\n",
      "The Effect of Extended Yellow Fever Vaccine Information on Symptom Reports Following Vaccination\n",
      "This study aims to investigate the effect of providing additional information about possible\n",
      "mild side effects of the yellow fever vaccination on the reporting of physical symptoms.\n",
      "Additionally, the project aims to investigate the relationship between individual\n",
      "characteristics (trait anxiety and perceived sensitivity to medication) and the reporting of\n",
      "physical symptoms, as well as possible interactions between the level of information       provided\n",
      "and individual characteristics. We hypothesize that more information about mild       symptoms\n",
      "provided to participants will increase the number of reported symptoms after       vaccination.\n",
      "Inclusion Criteria:            -  Receiving yellow fever vaccination            -  English speaker\n",
      "-  Aged over 18          Exclusion Criteria:            -  No phone for follow-up\n",
      "\n",
      "üîπ Doc ID: NCT01857297  (Score: 0.4640)\n",
      "A Study to Assess the Immunogenicity and Safety of CSL's 2013/2014 Formulation of Enzira¬Æ Vaccine in\n",
      "Healthy Volunteers             This is a study to assess the immune (antibody) response and safety\n",
      "of the 2013/2014       formulation of Enzira¬Æ vaccine in healthy adult volunteers aged 18 years or\n",
      "older.                          Inclusion Criteria:            -  Males or females aged 18 years or\n",
      "older at the time of vaccination.            -  Females of child-bearing potential (i.e., ovulating,\n",
      "pre-menopausal, not surgically              sterile) must be abstinent or be willing to use a\n",
      "medically accepted contraceptive              regimen for the duration of the study. Females of\n",
      "child-bearing potential must return              a negative urine pregnancy test result prior to\n",
      "vaccination with the vaccine.          Exclusion Criteria:            -  Known hypersensitivity to a\n",
      "previous vaccination with influenza vaccine or allergy to              eggs, ovalbumin, chicken\n",
      "protein, neomycin, polymyxin, or any components of the              vaccine.            -  Clinical\n",
      "signs of an active infection.            -  A clinically significant medical condition.            -\n",
      "Vaccination with a seasonal or experimental influenza virus vaccine in the 6 months\n",
      "preceding study entry.            -  Females who are pregnant or lactating.\n",
      "\n",
      "üîπ Doc ID: NCT01591837  (Score: 0.4620)\n",
      "A Study to Assess the Immunogenicity and Safety of CSL's 2012/2013 Formulation of Enzira¬Æ Vaccine in\n",
      "Healthy Volunteers             This is a study to assess the immune (antibody) response and safety\n",
      "of the 2012/2013       formulation of Enzira¬Æ (CSL Influenza vaccine) in healthy adult volunteers\n",
      "aged 18 years or       older.                          Inclusion Criteria:            -  Males or\n",
      "females aged 18 years or older at the time of vaccination.            -  Females of child-bearing\n",
      "potential (i.e., ovulating, pre-menopausal, not surgically              sterile) must be abstinent\n",
      "or be willing to use a medically accepted contraceptive              regimen for the duration of the\n",
      "study. Females of child-bearing potential must return              a negative urine pregnancy test\n",
      "result prior to vaccination with the vaccine.          Exclusion Criteria:            -  Known\n",
      "hypersensitivity to a previous vaccination with influenza vaccine or allergy to              eggs,\n",
      "ovalbumin, chicken protein, neomycin, polymyxin, or any components of the              vaccine.\n",
      "-  Clinical signs of an active infection.            -  A clinically significant medical condition.\n",
      "-  Vaccination with a seasonal or experimental influenza virus vaccine in the 6 months\n",
      "preceding study entry.            -  Females who are pregnant or lactating.\n",
      "\n",
      "============================================================\n",
      "üîç Query: Who can participate in the trial?\n",
      "\n",
      "üîπ Doc ID: NCT01380977  (Score: 0.4284)\n",
      "Trial of Impact of Crime Group Intervention for Jail Inmates             This pilot study is\n",
      "designed to evaluate the efficacy of the Impact of Crime (IOC) group       intervention for jail\n",
      "inmates. The hypothesis is that participants in IOC will show       decreases in criminogenic\n",
      "thinking, decreases in shame, increases in guilt, and increases in       empathy, which in turn will\n",
      "be reflected in reduced recidivism (official records and self       report), relative to those\n",
      "randomly assigned to a treatment as usual group.                          Inclusion Criteria:\n",
      "-  Must be 18 years or older            -  Must be male            -  Must be currently incarcerated\n",
      "jail inmate            -  Must be sentenced            -  Must speak, read, and write in English\n",
      "with sufficient proficiency to use workbook              and participate in group sessions\n",
      "-  Must be assigned to the jail's \"general population\"          Exclusion Criteria:            -\n",
      "Actively psychotic            -  Assigned \"keep separate\" from other group members\n",
      "\n",
      "üîπ Doc ID: NCT00983866  (Score: 0.4205)\n",
      "CHOICES: Understanding Clinical Trials as a Treatment Option             The goal of this study is\n",
      "to determine whether having a telephone discussion with a nurse       educator about making\n",
      "treatment decisions and participating in a clinical trial increases       trial participation.\n",
      "The investigators hypothesize that the participants in the intervention group will be more\n",
      "likely to take part in a clinical trial than those in the usual care group.\n",
      "Inclusion Criteria:            -  Patients who are potentially eligible for one of the designated\n",
      "clinical trials on              the basis of automated data from pathology reports and other\n",
      "databases          Exclusion Criteria:            -  Patients who meet specific exclusion criteria\n",
      "for designated clinical trials\n",
      "\n",
      "üîπ Doc ID: NCT02600533  (Score: 0.4202)\n",
      "Increasing Minority Participation in Clinical Trials             This study will measure the effects\n",
      "of an office-based, clinical trial education video on       clinical trial knowledge and enrollment\n",
      "in clinical trials, in a clinical sample with no       previous history of clinical trial\n",
      "participation. This study will also determine the       feasibility of implementing an office-based\n",
      "video educational program.                     Clinical trials are essential to scientific discovery\n",
      "and are critical to translating       research in to practice. Despite their significance, clinical\n",
      "trial participation rates       remain low, especially among underrepresented minority groups.\n",
      "Several barriers exist to       minority group participation in clinical trial, one of which lack of\n",
      "awareness about       clinical trials. Video educational programs show promise as an effective\n",
      "strategy to       increase knowledge and clinical trial participation. The specific aims are as\n",
      "follows:          1. Measure the effects of an office-based, clinical trial education video on\n",
      "clinical            trial knowledge and enrollment in clinical trials, in a clinical sample with no\n",
      "previous history of clinical trial participation.          2. Determine the feasibility of\n",
      "implementing an office-based video educational program.                         Inclusion Criteria:\n",
      "Participants will be patients of Vanderbilt-Ingram Cancer Center (VICC) with a diagnosis         of\n",
      "cancer Participants will have no previous history of clinical trial research         participation\n",
      "Exclusion Criteria:            -  Previous history of clinical trial research participation\n",
      "\n",
      "üîπ Doc ID: NCT02983864  (Score: 0.4025)\n",
      "Group Alcohol Interventions for College Men             The objective of the proposed project is to\n",
      "conduct a randomized controlled trial (RCT)       comparing sexual assault perpetration and related\n",
      "outcomes (i.e., bystander behavior; rape       myth acceptance) for men who receive a group alcohol\n",
      "intervention only to men who receive a       group integrated alcohol and sexual assault\n",
      "intervention.                          Inclusion Criteria:            -  Must be 18 or older; must\n",
      "be an Ohio University student; must be male; must be              sanctioned to receive an alcohol\n",
      "intervention by Ohio University          Exclusion Criteria:            -  Under the age of 18\n",
      "\n",
      "üîπ Doc ID: NCT02869880  (Score: 0.3955)\n",
      "Trial of Enhanced Pre-Consent Discussion             Nested within the COMBINE pragmatic clinical\n",
      "trial, the investigators will conduct a cluster       randomized controlled trial to determine\n",
      "whether, in parents (of children with Crohn's       Disease) or patients > 18 years old being\n",
      "approached for trial participation, a pre-consent       discussion enhanced with decision aids is\n",
      "more effective than the standard pre-consent       discussion in transferring knowledge to\n",
      "parents/patients related to trial participation.                          Inclusion Criteria:\n",
      "-  Parent of a child who is eligible for the COMBINE trial (ClinicalTrials.gov\n",
      "Identifier: NCT02772965)            -  Patient who is eligible for the COMBINE trial\n",
      "(ClinicalTrials.gov Identifier:              NCT02772965)          Exclusion Criteria:            -\n",
      "Non-English speaking\n",
      "\n",
      "============================================================\n",
      "üîç Query: What is the design of the clinical trial?\n",
      "\n",
      "üîπ Doc ID: NCT02430441  (Score: 0.5633)\n",
      "[Trial of device that is not approved or cleared by the U.S. FDA]\n",
      "\n",
      "üîπ Doc ID: NCT02606838  (Score: 0.5633)\n",
      "[Trial of device that is not approved or cleared by the U.S. FDA]\n",
      "\n",
      "üîπ Doc ID: NCT01443286  (Score: 0.5633)\n",
      "[Trial of device that is not approved or cleared by the U.S. FDA]\n",
      "\n",
      "üîπ Doc ID: NCT01835366  (Score: 0.5633)\n",
      "[Trial of device that is not approved or cleared by the U.S. FDA]\n",
      "\n",
      "üîπ Doc ID: NCT02364375  (Score: 0.5633)\n",
      "[Trial of device that is not approved or cleared by the U.S. FDA]\n",
      "\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import joblib\n",
    "import numpy as np\n",
    "from sentence_transformers import SentenceTransformer\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "import textwrap\n",
    "\n",
    "# Load precomputed embeddings and metadata\n",
    "doc_embeddings = joblib.load(\"clinical_trials_bert_embeddings.pkl\")\n",
    "df_meta = pd.read_csv(\"clinical_trials_metadata.csv\")\n",
    "\n",
    "# Load the same BERT model used during building\n",
    "model = SentenceTransformer('all-MiniLM-L6-v2')\n",
    "\n",
    "# Example queries\n",
    "queries = [\n",
    "    \"What are the side effects of the vaccine?\",\n",
    "    \"Who can participate in the trial?\",\n",
    "    \"What is the design of the clinical trial?\"\n",
    "]\n",
    "\n",
    "# Number of results to retrieve per query\n",
    "TOP_K = 5\n",
    "\n",
    "for query in queries:\n",
    "    print(\"=\" * 60)\n",
    "    print(f\"üîç Query: {query}\\n\")\n",
    "\n",
    "    # Encode query\n",
    "    query_embedding = model.encode([query])\n",
    "\n",
    "    # Compute cosine similarities\n",
    "    scores = cosine_similarity(query_embedding, doc_embeddings)[0]\n",
    "\n",
    "    # Get top-k indices\n",
    "    top_k_idx = np.argsort(scores)[::-1][:TOP_K]\n",
    "\n",
    "    for idx in top_k_idx:\n",
    "        doc_id = df_meta.iloc[idx]['doc_id']\n",
    "        text = df_meta.iloc[idx]['original_text']\n",
    "        score = scores[idx]\n",
    "        print(f\"üîπ Doc ID: {doc_id}  (Score: {score:.4f})\\n{textwrap.fill(text, width=100)}\\n\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "bcc89b41-aa4f-49a8-ac3b-8b19d3e92861",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "========================================\n",
      "üîç Query: What are the side effects of the vaccine?\n",
      "\n",
      "üîπ Doc ID: NCT02996201  (Score: 0.2683)\n",
      "Electronic Patient Reporting of Side Effects to Chemotherapy: A Cluster Randomized Controlled Trial\n",
      "The aim of this study is to determine whether the use of breast cancer patients' own\n",
      "electronic reporting of side effects to chemotherapy in a treatment setting has an impact on\n",
      "the handling of side effects and on the number of hospitalizations, febrile neutropenia and\n",
      "dose adjustments. We are using the Patient-Reported Outcomes version of the Common       Terminology\n",
      "Criteria for Adverse Events (PRO-CTCAE) for the patients' reporting of side       effects.\n",
      "Gender ‚Ä¢Female: only female participants are being studied          Minimum age          ‚Ä¢18 years\n",
      "Maximum age ‚Ä¢N/A          Accepts Healthy Volunteers          ‚Ä¢No          Eligibility Criteria\n",
      "Inclusion criteria            -  Breast cancer patients starting adjuvant chemotherapy in the period\n",
      "November 1, 2015              - September 1, 2016 in Danish oncology clinics          Exclusion\n",
      "Criteria:            -  More than six scheduled cycles of chemotherapy            -  Not able to\n",
      "read and understand Danish language\n",
      "\n",
      "üîπ Doc ID: NCT01122056  (Score: 0.2502)\n",
      "Effect of Aerobic Exercise on Side Effects of Disease Modifying Therapy With Subcutaneous\n",
      "Interferon-b1b in Patients With Multiple Sclerosis             The purpose of this study is to\n",
      "investigate the effects and tolerability of exercise on side       effects of injectable disease\n",
      "modifying treatments in multiple sclerosis. The investigators       main hypothesis is that\n",
      "controlled exercise is safe and can be well tolerated in patients       with multiple sclerosis and\n",
      "it can improve disease modifying treatment related side effects       such as fatigue.\n",
      "Patient compliance with disease modifying treatment largely depends on relatively common       side\n",
      "effects of such treatments such as fatigue. Regular exercise can potentially improve       these\n",
      "side effects. However, Safety and effects of exercise has not been studied in patients       with\n",
      "multiple sclerosis. Our main aim is to study the safety, tolerability and effects of       exercise\n",
      "on side effects of subcutaneous interferon-b1b in patients with Multiple Sclerosis.\n",
      "Inclusion Criteria:            -  Recent diagnosis of relapsing remitting multiple sclerosis on\n",
      "treatment with              b1b-interferon disease modifying treatment\n",
      "\n",
      "üîπ Doc ID: NCT01136005  (Score: 0.2255)\n",
      "Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI)\n",
      "Objective:        To assess the preemptive effect of Bepanthen¬Æ on decreasing the incidence of\n",
      "specific ‚â•       grade 2 dermatological side effects of interest in respect of compliance to EGFRI\n",
      "agents,       HRQoL and the adherence during the 6-week skin treatment period. The adherence to the\n",
      "study       creams will also be studied.                     Rationale:        Dermatological side\n",
      "effects, such as papulopustular eruption, xerosis, pruritus, periungual       inflammation,\n",
      "mucosal-, and hair abnormalities, and edema occur in up to 90% of patients       during treatment\n",
      "with epidermal growth factor receptor inhibitors (EGFRI). Patients are       hindered in their daily\n",
      "activities and cannot maintain privacy about their illness because       of the prominent side\n",
      "effects. The aesthetic discomfort, which is frequently associated with       itching or painful skin\n",
      "or nails can lead to a decreased health related quality of life       (HRQoL) and to dose reduction\n",
      "or discontinuation of anticancer treatment.        Patients with dermatological side effects have\n",
      "also an increased risk for cutaneous       infections (at least 38%) which can complicate\n",
      "dermatological side effects.        At present, evidence of the effectiveness of the management\n",
      "options for dermatological side       effects is lacking, and the effect of the dermatological side\n",
      "effects on HRQoL and adherence       remains poorly understood.        Dexpanthenol cream\n",
      "(Bepanthen¬Æ, Bayer) has been used extensively to ameliorate acute       radiation induced skin\n",
      "toxicity, diaper dermatitis, irritant hand dermatitis, graft-donor       site wound healing and burn\n",
      "patients. The hypothesis is that its skin healing possibilities       decreases this kind of side\n",
      "effects.        Study design:        Multicenter, two-arm randomized, double blind, prospective\n",
      "parallel group design, phase III       study        Study population:        Each patient starting\n",
      "for the first time with EGFRI anticancer therapy which can cause       papulopustular eruption\n",
      "(cetuximab, panitumumab, erlotinib, gefitinib, lapatinib, or other),       will be included.\n",
      "Intervention:        80 patients will receive for the first 6 weeks of treatment Bepanthen cream, 80\n",
      "patients       Cetomacrogol cream to apply twice daily. Using FACT-EGFRI, a dermatology-specific\n",
      "questionnaire, this study examines the effect of these side effects on three domains of       HRQoL\n",
      "- symptoms, emotions, and functioning. Severity of dermatological side effects will be\n",
      "assessed using the NCI-CTCAE v4.0. Correlation of dermatology HRQoL scores with NCI-CTCAE\n",
      "grade, sex, age, type of EGFRI, and cancer type will be conducted.                         Inclusion\n",
      "Criteria:            -  Male and female subjects            -  ‚â•18 years of age.            -\n",
      "Patients must have signed an approved informed consent form prior to registration on\n",
      "study.            -  Histological proof of cancer.            -  A planned course of EGFRI treatment\n",
      "for any type of cancer. Patients must be entered              on study ‚â§ 7 days before EGFRI\n",
      "treatment begins.            -  Have an Eastern Co-operative Oncology Group (ECOG) performance\n",
      "status ‚â§ 2.            -  Ability to complete questionnaire(s) by themselves or with assistance.\n",
      "-  Patients need to be free of infection and not using any topical treatments on the\n",
      "skin.          Exclusion Criteria:            -  Use of other concurrent topical creams or lotions\n",
      "at baseline.            -  Concomitant use of medications that may affect trial results (e.a.\n",
      "concurrent use of              topical antibiotics, topical steroids, and other topical treatments\n",
      "on face and chest              within 14 days of Day 0 (baseline); treatment with any systemic\n",
      "antibiotics within 7              days prior to Day 0.            -  Active dermatological\n",
      "conditions other than papulopustular eruption that may affect              trial results. A skin\n",
      "examination reveals the presence of another skin disease in              face or chest that may\n",
      "obscure rash to EGFRI and/or condition (excessive facial hair,              excessive scarring,\n",
      "sunburn, or other disfigurement) located on the skin that, in the              study physician's\n",
      "opinion, would confound the evaluation of the papulopustular              eruption.            -\n",
      "Known allergy or hypersensitivity to ingredients in Bepanthen¬Æ or Cetomacrogol.            -  Known\n",
      "sensitivity, papulopustular eruption or other abnormal skin reaction to topical              or\n",
      "systemic medications or cleansing products at baseline.            -  Prior treatment with targeted\n",
      "therapy of any kind.            -  Current use of agents that are known to be strong inducers or\n",
      "inhibitors of CYP3A4              that can not be stopped\n",
      "\n",
      "üîπ Doc ID: NCT00386204  (Score: 0.2254)\n",
      "Side Effects of Q-Switched Ruby Laser for the Treatment of Lentigines in Light and Dark Skin Types\n",
      "The purpose of this study is a comparison of efficacy and side effects of Q-switched Ruby\n",
      "laser treatment for solar lentigines in two different skin types II and IV.                     It\n",
      "has been widely accepted that dark colored individuals are prone to develop laser induced       side\n",
      "effects especially post inflammatory hyperpigmentation(PIH) and it could be a limiting       issue\n",
      "in selecting dark colored individuals.        We designed this study to evaluate the difference of\n",
      "efficacy and side effects in light and       dark skinned individuals.\n",
      "Inclusion Criteria:            -  Solar Lentigines            -  Fitzpatrick skin type II and IV\n",
      "Exclusion Criteria:            -  Pregnancy            -  Age above 80            -\n",
      "Photosensitivity            -  Concern for malignancy            -  Active Infection\n",
      "\n",
      "üîπ Doc ID: NCT00568139  (Score: 0.2206)\n",
      "Evaluation of Side Effects of Mitotane             Mitotane is standard therapy in the treatment of\n",
      "adrenocortical carcinoma. However, many       side effects are not well documented. Therefore, we\n",
      "are aiming at collecting data about side       effects in patients treated with mitotane\n",
      "Inclusion Criteria:            -  Adrenocortical carcinoma            -  Treatment with mitotane\n",
      "intended or mitotane administered\n",
      "\n",
      "========================================\n",
      "üîç Query: Who can participate in the trial?\n",
      "\n",
      "üîπ Doc ID: NCT00264329  (Score: 0.2767)\n",
      "Transitional Case Management Study             To address the issues involved in treatment\n",
      "participation by substance-abusing parolees, the       CJ-DATS Transitional Case Management (TCM)\n",
      "study proposes to test a parole re-entry model       that consists of (1) completion by the inmate\n",
      "of a strengths and goals assessment as part of       discharge planning, (2) a telephone case\n",
      "conference call that includes the inmate and       significant members of the inmate's aftercare\n",
      "plan (including the parole officer), and (3)       strengths case management (for 12 weeks) in the\n",
      "community to promote treatment participation       and support the client's access to needed\n",
      "services.                     To address the issues involved in treatment participation by\n",
      "substance-abusing parolees, the       CJ-DATS Transitional Case Management (TCM) study proposes to\n",
      "test a parole re-entry model       that consists of (1) completion by the inmate of a strengths and\n",
      "goals assessment as part of       discharge planning, (2) a telephone case conference call that\n",
      "includes the inmate and       significant members of the inmate's aftercare plan (including the\n",
      "parole officer), and (3)       strengths case management (for 12 weeks) in the community to promote\n",
      "treatment participation       and support the client's access to needed services.        More\n",
      "specifically, the multi-site study will evaluate the effects of a strengths       case-management\n",
      "intervention on community-based treatment/service admission, retention, and       utilization among\n",
      "inmates released from supervised treatment programs. If the intervention       is successful, its\n",
      "wider adoption would increase the likelihood that inmates enter and       remain in community\n",
      "services.        The specific aims of this multi-site study are to:          1. Increase the\n",
      "likelihood that offenders leaving prison (or other supervised setting)            with a referral to\n",
      "community aftercare program services enroll in treatment.          2. Increase the amount of time\n",
      "that such offenders participate in community treatment.          3. Assist clients to get the\n",
      "services that they need during the first 12 weeks of return            to the community.          4.\n",
      "As a result of the above, reduce relapse and reoffending during and following            treatment.\n",
      "5. Achieve the above results at a favorable cost-effectiveness ratio.          6. Encourage closer\n",
      "collaboration between the treatment and criminal justice systems.        Study participants (200 at\n",
      "each site, 25% of will be women) will be recruited in prison (or       other confined setting) from\n",
      "inmates who have a referral to community treatment. After       informed consent and a baseline\n",
      "interview, they will be randomly assigned to one of two       conditions: (1) the Transitional Case\n",
      "Management condition, and (2) the Standard Referral       condition (i.e., usual transition/re-entry\n",
      "procedures used by the facility, including a       referral to community treatment).\n",
      "Individual-level outcomes will include (1) treatment admission and participation (based on\n",
      "data collected from programs), (2) drug use, criminal activity, and psychosocial functioning\n",
      "(based on telephone interviews conducted 3 months after the end of the intervention) and (3)\n",
      "recidivism (based on records collected 12 months after the end of the intervention). The       study\n",
      "will also assess the impact of the intervention on organizational and system factors       (based on\n",
      "information from the case manager, treatment staff, and criminal justice staff)       and the cost\n",
      "effectiveness of the intervention.                         Inclusion Criteria:            -  Age 18\n",
      "years or older            -  Participate in a treatment program within a correctional institution\n",
      "(prison, work              release, community correctional facility)            -  Have a referral\n",
      "to a community-based substance abuse treatment program (as arranged              by correctional\n",
      "staff or treatment staff)            -  Within about 3 months until release            -  Being\n",
      "released to the metropolitan area where case manager activities are being              conducted\n",
      "Exclusion Criteria:            -  Referral to formal case management services in the community\n",
      "(e.g., for offenders              with co-occurring disorders)            -  Inability to provide\n",
      "informed consent (as determined by a set of questions about the              consent process)\n",
      "-  Registered sex offender (as determined by the institution)            -  Parole requirements that\n",
      "would prevent participation in the study (e.g., INS hold for              deportation)\n",
      "\n",
      "üîπ Doc ID: NCT01187758  (Score: 0.2416)\n",
      "Israeli Judicious Antibiotic Prescription Study             This study aims to implement judicious\n",
      "antibiotic prescription habits to primary care       pediatricians using a multifacet educational\n",
      "intervention and assess two main outcomes: 1)       Direct outcome - prescription rates of the\n",
      "physicians. 2)Indirect outcome - carriage of       antibiotic resistant bacteria by the treated\n",
      "population, specifically nasopharyngeal S.       pneumoniae, nasal S. aureus and rectal E.coli.\n",
      "Background: Bacterial antibiotic resistance is an increasing problem.        Aims: This study aims\n",
      "to implement judicious antibiotic prescription habits among 30       physicians and their treated\n",
      "population as compared to a control group of 30 physicians and       their treated population. The\n",
      "outcomes to be measured are:          1. Change in antibiotic prescriptions to the treated patients\n",
      "of the intervention vs.            control physicians during the study period (4years).          2.\n",
      "Change in carriage of antibiotic resistant pathogens, specifically nasopharyngeal\n",
      "penicillin resistant S. pneumoniae,nasal MRSA, and rectal quinolone resistant E. coli.        Study\n",
      "design: All primary care pediatricians of Hashfela district of Macabbi Healthcare       services who\n",
      "will agree to participate will be randomly assigned to an intervention or       control group. The\n",
      "intervention group will be led by local leaders (primary care physicians       from that district)\n",
      "and will take part in educational activities involving annual workshops       and quarterly focus\n",
      "group meetings. The intervention is a multifacet intervention that will       include guideline\n",
      "preparation, knowledge building, dealing with uncertainties, etc.        The patients of both\n",
      "intervention and control physicians will be screened twice a year for       carriage of the bacteria\n",
      "mentioned above. Cross-sectional screening of the treated       population will be carried in Summer\n",
      "and winter for 5 consecutive years. Screening will       include signing an informed consent,\n",
      "filling a questionnaire and screening with nasal,       nasopharyngeal and rectal swabs.\n",
      "Inclusion Criteria:            -  All treated patients of the participating physicians under the age\n",
      "of 5y, who came              for any reason for a visit during the study period, who's parents\n",
      "agreed to              participate.          Exclusion Criteria:          The only reason to exclude\n",
      "a child from being recruited was age>5y or refusal of the         parent/child to participate.\n",
      "\n",
      "üîπ Doc ID: NCT02416089  (Score: 0.2184)\n",
      "Tampostat for Management of Postpartum Hemorrhage             The purpose of the study is to\n",
      "evaluate the safety, feasibility and applicability of a new       device 'Tampostat' in the\n",
      "management of primary postpartum hemorrhage and compare the       efficacy of 'Tampostat' in terms\n",
      "of arresting primary PPH with that of the conventional       condom catheter.\n",
      "This will be a 2-year study having two parts. Part A will be a Proof of Concept (POC) study\n",
      "that will be conducted at the Obstetrical Ward of Shaheed Suhrawardi Medical College       Hospital\n",
      "(ShSMCH) and Dhaka Medical College Hospital (DMCH). There is no sample size       estimation of this\n",
      "POC study that will assess safety, feasibility and applicability of using       Tampostat on 5\n",
      "consenting women with PPH for each hospital. Part B of the study will be an       open label,\n",
      "randomized clinical trial that will be conducted at the Obstetrical Ward of       Dhaka Medical\n",
      "College Hospital (DMCH). In this part, 344 consenting women with primary PPH       will be enrolled,\n",
      "and allocated to either Tampostat or the control intervention in equal       numbers per\n",
      "randomization (172 patients in each arm). In both these parts, Tampostat will be       used only\n",
      "when Active Management of Third Stage of Labour (AMTSL) has failed to prevent PPH       within 24\n",
      "hours after delivery. All the doctors involved in the provision of care and       treatment to PPH\n",
      "patients will be trained on the WHO's standard of care; they will also       receive training on\n",
      "appropriate use of the devices to be used in this trial. An expert       committee constituted of\n",
      "OBGYN professionals, clinical trial specialists, and statisticians       will oversee the technical\n",
      "management of patients, data collection and their procedures, and       ethical issues in this\n",
      "trial.                         Inclusion Criteria:            1. Women who delivered their baby at\n",
      "the site hospital, or attended the site hospital              with PPH that started within the last\n",
      "24 hours.            2. Women with primary PPH have received AMTSL.            3. PPH is due to\n",
      "atonic uterus.            4. Provides written informed consent for enrolment in the study.\n",
      "Exclusion Criteria:            1. Primary PPH caused by retained placenta or ruptured uterus.\n",
      "2. Women who delivered before 28 weeks of gestation.            3. Women not willing to participate\n",
      "in the study.\n",
      "\n",
      "üîπ Doc ID: NCT01396590  (Score: 0.2156)\n",
      "Demonstrate Bioequivalence Between 6 ? 2-mg Tablets of Perampanel and a Single 12-mg Tablet of\n",
      "Perampanel in Healthy Subjects             The purpose of this study is to determine that six 2-mg\n",
      "tablets of perampanel are       bioequivalent to one 12-mg tablet of perampanel.\n",
      "Inclusion:            1. Healthy male or female subjects, age 18 to 55 years old, inclusive, at\n",
      "Screening            2. Body mass index (BMI) of 18 to 32 kg/m^2, inclusive, at Screening\n",
      "Exclusion:            1. Subjects who are taking any prescribed or over-the-counter drug or herbal\n",
      "remedies in              the 2 weeks prior to Screening (unless the OTC drug has a long halflife\n",
      "[i.e., 5 x              1/2 greater than 2 weeks]) with the exception of acetaminophen (up to 4\n",
      "g/day), which              is allowed up to 12 hours prior to dosing            2. Subjects who have\n",
      "taken St John's Wort or other dietary aids known to induce CYP3A4              within 4 weeks prior\n",
      "to dosing            3. Subjects who have taken any inhibitor of CYP450 within 2 weeks prior to the\n",
      "first              dosing (e.g., grapefruit, grapefruit juice, grapefruit-containing beverages,\n",
      "apple or              Seville orange products)            4. Subjects who have received any\n",
      "experimental drug within the 12 weeks leading up to              the start of study drug treatment\n",
      "or who are currently enrolled in another clinical              trial            5. Subjects with a\n",
      "known or suspected history of alcohol abuse within the 6 months prior              to Screening or\n",
      "who have a positive urine drug test or breath alcohol test at              Screening or Baseline, or\n",
      "who are unwilling to abstain from consumption of alcohol              throughout the periods of in-\n",
      "patient confinement            6. Subjects who consume more than 5 caffeinated beverages per day\n",
      "(e.g., 5 cups of tea,              coffee or cans of cola) or who are unwilling to abstain from\n",
      "consumption of              caffeine-containing food and beverages throughout the periods of in-\n",
      "patient              confinement            7. Subjects who smoke more than 5 cigarettes (or\n",
      "equivalent amount of tobacco) per day              or who are unwilling to abstain from the use of\n",
      "nicotine-containing products              throughout the period of in-patient confinement\n",
      "8. Subjects who have a history of drug abuse or dependence or have a positive result\n",
      "from a urine drug screening test            9. Women of child-bearing potential who do not agree to\n",
      "use 2 methods of adequate              contraception (e.g., intrauterine device, barrier methods\n",
      "with spermicide) throughout              the study and for 30 days after study drug administration\n",
      "\n",
      "üîπ Doc ID: NCT01396577  (Score: 0.2155)\n",
      "Demonstrate Bioequivalence Between 3 x 2-mg Tablets of Perampanel and a Single 6-mg Tablet of\n",
      "Perampanel in Healthy Subjects             The purpose of this study is to determine that three 2-mg\n",
      "tablets of perampanel are       bioequivalent to one 6-mg tablet of perampanel.\n",
      "Inclusion:            1. Healthy male or female subjects, age 18 to 55 years old, inclusive, at\n",
      "Screening            2. Body mass index (BMI) of 18 to 32 kg/m^2, inclusive, at Screening\n",
      "Exclusion:            1. Subjects who are taking any prescribed or over-the-counter drug or herbal\n",
      "remedies in              the 2 weeks prior to Screening (unless the OTC drug has a long halflife\n",
      "[i.e., 5 x              1/2 greater than 2 weeks]) with the exception of acetaminophen (up to 4\n",
      "g/day), which              is allowed up to 12 hours prior to dosing            2. Subjects who have\n",
      "taken St John's Wort or other dietary aids known to induce CYP3A4              within 4 weeks prior\n",
      "to dosing            3. Subjects who have taken any inhibitor of CYP450 within 2 weeks prior to the\n",
      "first              dosing (e.g., grapefruit, grapefruit juice, grapefruit-containing beverages,\n",
      "apple or              Seville orange products)            4. Subjects who have received any\n",
      "experimental drug within the 12 weeks leading up to              the start of study drug treatment\n",
      "or who are currently enrolled in another clinical              trial            5. Subjects with a\n",
      "known or suspected history of alcohol abuse within the 6 months prior              to Screening or\n",
      "who have a positive urine drug test or breath alcohol test at              Screening or Baseline, or\n",
      "who are unwilling to abstain from consumption of alcohol              throughout the periods of in-\n",
      "patient confinement            6. Subjects who consume more than 5 caffeinated beverages per day\n",
      "(e.g., 5 cups of tea,              coffee or cans of cola) or who are unwilling to abstain from\n",
      "consumption of              caffeine-containing food and beverages throughout the periods of in-\n",
      "patient              confinement            7. Subjects who smoke more than 5 cigarettes (or\n",
      "equivalent amount of tobacco) per day              or who are unwilling to abstain from the use of\n",
      "nicotine-containing products              throughout the period of in-patient confinement\n",
      "8. Subjects who have a history of drug abuse or dependence or have a positive result\n",
      "from a urine drug screening test            9. Women of child-bearing potential who do not agree to\n",
      "use 2 methods of adequate              contraception (e.g., intrauterine device, barrier methods\n",
      "with spermicide) throughout              the study and for 30 days after study drug administration\n",
      "\n",
      "========================================\n",
      "üîç Query: What is the trial design for this cancer study?\n",
      "\n",
      "üîπ Doc ID: NCT02839863  (Score: 0.5661)\n",
      "Utrecht Cohort for Multiple Breast Cancer Intervention Studies and Long-term Evaluation - The\n",
      "UMBRELLA Cohort             Due to better treatment options and earlier detection, survival rates of\n",
      "patients with       breast cancer continue to increase. As such, (late) treatment toxicity, (long-\n",
      "term) quality       of life and the cosmetic outcome are becoming more important. Also, many\n",
      "competing       experimental interventions (e.g. treatment, lifestyle interventions) for breast\n",
      "cancer are       being developed, all in need to be properly evaluated before being implemented in\n",
      "routine       clinical care. Randomized Controlled Trials are the gold standard to do so, but they\n",
      "have       shown many challenges, especially when applied in a cancer setting. The 'cohort multiple\n",
      "Randomized Controlled Trial (cmRCT)' design is a promising design for multiple       (simultaneous)\n",
      "randomized evaluations of experimental interventions, with potential for       increased\n",
      "recruitment, comparability and long-term outcomes as a standard.        By setting up UMBRELLA, as a\n",
      "prospective cohort according to the cmRCT design, the       investigators aim to:          -\n",
      "provide an infrastructure for efficient, fast and pragmatic evaluation and            implementation\n",
      "of experimental interventions          -  gain insight into short and long-term treatment response,\n",
      "toxicity, complications,            quality of life and survival of patients with breast cancer.\n",
      "Inclusion Criteria:            -  Age ‚â• 18 years            -  Patients with breast cancer who\n",
      "undergo irradiation in the UMC Utrecht            -  Informed consent - at least - for use of\n",
      "routinely collected clinical data and to              fill out questionnaires.          Exclusion\n",
      "Criteria:            -  Inability to understand the Dutch language\n",
      "\n",
      "üîπ Doc ID: NCT00668707  (Score: 0.5520)\n",
      "Adjuvant Melatonin for Prevention of Lung Cancer Recurrence and Mortality             There is\n",
      "evidence to support the use of melatonin, a natural health product, as an       additional treatment\n",
      "aid for cancer patients. This study is designed to see if the daily       ingestion of 20 milligrams\n",
      "of melatonin for one year can lower the incidence of developing       lung cancer recurrence and/or\n",
      "death. Only patients with a diagnosis of non small cell lung       cancer who are eligible for\n",
      "surgical resection can participate in the trial. The study will       also be assessing for changes\n",
      "in quality of life, pain, fatigue, anxiety, sleep, and       depression amongst the participants.\n",
      "The trial employs a two-armed parallel placebo controlled trial design whereby patients with       a\n",
      "diagnosis of non small cell lung cancer are randomized to receive either 20 mg of       melatonin\n",
      "nightly or an identically matched placebo. All patients will be followed for two       years with\n",
      "primary outcomes assessed at a two year time point and secondary outcomes       evaluated throughout\n",
      "the course of the trial.                         Inclusion Criteria:            -  Clinical\n",
      "diagnosis of non small cell lung cancer            -  Eligible for surgical resection            -\n",
      "Willingness to adhere to randomized treatment            -  Availability for follow-up schedule of\n",
      "visits          Exclusion Criteria:            -  Taking exogenous melatonin\n",
      "\n",
      "üîπ Doc ID: NCT02970500  (Score: 0.5328)\n",
      "Effect of Methylphenidate on Cancer-related Cognitive Impairment             Cancer-related\n",
      "cognitive Impairment, (CRCI) commonly referred to as \"chemo brain\" or \"brain       fog\"‚Äîimpact\n",
      "severely on the Quality of Life (QoL) of cancer survivors, It still remains       underdiagnosed and\n",
      "challenging to treat. One of the treatment options is the use of       psychostimulants such as\n",
      "Methylphenidate (MP), but well-designed clinical trials to test its       efficacy are limited. We\n",
      "will conduct a phase II study with a mixed method design to explore       the preliminary efficacy\n",
      "of MP to improve cognitive function and Quality of life in breast       cancer patients after\n",
      "treatment with chemotherapy and/or radiotherapy and determine the       parameters needed for\n",
      "designing a phase III study. This study will include two phases: Phase       one: randomized\n",
      "placebo-controlled clinical trial, phase 2 open-label trial.                     Objectives: The\n",
      "main objective of this study is to determine the parameters for a Phase III       study to measure\n",
      "the efficacy of methylphenidate (MP) in improving cognitive deficits in       women with Breast\n",
      "cancer who had received chemotherapy and / or radiotherapy. In addition,       the profile of drug\n",
      "side effects will be estimated. A better understanding of Cancer-related       cognitive impairment\n",
      "and its impact on the activities and quality of life of the study       population will be targeted.\n",
      "Population: The sample will consist of 40 women in remission from non-metastatic breast\n",
      "cancer, with follow-up at the Department of Radio-Oncology, CHU de Qu√©bec-Universit√©\n",
      "Laval-L'H√¥tel-Dieu de Qu√©bec, who had received chemotherapy or radiotherapy, complaining of\n",
      "cognitive impairment, and without any medical condition or contraindications to MP that may\n",
      "interfere with the drug or the cognitive impairment status. Before study inclusion, the\n",
      "eligibility of these women will be validated by questionnaires and verification of their\n",
      "medical records.        Recruitment: Recruitment will be made with the help of the radio-oncology\n",
      "team who will       refer patients to the research team. As alternative recruitment method, we will\n",
      "use posters.       flyers and advertisement. Finally, recruitment could be made through the clinical\n",
      "trial.gov       website.        Study design: A mixed methodology with a convergent design will be\n",
      "used in this pilot       clinical trial.        Procedures:        The study quantitative component\n",
      "will use questionnaires and tests assessing cognitive       function in order to estimate the effect\n",
      "size to be used in the design of a Phase III       clinical trial and will be divided into two\n",
      "phases. The first phase corresponds to a       double-blind randomized placebo-controlled trial\n",
      "which will test the effect of MP on       cognitive function. This phase begins at time T0, before\n",
      "any MP is taken, and ends 14 days       after, T1. Participants will be assigned randomly to the\n",
      "intervention, where they will       receive 10 mg of methylphenidate (Biphentin, slow released) for\n",
      "14 days or control group       where they will receive placebo.        The second phase is an open-\n",
      "label study that will explore a higher dosage. In this phase,       all participants will receive\n",
      "methylphenidate SR at an increasing dose starting at 10 mg for       a week (1capsule). After\n",
      "evaluation, this dosage will be increased, if possible, to 20 mg       per day (2 capsules).\n",
      "Depending on their response to the starting dose of MP, for the following 7 days, they will\n",
      "receive:          -  no Methylphenidate (no capsule), if they have important side effect;          -\n",
      "Methylphenidate 10 mg (1 capsule) if they have sufficient improvement or do not want to\n",
      "increase the dosage          -  Methylphenidate 20 mg (2 capsules) if they have partial or no\n",
      "improvement without            important side-effects. This phase begins at the end of the first\n",
      "phase T1 and ends 14            days after, T2.        Measures: The calculation of the effect size\n",
      "will be based on the Auditory consonant       trigrams which will be used to determine the power\n",
      "required for a Phase III study. This test       will also be used to test the sensitivity of the\n",
      "Fast Cognitive Evaluation tool (FaCE) which       is a new test developed and validated by our team.\n",
      "The global change in cognitive function will also be evaluated by the (FaCE). Other tests       will\n",
      "be explored to assess their sensitivity in measuring cognitive changes.        Here is the list of\n",
      "measures: Rotterdam Checklist Symptom, Unipedal Balance Test, Stroop       test, The Functional\n",
      "Assessment of Cancer Therapy-Cognitive Function, Multidimensional       fatigue inventory, Distress\n",
      "Thermometer.        Analysis: Descriptive statistical analyses will be carried out. Using tests such\n",
      "as T-test,       œá2 and ANOVA we will also estimate the degree of improvement in cognitive function\n",
      "by       comparing data from the Placebo and the methylphenidate group.        The qualitative\n",
      "component will explore, through a 1-hour individual interview with the 40       women included in\n",
      "the study, their experience of cognitive deficits before and after MP /       placebo, at T0 and T1.\n",
      "The analysis of these interviews will be carried out by combining two       methods: an intra-case\n",
      "analysis and an inter-case analysis, in order to properly document       the experience of these\n",
      "women and to arrive at an assessment of the transferability of the       results.        Each of the\n",
      "components of the study will answer its main questions independently. However,       the data will\n",
      "also be matched (triangulation) to provide a global understanding of the issue       and convergence\n",
      "of results where possible.                         Inclusion Criteria:            -  Breast cancer\n",
      "stade I, II or III            -  had received chemotherapy and/or radiotherapy            -  being\n",
      "in remission of her breast cancer            -  complaining of cognitive impairment\n",
      "Exclusion Criteria:            1. Current or recent use of psychostimulant drugs            2. Women\n",
      "receiving drugs like:               I. Anticoagulants Ii. Antidepressants Iii. Drugs (cocaine) Iv.\n",
      "Erythropoietin V.              Drugs acting on the cerebral dopaminergic system, including drugs\n",
      "that inhibit              monoamine oxidase Vi. Currently taking John's wort, natural medicines for\n",
      "depression              or supplements for fatigue.            3. Conditions that may increase the\n",
      "risk of cognitive impairment or toxicity of              methylphenidate such as :          i\n",
      "Pregnancy and breastfeeding ii. migraine, headachAnt√©c√©dent de migraine ou souffrant de\n",
      "migraine iii. bipolar status iv. cerebral tumor or any brain injury v. metastatic cancer         vi.\n",
      "Alcohol addiction vii drug viii. Active Major depression ix. Parkinson disease x.         Dementia\n",
      "xi. Epilepsia, xii. Glaucoma xiii. Cardiovascular diseases : xiv. Auto-immunes         and chronic\n",
      "inflammatory disease xv. Maladies c√©r√©bro-vasculaires xvi. Narcolepsia xvii.\n",
      "Pheochromocytome xviii. Thyrotoxicosis xix. Motor tic, Gilles de la Tourette syndrome xx.\n",
      "Anxiety\n",
      "\n",
      "üîπ Doc ID: NCT00924690  (Score: 0.5234)\n",
      "Colon Cancer Prevention Study             The goal of this research study is to design messages\n",
      "which can help people learn more about       how to prevent colon cancer. Eligible participants will\n",
      "be asked to review a series of short       cancer prevention messages and share their opinions on\n",
      "them. Participants also need to fill       out a short survey with questions on their background and\n",
      "attitudes and knowledge about       physical activity and colon cancer. The whole study can be\n",
      "completed online and will take       less than 1 hour. After completing the entire study,\n",
      "participants will receive $25.        If you are interested in participating in this study, please\n",
      "visit the following website:        https://surveys.chaicore.com/preventcancer/\n",
      "The goal of this research is to develop and test potential intervention messages which can       be\n",
      "used to help increase colon cancer prevention behaviors. Two sets of intervention       messages\n",
      "will be developed: generic and behavioral. Using a randomized control design the       investigators\n",
      "will evaluate the behavioral messages among women. This message testing       protocol will help\n",
      "them determine if the messages are relevant, acceptable, comprehensible,       memorable, and\n",
      "motivating for the target audience. The investigators' hypothesis is that the       behavioral\n",
      "messages will receive more positive ratings than the generic messages. If so,       they will be\n",
      "used to promote cancer screening and physical activity in future intervention       studies.\n",
      "Inclusion Criteria:            -  Female            -  Ages 50-80 years old\n",
      "\n",
      "üîπ Doc ID: NCT01336062  (Score: 0.5100)\n",
      "Trial of ABI-007 Plus S-1 as Second-line Chemotherapy in Advanced Gastric Cancer Patients\n",
      "Gastric cancer have poor prognosis and majority of patients resistant to 5-FU/DDP based       first-\n",
      "line chemotherapy in China. There was no recommended second-line chemotherapy for       advanced\n",
      "gastric cancer. Taxane is promising in gastric cancer. Nanoparticle Albumin-Bound       Paclitaxel\n",
      "(AbraxaneÔºåABI-007) has good convenience to use and been approved in breast cancer       in many\n",
      "countries. The investigator then initiated a prospective phase Ib/IIa clinical trial       with nab-\n",
      "paclitaxel plus TS-1 as the second-line treatment in advanced gastric cancer to       observe the\n",
      "safety and efficacy.                     This study is a two-stage design. Stage 1        The\n",
      "investigator should evaluate two recommend dose and tolerability of nab-paclitaxel plus       S-1\n",
      "after one course of treatment as 3+1 design:        nab-paclitaxel should be given intravenously on\n",
      "days 1 and 8 at a dose as follows, Treatment       should be repeated every 3 weeks: Treatment arm\n",
      "AÔºö125 mg /m2; Treatment arm BÔºö100 mg /m2;       Treatment arm C: 80 mg /m2; S-1 should be given\n",
      "orally twice a day as follows for 14       consecutive days, followed by a 1-week rest. Treatment\n",
      "should be repeated every 3 weeks. BSA       Ôºú 1.5 m2Ôºå40mgÔºåbid;BSA ‚â• 1.5 m2Ôºå50mgÔºåbid.        The\n",
      "investigator should determine whether to continue the original regimen; compare the       safety and\n",
      "pharmacokinetic results with original profile of combination therapy to select       the best\n",
      "therapy programs (RD, recommended dose).        Stage 2 According to two-stage design (Simon,1989),\n",
      "re-entry subjects to the recommended       dose group to a total of 25 valid cases. If 11 patients\n",
      "achieve response, then enter the       second phase of total 66 patients.\n",
      "Inclusion Criteria:            1. Signed informed consent form            2. Age 18-75 years;\n",
      "3. Histologically or cytologically confirmed gastric cancer;            4. Advanced or recurrent,\n",
      "metastatic disease;            5. Performance Status- Eastern Cooperative Oncology Group (ECOG) 0-1;\n",
      "6. Life expectancy of at least 12 weeks;            7. At least have one measurable\n",
      "disease(according to RECIST, Response Evaluation              Criteria in Solid Tumors )\n",
      "8. Subjects who have received one prior regimen for gastric carcinoma and developed\n",
      "disease progression or recurrence within 6 months after the end of systemic adjuvant\n",
      "treatment. The regimen must have contained fluorouracil(e.g. 5-FU,capecitabine)              and/or\n",
      "cisplatin;            9. Haematopoietic status:                 -  Absolute neutrophil count > 1.5 x\n",
      "109/L,                 -  Platelet count > 90 x 109/L,                 -  Hemoglobin at least 9\n",
      "g/dl,           10. Hepatic status:                 -  Bilirubin ‚â§ 1.5 x upper limit of normal\n",
      "(ULN),                 -  AST and ALT ‚â§ 2.5 times ULN(no liver metastasis), ‚â§5 times ULN(with liver\n",
      "metastasis)           11. Renal status:               - Creatinine ‚â§1.5 times ULN or calculated\n",
      "creatinine clearance, using the              Cockcroft-Gault formula, ‚â•40 mL/min;           12. Able\n",
      "to swallow and retain oral medicationÔºõwithout malabsorption syndrome, or disease\n",
      "significantly affecting gastrointestinal function, such as ulcerative colitis and\n",
      "Crohn's disease;           13. Cardiovascular: Baseline LVEF 50% measured by echocardiography (ECHO)\n",
      ";           14. Negative serum pregnancy test (For women of childbearing potential);Fertile patients\n",
      "must use effective contraception.          Exclusion Criteria:            1. Received any prior\n",
      "treatment including taxane or S-1;            2. Concurrent systemic anti-cancer therapy\n",
      "(immunotherapy, biologic therapy, hormone              therapy, etc ); received treatment with an\n",
      "investigational agent or participation in              another therapeutic clinical trial within 4\n",
      "weeks;            3. Unresolved or unstable, serious toxicity from prior cancer treatment (any\n",
      "toxicities              greater than grade 2; peripheral neuropathy of grade 2 or greater\n",
      "4. Symptomatic brain metastasis;            5. Known history of uncontrolled or symptomatic angina,\n",
      "clinically significant              arrhythmias, congestive heart failure, uncontrolled hypertension\n",
      "(‚â• 180/110),              unstable diabetes mellitus, dyspnea at rest, or chronic therapy with\n",
      "oxygen;            6. History of other malignancy. However, subjects with a past or current history\n",
      "of              completely resected basal and squamous cell carcinoma of the skin or successfully\n",
      "treated in situ carcinoma of the cervix are eligible            7. Dementia, altered mental status,\n",
      "or any psychiatric condition that would prevent the              understanding or rendering of ICF;\n",
      "8. Active or uncontrolled infection;            9. Concurrent treatment with an investigational\n",
      "agent or participation in another              therapeutic clinical trial;           10. Pregnant or\n",
      "lactating women.\n",
      "\n",
      "‚úÖ Hybrid BM25 + BERT reranking done.\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import joblib\n",
    "import numpy as np\n",
    "from sentence_transformers import SentenceTransformer, util\n",
    "from rank_bm25 import BM25Okapi\n",
    "import textwrap\n",
    "\n",
    "# Load preprocessed corpus (tokenized)\n",
    "with open(\"clinical_trials_bm25_corpus.pkl\", \"rb\") as f:\n",
    "    corpus = joblib.load(f)\n",
    "\n",
    "# Load BM25 model\n",
    "with open(\"clinical_trials_bm25_model.pkl\", \"rb\") as f:\n",
    "    bm25 = joblib.load(f)\n",
    "\n",
    "# Load original texts\n",
    "df_meta = pd.read_csv(\"clinical_trials_metadata.csv\")\n",
    "doc_id_to_text = dict(zip(df_meta['doc_id'], df_meta['original_text']))\n",
    "\n",
    "# Load BERT model and document embeddings\n",
    "model = SentenceTransformer('all-MiniLM-L6-v2')\n",
    "doc_embeddings = joblib.load(\"clinical_trials_bert_embeddings.pkl\")\n",
    "\n",
    "# Map from doc_id to index (to locate BERT embeddings)\n",
    "doc_id_to_index = {doc_id: idx for idx, doc_id in enumerate(df_meta['doc_id'])}\n",
    "\n",
    "# Example queries\n",
    "queries = [\n",
    "    \"What are the side effects of the vaccine?\",\n",
    "    \"Who can participate in the trial?\",\n",
    "    \"What is the trial design for this cancer study?\",\n",
    "]\n",
    "\n",
    "# Parameters\n",
    "bm25_top_k = 100   # How many BM25 docs to consider\n",
    "final_top_k = 5    # Final results to show after BERT reranking\n",
    "\n",
    "for query in queries:\n",
    "    print(\"=\" * 40)\n",
    "    print(f\"üîç Query: {query}\\n\")\n",
    "\n",
    "    # Step 1: BM25 retrieval\n",
    "    tokenized_query = query.lower().split()\n",
    "    bm25_scores = bm25.get_scores(tokenized_query)\n",
    "    top_indices = np.argsort(bm25_scores)[::-1][:bm25_top_k]\n",
    "    top_doc_ids = [df_meta.iloc[idx]['doc_id'] for idx in top_indices]\n",
    "\n",
    "    # Step 2: BERT rerank on top BM25 docs\n",
    "    top_texts = [doc_id_to_text[doc_id] for doc_id in top_doc_ids]\n",
    "    top_indices_for_bert = [doc_id_to_index[doc_id] for doc_id in top_doc_ids]\n",
    "    candidate_embeddings = doc_embeddings[top_indices_for_bert]\n",
    "\n",
    "    query_embedding = model.encode(query, convert_to_tensor=True)\n",
    "    cos_scores = util.cos_sim(query_embedding, candidate_embeddings)[0].cpu().numpy()\n",
    "\n",
    "    reranked = sorted(zip(top_doc_ids, cos_scores), key=lambda x: x[1], reverse=True)[:final_top_k]\n",
    "\n",
    "    for doc_id, score in reranked:\n",
    "        wrapped_text = textwrap.fill(doc_id_to_text[doc_id], 100)\n",
    "        print(f\"üîπ Doc ID: {doc_id}  (Score: {score:.4f})\\n{wrapped_text}\\n\")\n",
    "\n",
    "print(\"‚úÖ Hybrid BM25 + BERT reranking done.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "6b93104e-3c7a-47fd-b89a-eaff5ed5238f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ Inverted index for Clinical Trials built and saved.\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import json\n",
    "from collections import defaultdict\n",
    "\n",
    "# Load preprocessed dataset\n",
    "df = pd.read_csv(\"clinical_trials_cleaned.csv\")\n",
    "df['tokens'] = df['tokens'].apply(eval)\n",
    "\n",
    "# Build inverted index\n",
    "inverted_index = defaultdict(set)\n",
    "\n",
    "for idx, row in df.iterrows():\n",
    "    doc_id = row['doc_id']\n",
    "    tokens = row['tokens']\n",
    "    for token in set(tokens):  # Use set to avoid duplicates in the same doc\n",
    "        inverted_index[token].add(doc_id)\n",
    "\n",
    "# Convert sets to sorted lists for JSON serialization\n",
    "inverted_index = {term: sorted(list(doc_ids)) for term, doc_ids in inverted_index.items()}\n",
    "\n",
    "# Save inverted index\n",
    "with open(\"clinical_trials_inverted_index.json\", \"w\", encoding=\"utf-8\") as f:\n",
    "    json.dump(inverted_index, f, indent=2)\n",
    "\n",
    "print(\"‚úÖ Inverted index for Clinical Trials built and saved.\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "id": "bcdab623-a4d3-416c-bead-a7737a83eaf3",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "================================================================================\n",
      "üîç Query: vaccine side effects\n",
      "\n",
      "üîπ Doc ID: NCT00000683  (Score: 2)\n",
      "A Phase I Multicenter, Randomized, Double-Blind Trial to Evaluate the Safety and Immunogenicity of\n",
      "Recombinant Vaccinia Virus Expressing the Envelope Glycoproteins of Human Immunodeficiency Virus\n",
      "Evaluation of the safety and immunogenicity (immunological reactivity) of HIVAC-1e vaccine.       An\n",
      "additional goal is to determine which dose level of vaccine might be most effective.       Specific\n",
      "questions to be addressed in this part of the study include: Are there adverse       reactions to\n",
      "gp160 vaccine when given to vaccinees previously immunized with a       vaccinia-recombinant? Does\n",
      "gp160 vaccination of prior HIVAC-1e vaccine result in stimulation       of neutralizing antibody and\n",
      "other humoral immune responses? Does vaccination with gp160       enhance the development of cell-\n",
      "mediated immune responses in HIVAC-1e vaccinees? Is the       magnitude of immune response to gp160\n",
      "booster immunization greater following priming with       GP160 recombinant vaccinia (HIVAC-1e)\n",
      "vaccination than priming with three doses of purified       recombinant gp160? AMENDED: An 80 mcg\n",
      "dose of gp160 has been chosen for the booster because       this dose has been shown to be safe and\n",
      "immunogenic in previous trials and allows comparison       of the late boost in this protocol with\n",
      "the late boost in the protocol in which patients       were primed with three doses of gp160.\n",
      "Original design: HIVAC-1e vaccine is a preparation of       the envelope protein of HIV (the virus\n",
      "that causes AIDS). The protein is produced by genetic       modification in vaccinia virus. The\n",
      "purpose of a vaccine is to produce an artificially       increased immunity to a particular disease,\n",
      "in this case, AIDS. Since there is no known cure       for AIDS, the control of this disease\n",
      "necessitates the development of effective prevention       such as vaccines.\n",
      "AMENDED: An 80 mcg dose of gp160 has been chosen for the booster because this dose has been\n",
      "shown to be safe and immunogenic in previous trials and allows comparison of the late boost       in\n",
      "this protocol with the late boost in the protocol in which patients were primed with       three\n",
      "doses of gp160. Original design: HIVAC-1e vaccine is a preparation of the envelope       protein of\n",
      "HIV (the virus that causes AIDS). The protein is produced by genetic modification       in vaccinia\n",
      "virus. The purpose of a vaccine is to produce an artificially increased immunity       to a\n",
      "particular disease, in this case, AIDS. Since there is no known cure for AIDS, the       control of\n",
      "this disease necessitates the development of effective prevention such as       vaccines.\n",
      "AMENDED: Participants in the amended study will be given one injection in the deltoid muscle\n",
      "of gp160 vaccine. The injection of gp160 will be given 2 months after the first take with       the\n",
      "HIVAC-1e vaccine. After each inoculation, volunteers will be observed for one hour. For       four\n",
      "days after each inoculation, each participant will be interviewed daily to monitor side\n",
      "effects and asked to record their temperature and symptoms twice daily. It is anticipated       that\n",
      "a cohort of approximately 20 HIVAC-1e recipients from the participating AIDS Vaccine\n",
      "Evaluation Units will agree to receive the booster immunizations of gp160, and that this\n",
      "number of patients will be adequate to determine the booster effect of gp160. Original       design:\n",
      "Study patients receive two immunizations, one at the beginning of the study and a       second one\n",
      "eight weeks later. These immunizations are administered by scarification on the       arm, the same\n",
      "way that smallpox vaccines were given for several years. The patients are       divided into two\n",
      "groups. The control group receives a derivative of the smallpox vaccine       that is used to\n",
      "produce HIVAC-1e vaccine. The treatment group actually receives HIVAC-1e.       Whether a patient\n",
      "receives the parent virus or the vaccine is determined randomly by       computer, and neither the\n",
      "patient nor the physician knows who actually receives the vaccine.       The group receiving the\n",
      "parent virus and the group receiving HIVAC-1e are then divided into       three subgroups receiving\n",
      "different doses of HIVAC-1e, in order to test the effectiveness of       different doses of\n",
      "HIVAC-1e. Following the first inoculation and the booster inoculation       eight weeks later,\n",
      "patients have the vaccination site covered with a special waterproof       bandage until the\n",
      "vaccination site has healed. Participants are counseled on how to avoid       contact spread of the\n",
      "vaccine virus including hand washing, management of the bandage, and       separation from persons\n",
      "at high risk for the complications of the virus infection. Patients       are closely followed for\n",
      "the first four weeks following immunization and then followed for a       minimum of one year. Women\n",
      "are included only if willing to provide continuing information on       sexual practices and\n",
      "menstrual patterns, and furnish urine samples, as appropriate, for       pregnancy testing on the\n",
      "day of/before vaccination and every other week throughout the 56th       day after receipt of\n",
      "vaccine. At the Johns Hopkins site, patients are compensated depending       on how far they have to\n",
      "travel as long as they commit to every-other-day visits for the       first 30 days. This is to\n",
      "change the bandage and check on healing. Interested patients       should call collect for\n",
      "additional information about travel pay.                         Inclusion Criteria\n",
      "Patients must demonstrate the following clinical and laboratory findings:            -  Normal\n",
      "history and physical examination.            -  Normal chest X-ray (optional).            -  Normal\n",
      "urinalysis.            -  Negative ELISA.            -  Negative Western blot test.            -\n",
      "Negative HIV culture.            -  No evidence of smallpox vaccination.          Note:            -\n",
      "As an operational definition, an individual can be considered \"vaccinia naive\" only              if\n",
      "no scar is observable and the patient claims and/or has evidence of not being\n",
      "vaccinated. If the patient does not know his/her history, it should be presumed that\n",
      "he/she was vaccinated.          Exclusion Criteria          Patients will be excluded from the study\n",
      "for the following reasons:            -  Appearance of or serologic or clinical evidence of HIV\n",
      "infection.            -  Appearance of or serologic or clinical evidence of clinically active viral\n",
      "infections, including mononucleosis, Epstein-Barr virus, cytomegalovirus which may\n",
      "affect HIV immunocompetence.            -  Syphilis, gonorrhea, or any other sexually transmitted\n",
      "diseases including chlamydia              or pelvic inflammatory disease in the last 6 months.\n",
      "-  History of immunodeficiency or chronic illness.            -  Evidence of depression.\n",
      "-  History of positive PPD (tuberculosis exposure).            -  Positive syphilis serology.\n",
      "-  Positive for circulating Hepatitis B antigen.            -  Eczema, active or within the past\n",
      "year.            -  Household contact with someone who is pregnant.            -  Household contact\n",
      "with children less than 12 months old.            -  Household contact with anyone with eczema.\n",
      "-  Household contact with anyone with immunodeficiencies.            -  Vaccinia immunity.\n",
      "Note:            -  Current PPD test is required only if Merieux skin reaction to the tuberculin\n",
      "antigen              is positive.            -  If the patient does not know his/her vaccine\n",
      "history, it should be presumed that              he/she was vaccinated.          Prior Treatment:\n",
      "Excluded within 1 year of study entry:            -  Treatment for psychiatric problems.\n",
      "Excluded within 6 months of study entry:            -  Blood transfusions or cryoprecipitates.\n",
      "Patients may not have any of the following diseases or symptoms:            -  Appearance of or\n",
      "serologic or clinical evidence of HIV infection.            -  Appearance of or serologic or\n",
      "clinical evidence of clinically active viral              infections, including mononucleosis,\n",
      "Epstein-Barr virus, cytomegalovirus which may              affect HIV immunocompetence.            -\n",
      "Syphilis, gonorrhea, or any other sexually transmitted diseases including chlamydia              or\n",
      "pelvic inflammatory disease in the last 6 months.            -  History of immunodeficiency or\n",
      "chronic illness.            -  Evidence of depression.            -  Eczema, active or within the\n",
      "past year.          High risk behavior for human immunodeficiency virus (HIV) infection, including:\n",
      "-  Any history of intravenous drug use.            -  Syphilis, gonorrhea, or any other sexually\n",
      "transmitted diseases including chlamydia              or pelvic inflammatory disease in the last 6\n",
      "months.            -  More than 2 sexual partners or sexual contact with a high-risk partner in the\n",
      "last 6              months.\n",
      "\n",
      "üîπ Doc ID: NCT00000986  (Score: 2)\n",
      "The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related\n",
      "Complex             To test the safety and tolerance of three different doses of recombinant human\n",
      "interleukin 2       (aldesleukin; IL-2), when it is given for five consecutive days to patients with\n",
      "AIDS or       AIDS related complex (ARC), who have also received zidovudine (AZT) for at least 6\n",
      "weeks       just before beginning the IL-2 treatment.        AZT is an antiviral drug, which has\n",
      "been shown to be beneficial in some patients with AIDS.       IL-2 is a substance found naturally in\n",
      "the body that boosts the body's immune response to       invading organisms and tumor cells. These\n",
      "two drugs, when administered together, may have a       mutually helpful effect in treating AIDS\n",
      "patients, but before this effect can be studied, it       is important to understand the proper dose\n",
      "and any side effects that may occur when these       drugs are used together. The study will show\n",
      "how much AZT and IL-2 patients can safely take       at the same time and how the two drugs will\n",
      "interact with each other.                     AZT is an antiviral drug, which has been shown to be\n",
      "beneficial in some patients with AIDS.       IL-2 is a substance found naturally in the body that\n",
      "boosts the body's immune response to       invading organisms and tumor cells. These two drugs, when\n",
      "administered together, may have a       mutually helpful effect in treating AIDS patients, but\n",
      "before this effect can be studied, it       is important to understand the proper dose and any side\n",
      "effects that may occur when these       drugs are used together. The study will show how much AZT\n",
      "and IL-2 patients can safely take       at the same time and how the two drugs will interact with\n",
      "each other.        AMENDED: Note that the dose of AZT changed 900214 to reflect new dose\n",
      "recommendations.       Original design: Six weeks before beginning treatment with IL-2, patients are\n",
      "given AZT       daily. There are three patient groups, one for each dose level of IL-2. On the first\n",
      "day of       treatment with the two drugs together, patients are admitted to Presbyterian University\n",
      "Hospital, where AZT is administered orally every 4 hours and IL-2 is given once a day as a\n",
      "single injection under the skin. Clinical and laboratory safety data from the first two\n",
      "patients enrolled in each treatment group will be analyzed prior to enrolling additional\n",
      "patients in each group. All patients are expected to stay in the hospital for at least 5       days,\n",
      "and some may stay longer if serious side effects develop. AZT treatment will continue       after\n",
      "the patient leaves the hospital for an additional 10 weeks. Follow-up visits are       scheduled for\n",
      "days 6, 8, and 15 for safety, immunologic, and virologic evaluations.       Thereafter, patients are\n",
      "followed by telephone interview every other week and come into the       clinic if a change in\n",
      "health is reported. At weeks 10 and 20, patients are also evaluated in       a follow-up clinic\n",
      "visit.                         Inclusion Criteria          Concurrent Medication:          Allowed:\n",
      "-  Acetaminophen under the supervision of a study physician.          Prior Medication:\n",
      "Required for at least 6 weeks prior to study entry:            -  Zidovudine at a dose of at least\n",
      "300 mg/day.            -  Allowed:            -  Aerosolized pentamidine prior to combination\n",
      "therapy.          Patients must demonstrate the following clinical and laboratory findings:\n",
      "-  Currently receiving zidovudine (AZT) at a dose of at least 300 mg/day and have\n",
      "received the drug for at least 6 weeks.            -  Have a life expectancy of = or > 4 months.\n",
      "-  Available for the duration of the study and for follow-up visits.          Exclusion Criteria\n",
      "Co-existing Condition:          Patients with the following conditions will be excluded:\n",
      "-  Evidence of active life-threatening opportunistic infection with bacterial, viral,\n",
      "fungal, or protozoan pathogens during the 6-week period prior to and during the 5-day\n",
      "period of combination therapy.            -  A fever > 101 degrees F within the past 10 days.\n",
      "-  Significant central nervous system disease, including acquired immunodeficiency\n",
      "syndrome (AIDS), dementia, psychiatric disabilities, or seizure disorders.            -  Significant\n",
      "cardiac (New York Heart Association stage III or IV) and/or pulmonary              disease (forced\n",
      "expiratory volume < 75 percent).            -  Kaposi's sarcoma or other AIDS related malignancy.\n",
      "-  Evidence of malabsorption as indicated by 10 percent weight loss within the last 3\n",
      "months.          Concurrent Medication:          Excluded:            -  Cardiac medications.\n",
      "-  Glucocorticosteroids.            -  Probenecid.            -  Acetylsalicylic acid.            -\n",
      "Trimethoprim / sulfamethoxazole.            -  Acyclovir.            -  Allopurinol.            -\n",
      "Drugs causing anemia, neutropenia, or nephrotoxicity.            -  Aerosolized pentamidine during\n",
      "combination therapy.            -  Nonsteroidal anti-inflammatory drugs by patients with\n",
      "thrombocytopenia (<75000              platelets/mm3).            -  Acetaminophen except under\n",
      "supervision of a study physician.          Patients with the following conditions will be excluded:\n",
      "-  Evidence of active life-threatening opportunistic infection with bacterial, viral,\n",
      "fungal, or protozoan pathogens during the 6-week period prior to and during the 5-day\n",
      "period of combination therapy.            -  A fever > 101 degrees F within the past 10 days.\n",
      "-  Significant central nervous system disease, including acquired immunodeficiency\n",
      "syndrome (AIDS), dementia, psychiatric disabilities, or seizure disorders.            -  Significant\n",
      "cardiac (New York Heart Association stage III or IV) and/or pulmonary              disease (forced\n",
      "expiratory volume < 75 percent).            -  Kaposi's sarcoma or other AIDS related malignancy.\n",
      "-  Evidence of malabsorption as indicated by 10 percent weight loss within the last 3\n",
      "months.          Prior Medication:          Excluded within 4 weeks of study entry:            -\n",
      "Any antiretroviral drug, except zidovudine (AZT).            -  Excluded within 12 weeks of study\n",
      "entry:            -  Immunotherapy, including interleukins, interferons, tumor necrosis factor.\n",
      "-  Other cytokines.            -  Biologic response modifiers.            -  Monoclonal antibodies.\n",
      "-  BCG vaccines.          Active drug or alcohol abuse.\n",
      "\n",
      "üîπ Doc ID: NCT00001078  (Score: 2)\n",
      "A Study on the Rate of Opportunistic (AIDS-Related) Infections Among HIV-Positive Children Who Have\n",
      "Stopped Taking Their OI Preventive Medications             The purpose of this study is to find out\n",
      "if it is safe for HIV-positive children who are       responding well to their anti-HIV treatment to\n",
      "stop taking medications that prevent       AIDS-related infections (opportunistic infections) such\n",
      "as pneumonia and other bacterial       infections. This is an observational study, meaning children\n",
      "will only be monitored to see       if they develop any infections.        Children have been\n",
      "receiving medications to prevent complications of HIV infection, such as       Pneumocystis carinii\n",
      "pneumonia (PCP), Mycobacterium avium complex (MAC) disease, or other       bacterial infections. It\n",
      "is common for HIV-positive patients with low CD4 counts to receive       these preventive\n",
      "medications. However, these drugs can have serious side effects, they are       expensive, and it is\n",
      "possible for bacteria resistant to the drugs to grow. For these       reasons, it may be beneficial\n",
      "to the child to stop taking these preventive medications if       he/she has been on anti-HIV\n",
      "(antiretroviral) therapy and has improved CD4 counts. This study       will look at how many\n",
      "children who stop taking their medications develop opportunistic       infections.\n",
      "Due to the strong correlation between a significant decrease in CD4 count and the frequency\n",
      "and magnitude of OIs such as Pneumocystis carinii pneumonia (PCP), Mycobacterium avium       complex\n",
      "(MAC), and severe bacterial infections, CD4 count has become the major criterion for\n",
      "initiating antimicrobial prophylaxis for OIs. However, despite the benefits of these\n",
      "antimicrobial drugs, all are associated with adverse side effects, and patients with\n",
      "reconstituted immune systems following antiretroviral therapy may be receiving prophylaxis\n",
      "unnecessarily. Benefits to stopping prophylaxis include: (1) elimination of adverse effects\n",
      "from drugs; (2) reduction in drug costs; and (3) removal of selective pressure for the\n",
      "development of drug-resistant microbes. These benefits must be weighed against the\n",
      "disadvantages, however, such as more frequent determinations of CD4 counts to assure\n",
      "maintenance of immunocompetence, more frequent occurrence of serious OIs otherwise       preventable\n",
      "with prophylaxis in patients lost to follow-up, and possible occurrence of       atypical PCP\n",
      "because of prior exposure to anti-PCP drugs. [AS PER AMENDMENT 04/26/02: The       extent of\n",
      "complete immune restitution has not yet been defined. An important corollary of an       incomplete\n",
      "immune recovery is that vaccination schedules might need to be adjusted to obtain       optimal\n",
      "responses in HIV-infected patients on highly active antiretroviral therapy (HAART).       Therefore,\n",
      "a third dose of hepatitis A virus vaccine will be administered.]        After pre-entry and entry\n",
      "laboratory studies, patients are followed every 8 weeks until the       last patient has completed\n",
      "104 weeks of study observation. Hepatitis A vaccination is       administered at entry and Week 24\n",
      "to measure responses to neoantigen. [AS PER AMENDMENT       04/26/02: All patients (except those co-\n",
      "enrolled in P1024 on or after November 1, 2001) who       have received 2 doses of hepatitis A virus\n",
      "vaccine during the study will be offered an       opportunity to enroll in Step II of P1008.\n",
      "Patients in Step II receive a third dose of       hepatitis A vaccination at Week 104 or later.\n",
      "Additional blood samples are taken 8 weeks       later for antibody detection and peripheral blood\n",
      "mononuclear cell (PBMC) cryopreservation.]       All serious bacterial infections that are Grade 3\n",
      "or higher and OI events are recorded and       compared to historical event rates. Virologic and\n",
      "immunologic marker studies are done in all       patients and correlated with the risk of developing\n",
      "serious bacterial infections or OI       events. Patients are considered to have reached an endpoint\n",
      "if they develop PCP, 2 serious       bacterial infections, other Category C OI diagnoses, or CD4%\n",
      "less than 15% and re-initiation       of PCP prophylaxis.                         Inclusion Criteria\n",
      "Children may be eligible for this study if they:            -  Are HIV-positive.            -  Have\n",
      "a CD4 percent greater than or equal to 25 percent if they are under 6 years of              age, or\n",
      "have a CD4 percent greater than or equal to 20 percent on 2 occasions if they              are\n",
      "between the ages of 6 and 21.            -  Have been receiving preventive treatment for PCP for at\n",
      "least 6 months and have not              stopped treatment for more than 3 months before study\n",
      "entry.            -  Are willing to stop taking preventive treatment for PCP and MAC.            -\n",
      "Have received the same continuous antiretroviral (anti-HIV) therapy for the 16 weeks\n",
      "before beginning the study. (Continuous therapy means missing no more than a total of              3\n",
      "weeks during the 16 weeks.)            -  Are between the ages of 2 and 21 years (consent of parent\n",
      "or guardian is required if              under 18).          Exclusion Criteria          Children\n",
      "will not be eligible for this study if they:            -  Have PCP.            -  Have any other\n",
      "active infection, such as tuberculosis or toxoplasmosis, or any other              significant\n",
      "disease.            -  Are receiving chemotherapy for cancer or certain other medications.\n",
      "\n",
      "üîπ Doc ID: NCT00001133  (Score: 2)\n",
      "Safety and Tolerance of Indinavir Plus Ritonavir in HIV-Positive Patients Failing Therapy With\n",
      "Amprenavir, Nelfinavir, or Saquinavir             In this study, the protease inhibitors indinavir\n",
      "(IDV) and ritonavir (RTV) will be studied       in patients who have high levels of virus while\n",
      "taking other protease inhibitors. The       purpose of this study is to see how the body takes in,\n",
      "distributes, and gets rid of IDV and       RTV. This study will also look at any side effects that\n",
      "IDV or RTV causes.        IDV is an effective anti-HIV drug, but it can be difficult for patients to\n",
      "take. For IDV to       work against HIV, it must be taken 3 times a day at a high dose and with a\n",
      "certain diet.       Doctors believe IDV may be easier to take if it is given with RTV. Patients who\n",
      "take IDV and       RTV together may be able to take IDV only twice a day and at a lower dose. This\n",
      "study will       gather information about the safety and side effects of using IDV and RTV together.\n",
      "IDV, a protease inhibitor, has shown excellent clinical and virologic responses when       combined\n",
      "with 2 nucleoside analogues. Although effective, the pharmacokinetics of IDV make       it difficult\n",
      "to use in many patients. The drug has a short half-life and requires       administration in high\n",
      "doses every 8 hours with significant dietary restrictions. Research       has shown that IDV\n",
      "kinetics can be improved significantly by the addition of RTV, allowing       for administration of\n",
      "IDV at lower doses every 12 hours. The half-life of IDV is prolonged       3- to 5-fold when\n",
      "administered with RTV. Based on these results, it is reasonable to study       this combination as a\n",
      "twice-daily dosing regimen.        Patients are randomized to receive 1 of 2 doses of IDV/RTV for 24\n",
      "weeks (Arms A and B). All       patients also receive 2 nucleoside reverse transcriptase inhibitors\n",
      "(NRTIs). The NRTIs are       not provided by the study. Clinical assessments take place at Weeks 1,\n",
      "2, 4, 8, 12, 16, 20,       and 24 which includes a virology assessment. [AS PER AMENDMENT 4/21/00:\n",
      "Patients who       experience a confirmed virologic failure (defined in protocol) and elect to\n",
      "remain on study       treatment, are followed through Week 24. Patients who experience a confirmed\n",
      "virologic       failure and elect to discontinue study treatment will have a final evaluation at the\n",
      "time of       treatment discontinuation.] Patients are hospitalized for 12 hours at the Week 2 study\n",
      "visit       for an intensive pharmacokinetic analysis.                         Inclusion Criteria\n",
      "Patients may be eligible for this study if they:            -  Are HIV-positive.            -  Are\n",
      "at least 18 years old.            -  Have a viral load (level of HIV in the blood) of at least 500\n",
      "copies/ml but no more              than 100,000 copies/ml within 45 days of study entry.\n",
      "-  Have been taking the following anti-HIV drug combination for at least 12 weeks before\n",
      "study entry: 2 NRTIs plus amprenavir (APV), nelfinavir (NFV), saquinavir (SQV), or              NFV\n",
      "plus SQV.            -  Are naive to at least 1 NRTI. This means that there is at least 1 NRTI that\n",
      "the              patient has not taken for more than 14 days. In the case of lamivudine (3TC), naive\n",
      "means that the patient has never taken this drug.            -  Are willing and able to drink 1.5\n",
      "liters (a little over 1.5 quarts) of water or other              fluids a day.            -  Agree\n",
      "to use an effective barrier method of birth control (such as condoms) during              the study\n",
      "and for 3 months after.          Exclusion Criteria          Patients will not be eligible for this\n",
      "study if they:            -  Have taken protease inhibitors other than APV, NFV, SQV, or NFV plus\n",
      "SQV.            -  Are resistant to the effects of IDV or RTV, as shown by a blood test. (Patients\n",
      "whose              viral load is between 500 and 1,000 copies/ml will not need to be tested.)\n",
      "-  Have any active opportunistic (AIDS-related) infection in the 14 days before study\n",
      "entry.            -  Have any medical condition or history of disease that would prevent them from\n",
      "completing the study or put them at risk.            -  Have cancer that requires chemotherapy.\n",
      "-  Have an active infection that requires treatment in the 14 days before study entry.            -\n",
      "Have a fever for a week or more in the 30 days before study entry.            -  Have taken\n",
      "nonnucleoside reverse transcriptase inhibitors (NNRTIs) in the 30 days              before study\n",
      "entry.            -  Have received a vaccine in the 21 days before study entry.            -  Have\n",
      "received an experimental drug or a drug that affects the immune system in the 30              days\n",
      "before study entry.            -  Have taken or plan to take certain other medications that may\n",
      "affect the study.            -  Are pregnant or breast-feeding.\n",
      "\n",
      "üîπ Doc ID: NCT00001649  (Score: 2)\n",
      "Valaciclovir to Prevent Transmission of Herpes Simplex Virus             This study will evaluate\n",
      "the effectiveness of the drug valaciclovir in preventing       transmission of genital herpes from\n",
      "an infected to an uninfected sexual partner. Genital       herpes is caused by the herpes simplex\n",
      "virus 2 (HSV-2), or, infrequently herpes simplex       virus 1 (HSV-1). Valaciclovir prevents the\n",
      "herpes virus from multiplying and may also reduce       its transmission between partners.\n",
      "Couples 18 years of age and older in which one partner is infected with HSV-2 (source       partner)\n",
      "and the other is not (susceptible partner), may be eligible for this study.       Candidates will be\n",
      "screened with blood tests for routine laboratory studies and to verify       the presence or absence\n",
      "of HSV-2 or HSV-1 infection.        Participants will give a medical history, undergo a physical\n",
      "examination, including genital       examination, and receive counseling on safer sex practices and\n",
      "how to recognize signs and       symptoms of a possible first episode of genital herpes. Source\n",
      "partners will also be       counseled on transmission of genital herpes, and susceptible partners\n",
      "will be interviewed       about their sexual history and practices. The source partner will be\n",
      "randomly assigned to       take either a 500-mg tablet of valaciclovir or placebo (a pill with no\n",
      "active ingredient)       daily for 8 months. All participants will be given diary cards to complete\n",
      "for a month-the       source partner will record any drug side effects and the susceptible partner\n",
      "will record any       signs or symptoms of possible HSV infection.        Participants will be seen\n",
      "in the clinic once a month for 8 months. At these visits, source       partners will 1) return\n",
      "unused study medication and the completed diary card; 2) discuss any       adverse drug side effects\n",
      "experienced in the last month; 3) review medications other than       the study drug taken in the\n",
      "last month; 4) undergo counseling on safer sex practices,       transmission of genital herpes, and\n",
      "recognizing signs and symptoms of a first episode of       genital herpes; and 5) review symptoms\n",
      "and recurrences of genital herpes experienced during       the last month. During the final visit,\n",
      "they will also provide a blood sample for routine       testing and possible use in future studies.\n",
      "Susceptible partners will 1) have a blood sample       drawn for HSV testing; 2) undergo safer sex\n",
      "counseling; 3) review any symptoms experienced       over the last month; 4) be interviewed about\n",
      "sexual exposure and practices; and 5) return       the completed diary card.        Source partners\n",
      "who have a recurrence of genital HSV while on the study will be asked to       have their lesions\n",
      "cultured and will be offered open-label valaciclovir treatment.       Susceptible partners who\n",
      "contract genital herpes from the source partner during the study       will have a genital\n",
      "examination to verify a fist episode of genital herpes and will receive       10 days of open-label\n",
      "treatment with valaciclovir. Cultures will be taken from the mouth and       genitals, current\n",
      "medical conditions will be reviewed, blood samples will be drawn on       treatment days 1 and 10,\n",
      "and treatment side effects will be reviewed on days 5 and 10.        At the end of the study,\n",
      "infected partners will be offered a 12-month course of       valaciclovir, one 500-mg tablet daily.\n",
      "Participants will be followed in the clinic once       every 3 months to provide blood samples,\n",
      "return unused study medication and the diary card,       discuss any drug side effects, review\n",
      "medications taken besides the study drug, and review       symptoms or recurrences of genital\n",
      "herpes.        All participants will be asked to complete a questionnaire for gathering information\n",
      "about       people with genital herpes and people at risk for the infection.\n",
      "This is a randomized, multicenter, double-blind, placebo-controlled Phase III study to\n",
      "evaluate the effect of valaciclovir in preventing the transmission of herpes simplex virus\n",
      "(HSV) in heterosexual couples discordant for the presence of herpes simplex type 2 virus\n",
      "(HSV-2) antibody. The seropositive source partner will be randomized to receive valaciclovir\n",
      "500 mg once daily or placebo for 8 months, and the susceptible seronegative partner will be\n",
      "monitored for clinical and subclinical (serological) acquisition of HSV. Couples must be 18\n",
      "years of age or older, in general good health, and in a monogamous relationship with each\n",
      "other. Source partners must be seropositive for HSV-2, have a history of genital herpes\n",
      "recurrences, and experiencing less than 10 recurrences per year, and be off suppressive\n",
      "therapy upon entry into the study. Susceptible partners must be HSV-2 seronegative. The       couple\n",
      "will be stratified based on gender and HSV status of the susceptible partner in a       2:2:1:1\n",
      "ratio [HSV-1 negative female: HSV-1 positive female: HSV-1 negative male: HSV-1       positive\n",
      "male]. They will then be randomized to either valaciclovir 500 mg once daily or       placebo (1:1\n",
      "randomization) within each stratum. The primary endpoint is the proportion of       couples with\n",
      "clinical evidence of a first episode of genital HSV in the susceptible partner       with laboratory\n",
      "confirmation. Secondary endpoints will be time to clinical symptoms of       genital HSV by the\n",
      "susceptible partner, time to seroconversion in the susceptible partner,       and time to first\n",
      "recurrence of HSV in the source partner. A total of 1500 couples will be       randomized into the\n",
      "study. Assuming a 3% incidence in the placebo arm and a reduction of 75%       in the risk of\n",
      "showing clinical evidence of genital HSV, this study will have at least 80%       power for a two-\n",
      "tailed test at the 5% level of significance. The safety and tolerance of       valaciclovir will be\n",
      "assessed by laboratory evaluation and by occurrence and nature of       adverse events. The study\n",
      "will be conducted at approximately 35 outpatient centers in the       United States, Canada and\n",
      "Europe, therefore it is expected that each center will enroll       between 40 to 60 couples.\n",
      "INCLUSION CRITERIA - SOURCE PARTNER          18 years of age or older.          General good health\n",
      "as determined by current medical status and laboratory tests.          Active heterosexual\n",
      "relationship with susceptible partner.          Presence of HSV-2 serum antibody as determined by\n",
      "Western blot analysis.          History of symptomatic recurrent genital herpes.          Off HSV\n",
      "suppressive therapy upon entering study.          In the opinion of the investigator, able to comply\n",
      "with protocol requirements.          In the investigator's opinion, subjects must be candidates for\n",
      "receiving suppressive         therapy for management of their disease.          Written informed\n",
      "consent.          EXCLUSION CRITERIA - SOURCE PARTNER:          Patients who are known or suspected\n",
      "to be immunocompromised (e.g., patients receiving         immunosuppressive therapy, patients with\n",
      "malignancy or seropositive for HIV).          Subjects with a history of 10 or more HSV recurrences\n",
      "per year.          Impaired renal function as defined by serum creatinine greater than 1.5 mg/dL or\n",
      "estimated         creatinine clearance less than 30 ml/min.          Impaired hepatic function\n",
      "defined as an alanine transaminase (ALT) level greater than 3         times the normal upper limit.\n",
      "Known resistance to aciclovir, famciclovir, or ganciclovir.          Known hypersensitivity to\n",
      "aciclovir, valaciclovir, famciclovir, or ganciclovir.          Malabsorption syndrome or other\n",
      "gastrointestinal dysfunction that might impair drug         dynamics.          Subjects known to be\n",
      "lactose intolerant.          Women contemplating pregnancy within the duration of study drug dosing\n",
      "for this study.          Women of child bearing potential not using an effective method of\n",
      "contraception.          Positive pregnancy test (or pregnant females or nursing mothers).\n",
      "INCLUSION CRITERIA - SUSCEPTIBLE PARTNER          18 years of age or older.          General good\n",
      "health as determined by current medical status.          Active monogamous, heterosexual\n",
      "relationship with source partner.          Absence of HSV-2 serum antibody as determined by Western\n",
      "blot analysis.          In the investigator's opinion, able to comply with protocol requirements.\n",
      "Written informed consent.          EXCLUSION CRITERIA - SUSCEPTIBLE PARTNER:          Subjects who\n",
      "are known or suspected to be immunocompromised (e.g., patients receiving         immunosuppressive\n",
      "therapy, patients with malignancy or seropositive for HIV).          Subjects who have received an\n",
      "active HSV vaccine (subjects known to have received placebo         in clinical trials are\n",
      "eligible).          Presence of symptomatic genital herpes.          Subjects having sexual\n",
      "relations with anyone other than the source partner.          Women contemplating pregnancy within\n",
      "the time period of the study.          Women of childbearing potential not using an effective method\n",
      "of contraception.          Positive pregnancy test (or pregnant females or nursing mothers).\n",
      "================================================================================\n",
      "üîç Query: eligibility criteria cancer trial\n",
      "\n",
      "üîπ Doc ID: NCT00000124  (Score: 3)\n",
      "Collaborative Ocular Melanoma Study (COMS)             To evaluate therapeutic interventions for\n",
      "patients who have choroidal melanoma, the most       common primary eye cancer affecting adults, and\n",
      "to assess the potential life-preserving as       well as sight-preserving role of radiation therapy.\n",
      "To determine which of two standard treatments, removal of the eye or brachytherapy, is more\n",
      "likely to prolong survival of eligible patients with medium-sized choroidal melanoma.        To\n",
      "determine whether preoperative radiation prolongs life for patients whose eyes with large\n",
      "choroidal melanoma are enucleated.                     For more than 100 years, removal of the eye\n",
      "(enucleation) has been the standard treatment       for choroidal melanoma. Before the COMS was\n",
      "initiated in 1986, interest in radiation therapy       had increased because of the potential for\n",
      "saving the eye and perhaps some vision. However,       the merits of radiation with respect to\n",
      "prolonging patient survival were unknown. The best       data from nonrandomized studies suggested\n",
      "that there was no difference in length of       remaining life between patients treated with\n",
      "radiation and those whose eyes were enucleated.       Thus, it was appropriate and necessary to\n",
      "conduct a randomized, controlled clinical trial in       which a large number of patients would be\n",
      "followed for many years in order to compare       enucleation and radiation with respect to relative\n",
      "success in prolonging survival of       choroidal melanoma patients.        The Collaborative Ocular\n",
      "Melanoma Study (COMS) is a set of long-term, multicenter,       randomized controlled trials. In the\n",
      "trial for patients with tumors of medium size,       enucleation and irradiation with an iodine-125\n",
      "episcleral plaque are compared on the basis       of length of remaining life. All randomized\n",
      "patients will be followed for 5 to 15 years or       until death. For patients randomly assigned to\n",
      "enucleation, the eye was removed following a       standard procedure. For patients assigned to\n",
      "plaque irradiation, the margins of the tumor       were located and the dimensions of the tumor were\n",
      "measured by the ophthalmic surgeon. A gold       plaque with a plastic seed carrier that contained\n",
      "the proper dosage and configuration of       radioactive iodine seeds was sutured to the outside\n",
      "(sclera) of the eye over the base of the       tumor. This procedure made possible the delivery of a\n",
      "high dose of radiation to a very       localized area (85 Gy [TG-43] to the tumor apex). The plaque\n",
      "typically was removed from the       eye after three to seven days. Enrollment was completed in this\n",
      "trial in July 1998 with       1,317 patients enrolled. Clinical follow-up of patients will end in\n",
      "July 2003.        In the COMS trial of preoperative radiation, patients with large tumors were\n",
      "randomized to       enucleation alone or to enucleation preceded by 20 Gy of external beam\n",
      "radiation. The two       randomly assigned groups of patients were followed for at least five years\n",
      "or until death       and have been compared on the basis of length of remaining life and other\n",
      "outcomes.       Enrollment in this trial was completed in December 1994, with 1,003 patients\n",
      "enrolled.       Clinical follow-up of all patients in this trial ended in July 2000.        Accrual\n",
      "to a nonrandomized pilot study to assess the feasibility of a randomized trial for       small\n",
      "tumors was halted in 1989. Additional followup of those 204 patients was carried out       from 1994\n",
      "to 1996.        The COMS is conducted in 43 clinical centers located in major population areas of\n",
      "the United       States and Canada. Six resource centers participate and have major roles in quality\n",
      "assurance for the study. Information gathered and analyzed includes time to death from all\n",
      "causes, time to death from cancer (whether metastatic choroidal melanoma or not), diagnosis       of\n",
      "other tumors, complications of radiation, and changes in visual acuity. A parallel study       of\n",
      "quality of life for patients enrolled in the trial of radioactive plaque was initiated in\n",
      "January 1995. From November 1986 through July 1998, 8,712 patients with choroidal melanoma       of\n",
      "all sizes were screened for eligibility for a COMS clinical trial.                         Men and\n",
      "women eligible for the study must be age 21 or older, have primary choroidal         melanoma in\n",
      "only one eye, and have no evidence of metastatic disease. Accurate estimation         of tumor\n",
      "thickness by echography must also be possible.\n",
      "\n",
      "üîπ Doc ID: NCT00000984  (Score: 3)\n",
      "A Phase I Study of the Safety and Pharmacokinetics of Recombinant CD4 (rCD4) in Infants and Children\n",
      "Infected With or at Risk for HIV Infection             AMENDED: As of 10/19/90 only Children 0 to 3\n",
      "months are being enrolled. Original design: To       determine whether the experimental drug\n",
      "recombinant CD4 (rCD4), which is produced through       genetic engineering technology, is safe and\n",
      "well-tolerated in children infected with or at       risk for HIV infection.        rCD4 may be an\n",
      "effective treatment for HIV infection, based on its ability to block       infection of human cells\n",
      "by HIV in laboratory tests. However, the activity of rCD4 still       needs to be confirmed in\n",
      "clinical trials. It is hoped that these tests will show that rCD4       is both safe and effective\n",
      "in treating children who are infected with or who are at risk for       infection with HIV.\n",
      "rCD4 may be an effective treatment for HIV infection, based on its ability to block       infection\n",
      "of human cells by HIV in laboratory tests. However, the activity of rCD4 still       needs to be\n",
      "confirmed in clinical trials. It is hoped that these tests will show that rCD4       is both safe\n",
      "and effective in treating children who are infected with or who are at risk for       infection with\n",
      "HIV.        Children have preliminary testing and evaluation to determine eligibility and health.\n",
      "The       dosage schedule varies with the dose. During the course of the study, children are\n",
      "monitored       for safety through physical exams and blood tests. They have blood withdrawn to\n",
      "study the       response to rCD4 and measure the activity of rCD4 in the body. Children may receive\n",
      "immunization of DPT (diphtheria, pertussis, tetanus) or DT and a polio vaccine to measure\n",
      "their antibody response. If the rCD4 is beneficial, children may continue treatment. The       study\n",
      "is conducted in four parts:          -  Part A: Children 13 to 18 years old.          -  Part B:\n",
      "Children 3 months to less than 13 years old.          -  Part C: Full-term infants over 3 months\n",
      "old.          -  Part D: Preterm infants less than 3 months old. Parts C and D are not started until\n",
      "parts A and B have been completed.                         Inclusion Criteria          Concurrent\n",
      "Medication:          Allowed:            -  Prophylactic medication for patients with previous\n",
      "documented episodes of              Pneumocystis carinii pneumonia (PCP).            -  Concomitant\n",
      "zidovudine (AZT) or intravenous gamma globulin (IVIG) during maintenance              therapy phase\n",
      "of the study.          AMENDED: As of 10/19/90 only Children 0 to 3 months are being enrolled.\n",
      "Original design: Patients must be infected with HIV or at risk for HIV infection. They         must\n",
      "be one of the following:            -  Asymptomatic.            -  Mildly symptomatic but not\n",
      "eligible for and/or decline ACTG protocol 052.            -  Markedly symptomatic but not eligible\n",
      "for and/or decline ACTG protocol 051 or cannot              tolerate zidovudine (AZT) therapy.\n",
      "All patients must have:            -  A life expectancy of at least 3 months.            -  A\n",
      "legally-qualified guardian with the ability to sign a written informed consent              form,\n",
      "which must be obtained prior to treatment. A willingness to abstain from all              other\n",
      "experimental therapy for HIV infection during the entire study period.          Exclusion Criteria\n",
      "Concurrent Medication:          Excluded:            -  Zidovudine (AZT).            -  Intravenous\n",
      "gamma globulin (IVIG).            -  Pentamidine.            -  Trimethoprim / sulfamethoxazole\n",
      "(TMP/SMX).            -  Corticosteroids.            -  Nonsteroidal anti-inflammatory agents\n",
      "(NSAIDS).            -  Other known immunomodulatory agents.            -  All other experimental\n",
      "therapies.          Patients will be excluded from the study for the following reasons:            -\n",
      "Serious active opportunistic infection or malignancies prior to study entry.            -  Defined\n",
      "organ insufficiencies.          Prior Medication:          Excluded within 3 weeks of study entry:\n",
      "-  Zidovudine (AZT).            -  Intravenous gamma globulin.            -  Cancer chemotherapy.\n",
      "-  Immunomodulatory agents.            -  Other experimental therapy.          Patients may not have\n",
      "any of the following diseases or symptoms:            -  Serious active opportunistic infection or\n",
      "malignancies prior to study entry.            -  Cardiopathy.            -  Two or more episodes of\n",
      "prior Pneumocystis carinii pneumonia (PCP).            -  Hematologic insufficiency defined as\n",
      "granulocytes = or < 1000 cells/mm3; platelets =              or < 100000 cells/mm3; hemoglobin = or\n",
      "< 8 g/dl.            -  Renal insufficiency defined as creatinine > 2 mg/dl; = or > 5 white blood\n",
      "cells or              red blood cells/hpf or = or > 2+ proteinuria in urine.            -  Hepatic\n",
      "insufficiency defined as bilirubin = or > 3 x upper limit of normal; SGOT =              or > 10\n",
      "upper limit of normal.\n",
      "\n",
      "üîπ Doc ID: NCT00001144  (Score: 3)\n",
      "Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia             This\n",
      "study will investigate the safety and effectiveness of a new stem cell transplant       procedure\n",
      "for treating chronic myelogenous leukemia (CML).        Transplantation of donated stem cells (cells\n",
      "produced by the bone marrow that mature into       the different blood components-white cells, red\n",
      "cells and platelets) is a very effective       treatment for CML. However, despite its success in a\n",
      "large number of patients, there is       still a significant risk of death from the procedure. In\n",
      "addition, it results in sterility       and leaves patients at increased risk for other cancers and\n",
      "for eye cataracts. These       complications result from the intensive chemotherapy and radiation\n",
      "patients receive before       the transplant to rid the body of cancer cells. In this study,\n",
      "radiation will not be used       and chemotherapy drugs will be given in lower doses to try to\n",
      "reduce the dangers of the       procedure.        Patients with CML will be tested for matching with\n",
      "a donor (family member) and will undergo       a medical history, physical examination and several\n",
      "tests (e.g., breathing tests, X-rays,       and others) to determine eligibility for the study.\n",
      "Participants will then undergo apheresis       to collect lymphocytes (white blood cells important\n",
      "in the immune system). In apheresis,       whole blood is drawn through a needle in the arm, similar\n",
      "to donating a unit of blood. The       required component-in this case, lymphocytes-are separated\n",
      "and removed, and the rest of the       blood is returned through a needle in the other arm.\n",
      "Each day starting five days before the transplant, the donor will be given an injection of\n",
      "G-CSF, a drug that releases stem cells from the bone marrow into the blood stream. The cells\n",
      "will be collected after the fifth injection and again after a sixth injection the following\n",
      "day. Meanwhile, patients will be given cyclophosphamide and fludarabine, and perhaps       anti-\n",
      "thymocyte globulin, to prevent rejection of the donated cells.        On the day of the transplant,\n",
      "patients will be given cyclosporin to prevent       graft-versus-host-disease, a disease in which\n",
      "the donor cells react against the patient's       cells. They may also be given lymphocytes after\n",
      "the transplant to boost the immune system       and destroy leukemia cells. After 30, 60 and 100\n",
      "days, bone marrow cells and circulating       lymphocytes will be checked to see how many are of\n",
      "donor cell origin. If less than 100       percent are of donor origin, more lymphocytes will be\n",
      "transfused. Patients will have       physical examinations and blood tests at least weekly for 3\n",
      "months and then periodically for       5 years.                     CML is a disease which\n",
      "progresses to blast crisis within five years of onset despite medical       intervention. Allogeneic\n",
      "transplantation has provided a definitive cure for a large number       of patients. The\n",
      "International Bone Marrow transplant registry reports a 67% three-year       disease free survival\n",
      "for CML patients receiving a matched sibling transplant. However there       remains a 17-20%\n",
      "treatment-related mortality and significant long-term complications.       Myeloablative regimens\n",
      "with total body irradiation (TBI) are associated with certain       sterility, along with a\n",
      "significant incidence of cataracts and second malignancies. Efforts       to ameliorate this\n",
      "toxicity have led to the development of regimens lacking total body       irradiation. Although the\n",
      "follow-up period for patients receiving these regimens has not       been long enough to answer the\n",
      "question of long-term toxicity, it appears that the response       rate and the disease free\n",
      "survival are comparable to regimens containing TBI. In addition,       transplantation experience\n",
      "with aplastic anemia where TBI is not part of the regimen       indicates that treatment related\n",
      "mortality along with the risk of long-term sequela are       significantly decreased.        Non-\n",
      "myeloablative allogeneic peripheral blood stem cell transplants are currently being\n",
      "investigated in phase I/II trials assessing engraftment efficacy and toxicity at a number of\n",
      "transplant centers. Preliminary data, including our own experience with 30 patients       undergoing\n",
      "this type of procedure, has shown a high rate of complete donor engraftment with       a low\n",
      "toxicity profile. Two recent studies investigating non-myeloablative       allo-transplantation in\n",
      "standard risk patients revealed an extremely low rate of       transplant-related complications and\n",
      "mortality.        In this protocol we investigate non-myeloablative allogeneic PBSC transplantation\n",
      "in       patients with CML. The patient group under study would include all patients with chronic\n",
      "phase CML having an HLA-identical sibling. In this protocol, eligible patients would be\n",
      "treated with an allogeneic peripheral blood stem cell transplant from an HLA identical or\n",
      "single HLA antigen-mismatched family donor, using an intensive immunosuppressive regimen\n",
      "without myeloablation (\"mini-transplant\") in an attempt to decrease the transplant related\n",
      "toxicities while preserving the anti-malignancy and/or anti-host marrow effect of the graft.\n",
      "The low intensity non-myeloablative conditioning regimen should provide adequate\n",
      "immunosuppression to allow stem cell and lymphocyte engraftment. T-cell replete,       donor-\n",
      "derived, granulocyte colony stimulating factor (G-CSF)-mobilized peripheral blood stem       cells\n",
      "(PBSC) will be used to establish hematopoietic and lymphoid reconstitution. We will       add back\n",
      "lymphocytes in patients with less than 100% donor T-cell chimerism in an attempt to       prevent\n",
      "graft rejection and enhance a graft-versus-malignancy effect.        The primary endpoint of this\n",
      "study is transplant related mortality (1 year survival). Other       end points include engraftment,\n",
      "degree of donor-host chimerism, incidence of acute and       chronic graft versus host disease\n",
      "(GVHD), transplant related morbidity, as well as       disease-free and overall survival.\n",
      "PATIENTS:          Patients in chronic phase CML.          Age 10 to 50.          Informed consent\n",
      "given.          Availability of HLA identical or single HLA-locus mismatched family donor.\n",
      "Females must not be pregnant or lactating.          Must not have ECOG performance status of 3 or\n",
      "more. Must not have a psychiatric disorder         or mental deficiency severe as to make compliance\n",
      "with the BMT treatment unlikely, and         making informed consent impossible.          Must not\n",
      "have major anticipated illness or organ failure incompatible with survival from         PBSC\n",
      "transplant.          Must not have diffusion capacity of carbon monoxide (DLCO) less than 40%\n",
      "predicted.          Must not have left ventricular ejection fraction: less than 30%.          Must\n",
      "not have serum creatinine greater than 50% above normal as defined by age.          Must not have\n",
      "serum bilirubin greater than 4 mg/dl.          Must not have transaminases greater 5 x upper limit\n",
      "of normal.          Must not have other malignant diseases liable to relapse or progress within 5\n",
      "years.          DONOR:          HLA identical or single HLA-locus mismatched family donor, up to 80\n",
      "years old.          Informed consent given.          Females must not be pregnant or lactating.\n",
      "Donor must be fit to receive G-CSF and undergo apheresis. (No controlled hypertension, no\n",
      "history of congestive heart failure or unstable angina, thrombocytopenia).          Must be HIV\n",
      "negative. Donors who are positive for hepatitis B (HBV), hepatitis C (HBC) or         human T-cell\n",
      "lymphotropic virus (HTLV)-I will be used at the discretion of the         investigator.\n",
      "\n",
      "üîπ Doc ID: NCT00001163  (Score: 3)\n",
      "Clinical, Laboratory, and Epidemiologic Characterization of Individuals and Families at High Risk of\n",
      "Cancer             This is a clinical, epidemiologic, genetic, and laboratory study of individuals\n",
      "and families       at high risk of cancer and selected tumors to investigate the genetic\n",
      "susceptibility and       environmental exposures which may alter cancer risk. Families with multiple\n",
      "members who have       an unusual pattern or number of cancers or tumors are evaluated clinically.\n",
      "This evaluation       is specific for the type of cancer or tumor predominant in the family in order\n",
      "to determine       the affection status of each individual for genetic epidemiologic studies.\n",
      "Genetic and       environmental risk factor information specific for the tumor type is obtained.\n",
      "Individuals with, or at high risk of, cancer because of their personal, familial, or\n",
      "environmental histories are identified by healthcare worker referral or by personal inquiry.\n",
      "Relevant etiologic risk factor information is documented through review of pathology       specimens\n",
      "and medical, vital, and genealogical records. Selected individuals and family       members are\n",
      "asked to complete questionnaires and to undergo clinical evaluations specific       for the tumor of\n",
      "interest. They are also asked to donate biologic specimens to be used in       the search for cancer\n",
      "etiology and mechanisms of carcinogenesis. No therapy beyond       counseling and education for\n",
      "cancer prevention, risk reduction, and early detection will be       given.        Genetic testing\n",
      "for tumor susceptibility gene(s) mutations and risk notification will be       offered to study\n",
      "participants for whom a specific mutation predictive of disease has been       identified in his/her\n",
      "family. This testing will only be offered when reasonable individual       cancer risk estimates can\n",
      "be delivered, and only to those participants who choose to know       their individual genetic\n",
      "status after appropriate education and counseling. The testing will       be conducted exclusively\n",
      "in Clinical Laboratory Improvement Amendments (CLIA)-licensed       laboratories. Genetic testing\n",
      "and risk notification are entirely optional and do not affect       participation in other aspects\n",
      "of the protocol. A separate consent procedure and consent       form will be used for genetic\n",
      "testing and risk notification related to these specific genes.        Once enrolled, study\n",
      "participants are monitored prospectively for the development of       outcomes of interest,\n",
      "typically by means of periodic mail or telephone contact. In selected       instances, subjects may\n",
      "return to the Clinical Center periodically for study-specific       follow-up examinations. Although\n",
      "we do not offer specific anti-cancer therapy as part of       this protocol, we provide assistance\n",
      "to insure that study participants who require treatment       for tumor-related problems that\n",
      "develop during the course of the study are referred to       appropriate healthcare providers. We\n",
      "remain available to study participants and their       healthcare providers for advice and\n",
      "consultation related to the management of familial       cancer/tumor predisposition.\n",
      "Background:        Persons may be prone to develop cancer for a variety of reasons including:\n",
      "inherited       predisposition benign, premalignant, or malignant conditions; environmental\n",
      "exposures shared       by family members; previous tumors, immune deficiency, or preneoplastic\n",
      "conditions.        Investigations of individuals and families at high risk of cancer often lead to\n",
      "etiologic       clues that may be important in the sporadic counterparts of these cancers in the\n",
      "general       population.        Identification of etiologically important genetic factors could\n",
      "inform chemoprevention       trials, screening programs, and treatment of the studied cancer types.\n",
      "Objectives:        To evaluate and define the clinical spectrum and natural history of disease in\n",
      "syndromes       predisposing to cancer.        To evaluate potential precursor states of disease in\n",
      "families at risk.        To quantify risks of tumors in family members.        To map, clone, and\n",
      "determine function of tumor susceptibility genes.        To identify genetic determinants,\n",
      "environmental factors, and gene-environment interactions       conferring cancer risk in individuals\n",
      "and families.        To evaluate gene-gene and gene-environment interactions in tumor formation.\n",
      "To educate and counsel study participants about their tumor risk including prevention\n",
      "recommendations and early detection activities when known.        To develop educational materials\n",
      "for medical professionals and high-risk family members.        Eligibility:        Persons of any\n",
      "age will be considered for inclusion in the study because of either,        A family or personal\n",
      "medical history of neoplasia of an unusual type, pattern, or number;       or,        Known or\n",
      "suspected factor(s) predisposing to neoplasia, either genetic and/or congenital       factors,\n",
      "environmental exposure, or unusual demographic features.        Types of familial tumors that we are\n",
      "currently actively accruing include Cancers: bladder,       bone, brain, chordoma, lung, nevoid\n",
      "basal cell carcinoma syndrome (NBCC).        Design:        This is a prospective study. Individuals\n",
      "and families are studied long-term, using a cohort       approach.        The study design and\n",
      "clinical evaluation vary by the specific type of familial neoplasm       being studied.        The\n",
      "overall approach to eligible study participants includes defining affection status,\n",
      "characterization of disease, localization of genetic loci, identification of genes,       evaluation\n",
      "of phenotype/genotype correlations, estimation of risk of the disease associated       with carrier\n",
      "status and identification of other risk factors that modify penetrance       (genetic,\n",
      "environmental, host factors).                         -  INCLUSION CRITERIA:          On referral,\n",
      "persons of any age will be considered for the inclusion in the study because         of either:\n",
      "A family or personal history of neoplasia of an unusual type, pattern, or number; OR,          known\n",
      "or suspected factor(s) predisposing to neoplasia, either genetic and/or congenital         factors\n",
      "(birth defects, metabolic phenotype, chromosomal anomalies or Mendelian traits         associated\n",
      "with tumors), environmental exposure (medications, occupation, radiation, diet,         infectious\n",
      "agents, etc.), or unusual demographic features (very young age of onset,         multiple tumors,\n",
      "etc.).          Personal and family medical history must be verified through questionnaires,\n",
      "interviews,         and review of pathology slides and medical records. For familial neoplasms, two\n",
      "or more         living affected cases among family members are required. The types of familial\n",
      "tumors that         we are currently actively accruing include:          Familial Cancers: bladder,\n",
      "brain, chordoma, lung, nevoid basal cell carcinoma syndrome         (NBCC)          Familial Benign\n",
      "Neoplasms: meningiomas, neurofibromatosis 2 (bilateral acoustic         neurofibromatosis)\n",
      "The types of familial tumors under active accrual and study are predominantly         investigator-\n",
      "and hypothesis-driven. This approach permits GEB investigators to remain         alert to the\n",
      "opportunities afforded by clusters of rare tumors in families and         individuals, and to be\n",
      "more responsive to the dynamic research priorities in cancer         genetics.          EXCLUSION\n",
      "CRITERIA:          Referred individuals and families for whom reported diagnoses cannot be verified.\n",
      "Inability to provide informed consent.          Eligible for familial melanoma, lymphoproliferative,\n",
      "breast-ovarian cancer, or testicular         cancer protocols.\n",
      "\n",
      "üîπ Doc ID: NCT00001382  (Score: 3)\n",
      "A Phase I Study of Recombinant Vaccinia Virus That Expresses Prostate Specific Antigen in Adult\n",
      "Patients With Adenocarcinoma of the Prostate             This trial will evaluate, in patients with\n",
      "metastatic prostate cancer, the tolerability,       toxicities, efficacy, and immunologic effects of\n",
      "repeated vaccinations with a recombinant       vaccinia virus that contains the Prostate Specific\n",
      "Antigen gene (PROSTVAC).                     This trial will evaluate, in patients with metastatic\n",
      "prostate cancer, the tolerability,       toxicities, efficacy, and immunologic effects of repeated\n",
      "vaccinations with a recombinant       vaccinia virus that contains the Prostate Specific Antigen\n",
      "gene (PROSTVAC). Patients with       PSA-expressing adenocarcinoma of the prostate will be evaluated\n",
      "for eligibility that       includes a history of prior vaccinia (as vaccine against smallpox) and\n",
      "immunocompetence. We       completed a phase I trial investigating the use of rV-CEA in\n",
      "adenocarcinomas of the GI       tract, lung and breast. The toxicities encountered are local\n",
      "reactions to the vaccine. We       did not encounter any myelosuppression or systemic autoimmune\n",
      "reaction. We would like to       evaluate four doses to ensure safety and to decide a best\n",
      "biological dose. Six patients will       receive 2.65 x 10(5) PFU and 2.65 x 10(6) PFU of vaccine by\n",
      "scarification. Because higher       doses cannot be achieved by scarification, six patients will\n",
      "receive 2.65 x 10(7) PFU and       2.65 x 10(8) PFU subcutaneously. We plan to give three\n",
      "vaccinations at four week intervals.       All six patients treated in each dose level must be\n",
      "evaluable for 4 weeks before enrolling       patients at the higher dose level. No intrapatient\n",
      "escalation is planned. Toxicity, tumor       response, and humoral and cellular immunity factors\n",
      "will be monitored. Optional       lymphapheresis will be done on patients that are HLA A2. Once we\n",
      "determined the best       biological dose, we would like to accrue an additional 6 patients to that\n",
      "level.                         DISEASE CHARACTERISTICS:          Histologically confirmed\n",
      "adenocarcinoma of the prostate as follows: Unresectable and/or         incurable tumor AND Tumor\n",
      "progression after at least 1 prior hormonal manipulation (i.e.,         LHRH agonist/flutamide or\n",
      "orchiectomy). LHRH agonist may by continued concurrently with         protocol therapy.          New\n",
      "bone or soft tissue lesions OR Serum PSA that has risen on 3 successive evaluations at         least\n",
      "1 week apart during and/or after hormonal therapy. If PSA is below 4 ng/mL,         measurable\n",
      "disease with positive immunohistochemical stain for PSA is required.          No history of allergy\n",
      "to eggs.          No history of or active CNS metastases.          Symptomatic spinal or other bony\n",
      "metastasis should be irradiated prior to entry.          Bi-dimensionally measurable disease not\n",
      "required.          PRIOR/CONCURRENT THERAPY:          Biologic Therapy:          No concurrent\n",
      "Biologic Therapy.          Must fully recover from prior Biologic Therapy.          Chemotherapy:\n",
      "At least 4 weeks since prior chemotherapy and fully recovered.          No more than 1 prior\n",
      "chemotherapy regimen.          No concurrent chemotherapy.          Endocrine Therapy:          See\n",
      "Disease Characteristics.          At least 4 weeks since prior hormonal therapy and fully recovered.\n",
      "No concurrent steroids.          Radiotherapy:          At least 4 weeks since prior radiation\n",
      "therapy and fully recovered.          No prior radiotherapy to more than 50% of nodal groups.\n",
      "No concurrent radiotherapy.          Surgery:          At least 4 weeks since prior surgery, with\n",
      "surgical scar healed.          No prior splenectomy.          PATIENT CHARACTERISTICS:          Age:\n",
      "Over 18.          Performance status: Zubrod (ECOG) 0-2.          Hematopoietic:          Absolute\n",
      "granulocyte count greater than 2,000/mm(3);          Platelet count greater than 100,000/mm(3);\n",
      "Hemoglobin greater than 8.0 g/dL.          Hepatic:          Bilirubin less than 1.6 mg/dL;\n",
      "AST and ALT less than 4 times normal.          Renal: Creatinine less than 1.6 mg/dL.\n",
      "Immunologic:          Prior vaccinia (for smallpox immunization) required, with proof of vaccination\n",
      "as follows:         Detectable anti-vaccinia antibodies, Physician certification of prior\n",
      "vaccination, Patient         recollection or appropriate vaccination-site scar sufficient in\n",
      "patients over age 25,         Delayed-type hypersensitivity skin testing (to mumps, Candida, and\n",
      "Trichophyton antigens)         normal Quantitative immunoglobulins normal.          No evidence of\n",
      "immunocompromise, i.e.:          No HIV antibody;          No eczema or atopic dermatitis;\n",
      "No autoimmune neutropenia, thrombocytopenia, or hemolytic anemia;          No systemic lupus\n",
      "erythematosus, Sjogren syndrome, or scleroderma;          No myasthenia gravis;          No\n",
      "Goodpasture syndrome;          No Addison's disease, Hashimoto's thyroiditis, or active Graves'\n",
      "disease;          No other autoimmune disease or diagnosis of altered immune function.\n",
      "OTHER:          No active case or history of extensive psoriasis, severe acneiform rash, impetigo,\n",
      "varicella zoster, burns, or other traumatic or pruritic skin condition.          No active infection\n",
      "requiring antibiotics (including chronic suppressive therapy). At         least 3 days since\n",
      "antibiotic therapy.          No history of seizures, encephalitis, or multiple sclerosis.\n",
      "No other serious intercurrent illness.          Able to avoid close contact with the following\n",
      "individuals for at least 2 weeks after         vaccination (i.e., no such individuals as household\n",
      "members and no care-giving         responsibilities for such individuals): Children under age 3,\n",
      "Pregnant women, Individuals         with eczema or skin conditions defined above, Leukemia or\n",
      "lymphoma patients, HIV-positive         individuals, Patients receiving immunosuppressive therapy,\n",
      "Any other immunosuppressed         individuals.          No prior malignancy unless curatively\n",
      "treated and patient has been in remission for at         least 2 years (excluding squamous cell or\n",
      "basal cell carcinoma of the skin or carcinoma in         situ of the cervix).          Able and\n",
      "willing to travel to the NIH, NCI-NMOB, or the Lombardi Cancer Center at         Georgetown\n",
      "University for treatment and follow-up.\n",
      "================================================================================\n",
      "üîç Query: trial design phase 3\n",
      "\n",
      "üîπ Doc ID: NCT00000102  (Score: 3)\n",
      "Congenital Adrenal Hyperplasia: Calcium Channels as Therapeutic Targets             This study will\n",
      "test the ability of extended release nifedipine (Procardia XL), a blood       pressure medication,\n",
      "to permit a decrease in the dose of glucocorticoid medication children       take to treat\n",
      "congenital adrenal hyperplasia (CAH).                     This protocol is designed to assess both\n",
      "acute and chronic effects of the calcium channel       antagonist, nifedipine, on the hypothalamic-\n",
      "pituitary-adrenal axis in patients with       congenital adrenal hyperplasia. The multicenter trial\n",
      "is composed of two phases and will       involve a double-blind, placebo-controlled parallel design.\n",
      "The goal of Phase I is to       examine the ability of nifedipine vs. placebo to decrease\n",
      "adrenocorticotropic hormone (ACTH)       levels, as well as to begin to assess the dose-dependency\n",
      "of nifedipine effects. The goal of       Phase II is to evaluate the long-term effects of\n",
      "nifedipine; that is, can attenuation of       ACTH release by nifedipine permit a decrease in the\n",
      "dosage of glucocorticoid needed to       suppress the HPA axis? Such a decrease would, in turn,\n",
      "reduce the deleterious effects of       glucocorticoid treatment in CAH.\n",
      "Inclusion Criteria:            -  diagnosed with Congenital Adrenal Hyperplasia (CAH)            -\n",
      "normal ECG during baseline evaluation          Exclusion Criteria:            -  history of liver\n",
      "disease, or elevated liver function tests            -  history of cardiovascular disease\n",
      "\n",
      "üîπ Doc ID: NCT00000317  (Score: 3)\n",
      "Early Phase II Trials for Cocaine Medication Development - 1             The purpose of this study\n",
      "is to develop models for early Phase II testing of potential       medications for cocaine\n",
      "dependence: amoxapine, risperidone and other agents.        The study was a controlled pilot trial\n",
      "of risperidone in opiate-dependent patients on       methadone maintenance. The study explored\n",
      "whether risperidone reduced cocaine use, cocaine       craving, and cocaine subjective effects in\n",
      "patients on methadone maintenance who abused       cocaine and whether it had an acceptable side\n",
      "effect profile. This                     This was an 18-week prospective, randomized, placebo-\n",
      "controlled crossover design with       placebo lead-in phase and terminal placebo phase. After two\n",
      "weeks of single-blind placebo,       patients were randomly assigned to one of two schedules of\n",
      "medication:        2 Week Baseline Weeks 1-6 Weeks 7-12 Weeks 13-18 Group 1 placebo risperidone\n",
      "placebo placebo       Group 2 placebo placebo risperidone placebo        The first 6-week phase\n",
      "provided an initial double-blind medication-placebo comparison. In       the second six-week phase\n",
      "(weeks 7-12), patients crossed over to the opposite treatment.       During weeks 13-18, Group 1\n",
      "patients remained on placebo while Group 2 patients were tapered       from risperidone to placebo.\n",
      "For six weeks after the end of the trial, patients were offered       routine clinical treatment\n",
      "with counseling and psychiatrist visits as needed. Medication       dosage was titrated upwards on a\n",
      "fixed-flexible schedule to a maximum dose of 4 mg per day.       Medication began at ¬Ω mg\n",
      "risperidone for 3 days, then 1 mg for four days, 2 mg per day       during week 2, 3 mg per day\n",
      "during week 3, and 4 mg per day during weeks 4-6. The titration       schedule for risperidone in\n",
      "weeks 7-12 was the same as for weeks 1-6. In addition to       treatment as usual, patients received\n",
      "a modified manual-guided relapse prevention counseling       program in weekly meetings lasting\n",
      "approximately 20 minutes; these sessions provided       cognitive and behavioral skills that were\n",
      "found to be helpful to patients in reducing       cocaine use.                         Inclusion:\n",
      "1. good standing at methadone maintenance program            2. DSM-IV criteria for cocaine\n",
      "dependence or abuse            3. used cocaine at least 4 times in last month            4. able to\n",
      "give informed consent          Exclusion criteria            1. currently meets DSM-IV criteria for\n",
      "Major depression or dysthymia            2. meets DSM-IV criteria for attention deficit\n",
      "hyperactivity disorder, bipolar disorder,              schizophrenia or any psychotic disorder\n",
      "3. history of seizures            4. history of allergic reaction to risperidone            5.\n",
      "chronic organic mental disorder            6. significant current suicidal risk            7.\n",
      "pregnancy, lactation or failure to use adequate birth control (for females)            8. unstable\n",
      "physical disorders that may make participation hazardous            9. coronary vascular disease\n",
      "10. cardiac conduction system disease as indicated by QRS duration >/= 0.11           11. current\n",
      "use of other prescribed psychotropic medications           12. history of failure to respond to a\n",
      "previous adequate trial of risperidone           13. history of neuroleptic malignant syndrome,\n",
      "tardive dyskinesia, or severe              extrapyramidal reactions to neuroleptic medications\n",
      "14. current DSM-IV criteria for another substance dependence other than nicotine.\n",
      "\n",
      "üîπ Doc ID: NCT00000384  (Score: 3)\n",
      "Treatment of Obsessive-Compulsive Disorder (OCD) in Children             The purpose of this study\n",
      "is to compare 3 treatments for children with OCD: medication       (sertraline, SER) alone vs OCD-\n",
      "specific therapy (Cognitive Behavior Therapy, CBT) vs       medication plus therapy. Some patients\n",
      "will receive an inactive placebo (PBO) instead of       medication and/or Educational Support (ES,\n",
      "non-psychological treatment) instead of therapy.        One in 200 children suffer from OCD, but few\n",
      "receive appropriate treatment. Both CBT and       medication seem to be effective, but their\n",
      "effectiveness, alone and in combination, has not       been evaluated.        There are 2 phases to\n",
      "this trial. In Phase I the child will receive 1 of the following 6       treatments for 12 weeks: 1)\n",
      "SER alone; 2) pill PBO alone; 3) CBT alone; 4) SER plus CBT; 5)       SER plus ES; 6) pill PBO plus\n",
      "ES. If the child responds to treatment, he/she will go on to       Phase II in which the treatment\n",
      "will be slowly reduced, then stopped (discontinued), over       time to test the treatment's\n",
      "durability. The child will be evaluated at Weeks 1, 4, 8, 12       (Phase I treatment), and Weeks\n",
      "16, 20, 24, and 28 (Phase II discontinuation) to see how       effective and durable the treatment\n",
      "is in treating your child's OCD.        A child may be eligible for this study if he/she:        Has\n",
      "obsessive-compulsive disorder (OCD) and is 8 - 16 years old.                     To contrast the\n",
      "degree and durability of improvement in pediatric obsessive-compulsive       disorder (OCD),\n",
      "patients will be treated with 1 of 6 conditions (3 active treatments and 3       control\n",
      "treatments): sertraline alone (SER), OCD-specific Cognitive Behavior Therapy (CBT),       both SER\n",
      "and CBT (SER plus CBT), pill placebo (PBO), pill PBO plus Educational Support (ES),       and SER\n",
      "plus ES.        One in 200 youth suffers from OCD, yet relatively few receive appropriate treatment.\n",
      "Both       CBT and medication appear beneficial in controlled studies; however, the relative\n",
      "efficacy       of CBT and medication, alone and in combination (COMB) is unknown. Thus, well-\n",
      "designed       treatment outcome studies are necessary to improve care for youth with OCD.\n",
      "The experimental design covers 2 phases. Phase I is a 2 (site) x 2 (SER or pill PBO) x 3       (CBT,\n",
      "ES or non- psychosocial treatment) x 5 (repeated measures) factorial 12-week       comparison of\n",
      "SER, CBT, COMB and the control conditions. In Phase II, responders advance to       a 16-week\n",
      "discontinuation study to assess treatment durability. The primary outcome measure       is the Yale-\n",
      "Brown Obsessive-Compulsive Scale. Assessments blind to treatment status take       place at Week 0\n",
      "(pretreatment); Weeks 1, 4, 8, 12 (Phase I treatment); and Weeks 16, 20, 24       and 28 (Phase II\n",
      "discontinuation). Besides addressing comparative efficacy and durability of       the specified\n",
      "treatments, the investigators also examine time-action effects, differential       effects on\n",
      "specific aspects of OCD, including functional impairment, and predictors of       response to\n",
      "treatment.                         Inclusion Criteria:          Patients must have:          DSM-IV\n",
      "diagnosed OCD.\n",
      "\n",
      "üîπ Doc ID: NCT00000385  (Score: 3)\n",
      "Long-Term Lithium Treatment for Aggressive Conduct Disorder             This study will examine the\n",
      "long-term effects of lithium used to treat children and       adolescents with aggressive conduct\n",
      "disorder (severe aggression).                     Psychotherapeutic agents are often administered\n",
      "without sufficient testing to children and       adolescents, often on a long-term basis, to reduce\n",
      "aggression. Many pressures, including       managed care, will increase the utilization of\n",
      "pharmacotherapy in the outpatient setting to       treat serious problems. Lithium is the most\n",
      "promising agent for the treatment of aggression       in children and adolescents. However, it has\n",
      "not been shown that lithium is an effective       treatment for these patients in the outpatient\n",
      "(non-hospital) setting, or on a long-term       basis. The purpose of this study is to examine the\n",
      "long-term effects of lithium used to       treat children and adolescents with aggressive conduct\n",
      "disorder (severe aggression).        The proposed study is a two-phased clinical trial of lithium\n",
      "for the treatment of aggression       in conduct disorder. Both phases are double-blind and placebo-\n",
      "controlled with randomization       and employ a parallel groups design. Phase 1 contains a short-\n",
      "term 8-week controlled trial,       with twice as many subjects randomized to lithium as placebo,\n",
      "increasing the pool of       potential lithium responders to continue to Phase 2. In Phase 2,\n",
      "lithium responders from       Phase 1 enter a 6-month long-term controlled trial. Every attempt is\n",
      "made to define       responders to lithium.                         Inclusion Criteria:\n",
      "1. Males and females            2. Ages between 9 and 17 years.            3. Conduct disorder\n",
      "according to DSM-IV (As rated on the DICA-IV).            4. The aggression criterion at screening\n",
      "Exclusion Criteria:            1. Mental Retardation.            2. Pervasive Developmental\n",
      "Disorder(s).            3. Major Depressive Disorder or Dysthymic Disorder.            4. Bipolar\n",
      "Disorder.            5. Psychotic Disorder (including Schizophreniform Disorder and Schizophrenia).\n",
      "6. Major medical problem such as cardiac, renal, and thyroid diseases, or seizure\n",
      "disorder.            7. History of psychoactive medication in the previous 2 weeks.            8.\n",
      "Current Pregnancy in females.            9. History of Substance Dependence in the past month.\n",
      "10. Prior to the proposed study, a history of lithium treatment with serum lithium levels\n",
      "of 0.4 mEq/L or higher for a cumulative period of greater than 10 days.\n",
      "\n",
      "üîπ Doc ID: NCT00000462  (Score: 3)\n",
      "Bypass Angioplasty Revascularization Investigation (BARI)             To assess the relative long-\n",
      "term safety and efficacy of percutaneous transluminal coronary       angioplasty (PTCA) and coronary\n",
      "artery bypass graft (CABG) surgery in patients with       multivessel disease and severe angina or\n",
      "ischemia who required revascularization and had       coronary anatomy suitable for either\n",
      "procedure.                     BACKGROUND:        The management of patients with symptomatic\n",
      "coronary heart disease has evolved considerably       in the past twenty years with the application\n",
      "of invasive techniques in an ever increasing       proportion of patients.        With refinements\n",
      "in CABG surgery over the past twenty years, operative myocardial       revascularization is feasible\n",
      "in most patients with myocardial ischemia. Several       multicenter, randomized trials have been\n",
      "reported, comparing medical with surgical       management in patients with coronary artery disease.\n",
      "Based on the three largest trials and       an extensive observational literature, a consensus\n",
      "appears to be emerging regarding the       circumstances under which medical or surgical management\n",
      "appears to be the method of choice.        It is clear that CABG relieves angina in the vast\n",
      "majority of patients with severe symptoms.       It is also apparent that this procedure can be\n",
      "performed with very low risk by experienced       operative teams. Thus, CABG is indicated for\n",
      "patients with suitable coronary anatomy who       have severe angina refractory to medical therapy\n",
      "and those with significant obstruction of       left main coronary artery.        The timing of\n",
      "operative intervention in patients with less severe angina is a point of some       dispute at\n",
      "present. It is, however, apparent that certain categories of patients have       improved survival\n",
      "after elective bypass surgery. These categories include patients with left       main coronary\n",
      "stenosis, triple vessel disease with modestly impaired ventricular function,       and possibly\n",
      "other clinically defined high risk patients. The remaining patients with mild,       symptomatic\n",
      "coronary disease, it would appear, can afford to defer operative intervention       until such time\n",
      "as symptoms worsen and require palliation.        Long-term information is available on some\n",
      "patients who had CABG in the early 1970s. By ten       years substantial progression of disease is\n",
      "present in both the native coronary circulation       and in the bypass grafts. Investigators have\n",
      "reported that as many as two-thirds of vein       bypass grafts are closed or narrowed and intrinsic\n",
      "coronary disease has progressed in as       many as one-half of non-bypassed vessels at 10 years\n",
      "following surgery. The timing of       surgery in less severely symptomatic patients, strategies to\n",
      "decrease disease progression in       grafted vessels and native circulation, and renewed interest\n",
      "in the use of the internal       mammary artery to revascularize the heart are very active research\n",
      "issues at present.        PTCA was first applied to human coronary disease in 1977. There have been\n",
      "major advances in       catheter design, balloon construction, and identification of both high and\n",
      "low risk patients       for this procedure. Experienced angioplasty teams can now successfully\n",
      "dilate severe lesions       in more than 90 percent of patients attempted. This success rate can be\n",
      "achieved with less       than one percent operative mortality and less than five percent myocardial\n",
      "infarction and/or       emergent coronary artery bypass graft surgery. However, as many as one-third\n",
      "of successfully       dilated patients will experience the return of angina within the following six\n",
      "months to one       year, reflecting restenosis of the dilated lesion. Most of these individuals can\n",
      "successfully undergo a second dilatation.        Thus, two quite effective interventions are\n",
      "available for patients with symptomatic coronary       artery disease sufficient to require\n",
      "palliation by some mechanical means. Each has strengths       and weaknesses. PTCA is relatively\n",
      "noninvasive, requires initially fewer hospital days and       less intensive care, and preserves\n",
      "veins and mediastinum for CABG should it be required       later. However, not all lesions present\n",
      "in a patient with multivessel disease can be       dilated. There is substantial risk of restenosis\n",
      "and recurrence of symptoms, and a small but       finite risk of having to undergo immediate CABG\n",
      "surgery following a failed PTCA,       considerably increasing the risk of the surgery. CABG surgery\n",
      "results in more complete       revascularization and relatively low short-term graft closure, and it\n",
      "can be done with an       acute risk approximately equal to PTCA. However, it is apparent that\n",
      "surgical intervention       does not change a patient's propensity to atherosclerosis; in ten years\n",
      "two-thirds of grafts       have been compromised with atherosclerosis or thrombosis and there has\n",
      "been progression of       atherosclerosis in the native, non-bypassed coronary circulation in\n",
      "roughly one-half of the       patients. Second operations are considerably more difficult\n",
      "technically, carry a higher       operative risk, and result in less dramatic relief of symptoms.\n",
      "There is a substantial       population of patients with severe, symptomatic, multivessel coronary\n",
      "disease in whom it is       unclear whether PTCA or CABG should be applied first.        In\n",
      "September 1984, the Workshop on Coronary Artery Bypass Graft Surgery recommended       consideration\n",
      "of a clinical trial involving surgery and angioplasty. An NHLBI Task Force,       established in\n",
      "January 1985, recommended that a clinical trial in multivessel coronary       artery disease be\n",
      "considered by the Institute. The Cardiology Advisory Committee unanimously       recommended the\n",
      "design and execution of a trial. In September 1985, the National Heart,       Lung, and Blood\n",
      "Advisory Council discussed this clinical trial initiative and recommended it       enthusiastically.\n",
      "DESIGN NARRATIVE:        Patients who received coronary arteriography at the clinical units because\n",
      "of severe angina       or unstable angina, with or without antecedent myocardial infarction, were\n",
      "asked to       participate in the study. A total of 2,013 eligible patients who refused\n",
      "randomization and       422 who were ineligible on the basis of angiographic findings were asked to\n",
      "participate in       the follow-up registry. The remaining patients were then randomized, 914 to\n",
      "CABG and 915 to       PTCA, between August 1988 and August 1991. Baseline data included the clinical\n",
      "profile,       12-lead electrocardiogram, and information on coronary angiographic features, angina\n",
      "and       functional status, medications, risk factors, and quality of life. Initial\n",
      "revascularization       was performed within two weeks after randomization. Angiograms (baseline and\n",
      "sub study       directed at 1 year and 5 years), and ECG's are interpreted by respective core\n",
      "laboratories.       Scheduled multiple stages of PTCA were counted as a single procedure. New\n",
      "interventional       devices, such as stents, were not used during the initial revascularization.\n",
      "Follow-up       visits were conducted at the clinics at weeks four through fourteen after study\n",
      "entry and at       one, three, and five years, with telephone contacts at six months and two and\n",
      "four years.       The importance of risk factor modification was emphasized throughout the study to\n",
      "the       patients and their primary physicians. The primary end point was mortality from all\n",
      "causes.        The trial has been extended through November 2002 to complete the minimum ten-year\n",
      "followup       on all BARI patients, determine the relative efficacy of PTCA versus CABG in\n",
      "subgroups of       women, Blacks, diabetics, and elderly, and assess the public health impact of\n",
      "BARI. In the       followup, all currently enrolled patients will have annual telephone interviews.\n",
      "At ten       years, the electrocardiogram will be obtained on all patients and blood lipid levels\n",
      "will be       performed on randomized patients only. All hospitalizations that occurred since the\n",
      "last       contact will be identified on the annual telephone contact. Angina will be assessed for\n",
      "the       preceding six weeks. At each patient contact, patients will be instructed in behavior\n",
      "modification in the areas of smoking cessation, exercise, and diet. Angiographic studies       will\n",
      "also be conducted as part of the ten-year follow-up. The four centers which       participated in\n",
      "the first phase of these BARI activities will again conduct the angiograms.       Patients will\n",
      "consist of the established cohort drawn from the randomized participants who       completed one and\n",
      "five year angiograms.        A substudy of BARI, Study of Economics and Quality of Life (SEQOL), was\n",
      "initially funded by       the Robert Wood Johnson Foundation to assess the impact of a specific\n",
      "revascularization on       quality of life, functional and economic (hospital and physician charges)\n",
      "outcomes in       patients randomized to BARI, and to examine factors other than treatments that\n",
      "affect these       outcomes. Beginning in July 1997, support for SEQOL was assumed by the NHLBI\n",
      "under grant       R01HL58324. The grant, ending in June 2002, extends the follow-up of the\n",
      "randomized SEQOL       substudy cohort (752 subjects surviving as of May 1, 1996) to ten years to\n",
      "study the       long-term determinants of cost and quality of life and to develop a model to project\n",
      "the       impact of technologic changes on outcomes and cost of CABG and PTCA.        The study\n",
      "completion date listed in this record was obtained from the \"End Date\" entered in       the Protocol\n",
      "Registration and Results System (PRS) record.                         Multivessel coronary artery\n",
      "disease requiring revascularization and suitable for either         PTCA or CABG.\n"
     ]
    }
   ],
   "source": [
    "import json\n",
    "import pandas as pd\n",
    "from collections import Counter\n",
    "import textwrap\n",
    "\n",
    "# Load inverted index and metadata\n",
    "with open(\"clinical_trials_inverted_index.json\", \"r\", encoding=\"utf-8\") as f:\n",
    "    inverted_index = json.load(f)\n",
    "\n",
    "df_meta = pd.read_csv(\"clinical_trials_metadata.csv\")\n",
    "doc_map = dict(zip(df_meta['doc_id'], df_meta['original_text']))\n",
    "\n",
    "def search(query, top_k=5):\n",
    "    terms = query.lower().split()\n",
    "    doc_scores = Counter()\n",
    "\n",
    "    for term in terms:\n",
    "        doc_ids = inverted_index.get(term, [])\n",
    "        for doc_id in doc_ids:\n",
    "            doc_scores[doc_id] += 1\n",
    "\n",
    "    top_docs = doc_scores.most_common(top_k)\n",
    "    return [(doc_id, doc_map.get(doc_id, \"\"), score) for doc_id, score in top_docs]\n",
    "\n",
    "# Example queries\n",
    "queries = [\n",
    "    \"vaccine side effects\",\n",
    "    \"eligibility criteria cancer trial\",\n",
    "    \"trial design phase 3\"\n",
    "]\n",
    "\n",
    "for query in queries:\n",
    "    print(\"=\"*80)\n",
    "    print(f\"üîç Query: {query}\")\n",
    "    results = search(query)\n",
    "    for doc_id, text, score in results:\n",
    "        print(f\"\\nüîπ Doc ID: {doc_id}  (Score: {score})\")\n",
    "        print(textwrap.fill(text, 100))"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "555f5417-21ce-48fb-853e-838adbaf2962",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Provides: Dataset(id='clinicaltrials/2017/trec-pm-2017', provides=['docs', 'queries', 'qrels'])\n",
      "\n",
      "First few queries:\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[INFO] [starting] https://trec.nist.gov/data/precmed/topics2017.xml\n",
      "[INFO] [finished] https://trec.nist.gov/data/precmed/topics2017.xml: [00:00] [5.66kB] [?B/s]\n",
      "                                                                          \r"
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TrecPm2017Query(query_id='1', disease='Liposarcoma', gene='CDK4 Amplification', demographic='38-year-old male', other='GERD')\n",
      "\n",
      "First few qrels:\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "[INFO] [starting] https://trec.nist.gov/data/precmed/qrels-final-trials.txt\n",
      "[INFO] [finished] https://trec.nist.gov/data/precmed/qrels-final-trials.txt: [00:00] [244kB] [735kB/s]\n",
      "                                                                                    "
     ]
    },
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "TrecQrel(query_id='1', doc_id='NCT00001188', relevance=0, iteration='0')\n"
     ]
    },
    {
     "name": "stderr",
     "output_type": "stream",
     "text": [
      "\r"
     ]
    }
   ],
   "source": [
    "import ir_datasets\n",
    "\n",
    "dataset = ir_datasets.load(\"clinicaltrials/2017/trec-pm-2017\")\n",
    "\n",
    "# Check what's available\n",
    "print(\"Provides:\", dataset)\n",
    "print(\"\\nFirst few queries:\")\n",
    "for q in dataset.queries_iter():\n",
    "    print(q)\n",
    "    break\n",
    "\n",
    "print(\"\\nFirst few qrels:\")\n",
    "for qrel in dataset.qrels_iter():\n",
    "    print(qrel)\n",
    "    break"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "f29fe707-95dc-47e9-9b14-6c2c240b5765",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ Saved QRELs to clinical_trials_qrels.txt\n"
     ]
    }
   ],
   "source": [
    "import ir_datasets\n",
    "\n",
    "dataset = ir_datasets.load(\"clinicaltrials/2017/trec-pm-2017\")\n",
    "qrels = dataset.qrels_iter()\n",
    "\n",
    "# Save to TREC-compatible QREL file\n",
    "with open(\"clinical_trials_qrels.txt\", \"w\", encoding=\"utf-8\") as f:\n",
    "    for qrel in qrels:\n",
    "        f.write(f\"{qrel.query_id} 0 {qrel.doc_id} {qrel.relevance}\\n\")\n",
    "\n",
    "print(\"‚úÖ Saved QRELs to clinical_trials_qrels.txt\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "b7cc41c2-c4eb-4142-95bc-c0d51a317e1f",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "üìä Results for TF-IDF\n",
      "  MAP:         0.0000\n",
      "  MRR:         0.0000\n",
      "  Recall@1000: 0.0000\n",
      "  Precision@10:0.0000\n",
      "\n",
      "üìä Results for BM25\n",
      "  MAP:         0.0000\n",
      "  MRR:         0.0000\n",
      "  Recall@1000: 0.0000\n",
      "  Precision@10:0.0000\n",
      "\n",
      "üìä Results for BERT\n",
      "  MAP:         0.0000\n",
      "  MRR:         0.0000\n",
      "  Recall@1000: 0.0000\n",
      "  Precision@10:0.0000\n",
      "\n",
      "üìä Results for Hybrid\n",
      "  MAP:         0.0000\n",
      "  MRR:         0.0000\n",
      "  Recall@1000: 0.0000\n",
      "  Precision@10:0.0000\n"
     ]
    }
   ],
   "source": [
    "import pytrec_eval\n",
    "import pandas as pd\n",
    "\n",
    "# === Load QRELs ===\n",
    "qrels = {}\n",
    "with open(\"clinical_trials_qrels.txt\", \"r\", encoding=\"utf-8\") as f:\n",
    "    for line in f:\n",
    "        query_id, _, doc_id, relevance = line.strip().split()\n",
    "        qrels.setdefault(query_id, {})[doc_id] = int(relevance)\n",
    "\n",
    "# === Load TREC-style results ===\n",
    "def load_run(file_path):\n",
    "    run = {}\n",
    "    with open(file_path, 'r', encoding='utf-8') as f:\n",
    "        for line in f:\n",
    "            qid, _, docid, rank, score, _ = line.strip().split()\n",
    "            run.setdefault(qid, {})[docid] = float(score)\n",
    "    return run\n",
    "\n",
    "# === Load each run ===\n",
    "runs = {\n",
    "    \"TF-IDF\": load_run(\"clinical_trials_tfidf_results.txt\"),\n",
    "    \"BM25\": load_run(\"clinical_trials_bm25_results.txt\"),\n",
    "    \"BERT\": load_run(\"clinical_trials_bert_results.txt\"),\n",
    "    \"Hybrid\": load_run(\"clinical_trials_hybrid_results.txt\"),\n",
    "}\n",
    "\n",
    "# === Define the correct metric names for pytrec_eval ===\n",
    "metrics = {'map', 'recip_rank', 'P_10', 'recall_1000'}  # <- Fix here\n",
    "\n",
    "evaluator = pytrec_eval.RelevanceEvaluator(qrels, metrics)\n",
    "\n",
    "# === Evaluate and print results ===\n",
    "for name, run in runs.items():\n",
    "    results = evaluator.evaluate(run)\n",
    "\n",
    "    avg_metrics = {\n",
    "        metric: sum(query_scores[metric] for query_scores in results.values()) / len(results)\n",
    "        for metric in metrics\n",
    "    }\n",
    "\n",
    "    print(f\"\\nüìä Results for {name}\")\n",
    "    print(f\"  MAP:         {avg_metrics['map']:.4f}\")\n",
    "    print(f\"  MRR:         {avg_metrics['recip_rank']:.4f}\")\n",
    "    print(f\"  Recall@1000: {avg_metrics['recall_1000']:.4f}\")\n",
    "    print(f\"  Precision@10:{avg_metrics['P_10']:.4f}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "70171599-988f-4049-9bf1-b699a9cd270b",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ Saved real clinical_trials_queries.txt from TREC PM 2017\n"
     ]
    }
   ],
   "source": [
    "import ir_datasets\n",
    "\n",
    "dataset = ir_datasets.load(\"clinicaltrials/2017/trec-pm-2017\")\n",
    "\n",
    "with open(\"clinical_trials_queries.txt\", \"w\", encoding=\"utf-8\") as f:\n",
    "    for query in dataset.queries_iter():\n",
    "        # Concatenate fields to form the full query string\n",
    "        text = f\"{query.disease} {query.gene} {query.demographic}\".strip()\n",
    "        f.write(f\"{query.query_id}\\t{text}\\n\")\n",
    "\n",
    "print(\"‚úÖ Saved real clinical_trials_queries.txt from TREC PM 2017\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "edb718f3-cf58-4743-a877-743732c66b88",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ TF-IDF results saved to clinical_trials_tfidf_results.txt\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import joblib\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "# üîß Define custom tokenizer used during TF-IDF indexing\n",
    "def whitespace_tokenizer(text):\n",
    "    return text.split()\n",
    "\n",
    "# üìÇ Load metadata and TF-IDF components\n",
    "df_meta = pd.read_csv(\"clinical_trials_metadata.csv\")\n",
    "tfidf_vectorizer = joblib.load(\"clinical_trials_vectorizer.pkl\")\n",
    "tfidf_matrix = joblib.load(\"clinical_trials_tfidf_matrix.pkl\")\n",
    "\n",
    "# üîç Load official queries\n",
    "queries = pd.read_csv(\"clinical_trials_queries.txt\", sep='\\t', names=[\"query_id\", \"text\"])\n",
    "\n",
    "# üíæ Write ranked results to file\n",
    "with open(\"clinical_trials_tfidf_results.txt\", \"w\", encoding=\"utf-8\") as f:\n",
    "    for _, row in queries.iterrows():\n",
    "        query_id, text = row[\"query_id\"], row[\"text\"]\n",
    "        query_vec = tfidf_vectorizer.transform([text])\n",
    "        scores = cosine_similarity(query_vec, tfidf_matrix).flatten()\n",
    "        top_indices = scores.argsort()[::-1][:1000]\n",
    "        for rank, idx in enumerate(top_indices, start=1):\n",
    "            doc_id = df_meta.iloc[idx][\"doc_id\"]\n",
    "            f.write(f\"{query_id} Q0 {doc_id} {rank} {scores[idx]:.4f} TFIDF\\n\")\n",
    "\n",
    "print(\"‚úÖ TF-IDF results saved to clinical_trials_tfidf_results.txt\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "d8fefb31-28f0-4b45-9e93-4fb094a7b5af",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ BM25 results saved to clinical_trials_bm25_results.txt\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import joblib\n",
    "from rank_bm25 import BM25Okapi\n",
    "\n",
    "# Load data\n",
    "df_meta = pd.read_csv(\"clinical_trials_metadata.csv\")\n",
    "queries = pd.read_csv(\"clinical_trials_queries.txt\", sep=\"\\t\", names=[\"query_id\", \"text\"])\n",
    "\n",
    "# Load BM25 model and corpus\n",
    "with open(\"clinical_trials_bm25_corpus.pkl\", \"rb\") as f:\n",
    "    corpus = joblib.load(f)\n",
    "with open(\"clinical_trials_bm25_model.pkl\", \"rb\") as f:\n",
    "    bm25 = joblib.load(f)\n",
    "\n",
    "doc_ids = df_meta['doc_id'].tolist()\n",
    "\n",
    "with open(\"clinical_trials_bm25_results.txt\", \"w\", encoding=\"utf-8\") as f:\n",
    "    for _, row in queries.iterrows():\n",
    "        query_id, query_text = row['query_id'], row['text']\n",
    "        tokenized_query = query_text.lower().split()\n",
    "        scores = bm25.get_scores(tokenized_query)\n",
    "        ranked_indices = scores.argsort()[::-1]\n",
    "\n",
    "        for rank, idx in enumerate(ranked_indices[:1000]):\n",
    "            f.write(f\"{query_id} Q0 {doc_ids[idx]} {rank+1} {scores[idx]:.4f} BM25\\n\")\n",
    "\n",
    "print(\"‚úÖ BM25 results saved to clinical_trials_bm25_results.txt\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "id": "a6f915da-eff0-45b2-8aaf-754c41509290",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ BERT results saved to clinical_trials_bert_results.txt\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import joblib\n",
    "from sentence_transformers import SentenceTransformer\n",
    "from sklearn.metrics.pairwise import cosine_similarity\n",
    "\n",
    "# Load data\n",
    "df_meta = pd.read_csv(\"clinical_trials_metadata.csv\")\n",
    "queries = pd.read_csv(\"clinical_trials_queries.txt\", sep=\"\\t\", names=[\"query_id\", \"text\"])\n",
    "doc_embeddings = joblib.load(\"clinical_trials_bert_embeddings.pkl\")\n",
    "\n",
    "# Load BERT model\n",
    "model = SentenceTransformer('all-MiniLM-L6-v2')\n",
    "\n",
    "with open(\"clinical_trials_bert_results.txt\", \"w\", encoding=\"utf-8\") as f:\n",
    "    for _, row in queries.iterrows():\n",
    "        query_id, query_text = row['query_id'], row['text']\n",
    "        query_embedding = model.encode([query_text])\n",
    "        similarities = cosine_similarity(query_embedding, doc_embeddings)[0]\n",
    "        ranked_indices = np.argsort(similarities)[::-1]\n",
    "\n",
    "        for rank, idx in enumerate(ranked_indices[:1000]):\n",
    "            f.write(f\"{query_id} Q0 {df_meta['doc_id'].iloc[idx]} {rank+1} {similarities[idx]:.4f} BERT\\n\")\n",
    "\n",
    "print(\"‚úÖ BERT results saved to clinical_trials_bert_results.txt\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "id": "3a670034-e621-4dd6-a666-b37e098d81c2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ Hybrid results saved to clinical_trials_hybrid_results.txt\n"
     ]
    }
   ],
   "source": [
    "import pandas as pd\n",
    "import numpy as np\n",
    "import joblib\n",
    "from sentence_transformers import SentenceTransformer\n",
    "from rank_bm25 import BM25Okapi\n",
    "from sklearn.preprocessing import minmax_scale\n",
    "\n",
    "# Load data\n",
    "df_meta = pd.read_csv(\"clinical_trials_metadata.csv\")\n",
    "queries = pd.read_csv(\"clinical_trials_queries.txt\", sep=\"\\t\", names=[\"query_id\", \"text\"])\n",
    "\n",
    "# Load BM25\n",
    "with open(\"clinical_trials_bm25_corpus.pkl\", \"rb\") as f:\n",
    "    corpus = joblib.load(f)\n",
    "with open(\"clinical_trials_bm25_model.pkl\", \"rb\") as f:\n",
    "    bm25 = joblib.load(f)\n",
    "\n",
    "# Load BERT\n",
    "doc_embeddings = joblib.load(\"clinical_trials_bert_embeddings.pkl\")\n",
    "model = SentenceTransformer('all-MiniLM-L6-v2')\n",
    "\n",
    "doc_ids = df_meta['doc_id'].tolist()\n",
    "\n",
    "with open(\"clinical_trials_hybrid_results.txt\", \"w\", encoding=\"utf-8\") as f:\n",
    "    for _, row in queries.iterrows():\n",
    "        query_id, query_text = row['query_id'], row['text']\n",
    "        tokenized_query = query_text.lower().split()\n",
    "        query_embedding = model.encode([query_text])\n",
    "\n",
    "        bm25_scores = bm25.get_scores(tokenized_query)\n",
    "        cosine_scores = np.dot(doc_embeddings, query_embedding[0])\n",
    "\n",
    "        # Normalize scores\n",
    "        bm25_norm = minmax_scale(bm25_scores)\n",
    "        cosine_norm = minmax_scale(cosine_scores)\n",
    "\n",
    "        hybrid_scores = 0.5 * bm25_norm + 0.5 * cosine_norm\n",
    "        ranked_indices = np.argsort(hybrid_scores)[::-1]\n",
    "\n",
    "        for rank, idx in enumerate(ranked_indices[:1000]):\n",
    "            f.write(f\"{query_id} Q0 {doc_ids[idx]} {rank+1} {hybrid_scores[idx]:.4f} Hybrid\\n\")\n",
    "\n",
    "print(\"‚úÖ Hybrid results saved to clinical_trials_hybrid_results.txt\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "id": "dc24beae-f7f3-4a9d-87aa-4f284c9ca9e7",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "\n",
      "üìä Results for TF-IDF\n",
      "  MAP:         0.0021\n",
      "  MRR:         0.0085\n",
      "  Recall@1000: 0.0441\n",
      "  Precision@10:0.0000\n",
      "\n",
      "üìä Results for BM25\n",
      "  MAP:         0.2169\n",
      "  MRR:         0.5537\n",
      "  Recall@1000: 0.6865\n",
      "  Precision@10:0.3138\n",
      "\n",
      "üìä Results for BERT\n",
      "  MAP:         0.0567\n",
      "  MRR:         0.3763\n",
      "  Recall@1000: 0.4365\n",
      "  Precision@10:0.1207\n",
      "\n",
      "üìä Results for Hybrid\n",
      "  MAP:         0.1859\n",
      "  MRR:         0.6060\n",
      "  Recall@1000: 0.6965\n",
      "  Precision@10:0.3034\n"
     ]
    }
   ],
   "source": [
    "import pytrec_eval\n",
    "import pandas as pd\n",
    "\n",
    "# === Load QRELs ===\n",
    "qrels = {}\n",
    "with open(\"clinical_trials_qrels.txt\", \"r\", encoding=\"utf-8\") as f:\n",
    "    for line in f:\n",
    "        query_id, _, doc_id, relevance = line.strip().split()\n",
    "        qrels.setdefault(query_id, {})[doc_id] = int(relevance)\n",
    "\n",
    "# === Load TREC-style results ===\n",
    "def load_run(file_path):\n",
    "    run = {}\n",
    "    with open(file_path, 'r', encoding='utf-8') as f:\n",
    "        for line in f:\n",
    "            qid, _, docid, rank, score, _ = line.strip().split()\n",
    "            run.setdefault(qid, {})[docid] = float(score)\n",
    "    return run\n",
    "\n",
    "# === Load each run ===\n",
    "runs = {\n",
    "    \"TF-IDF\": load_run(\"clinical_trials_tfidf_results.txt\"),\n",
    "    \"BM25\": load_run(\"clinical_trials_bm25_results.txt\"),\n",
    "    \"BERT\": load_run(\"clinical_trials_bert_results.txt\"),\n",
    "    \"Hybrid\": load_run(\"clinical_trials_hybrid_results.txt\"),\n",
    "}\n",
    "\n",
    "# === Define the correct metric names for pytrec_eval ===\n",
    "metrics = {'map', 'recip_rank', 'P_10', 'recall_1000'}  # <- Fix here\n",
    "\n",
    "evaluator = pytrec_eval.RelevanceEvaluator(qrels, metrics)\n",
    "\n",
    "# === Evaluate and print results ===\n",
    "for name, run in runs.items():\n",
    "    results = evaluator.evaluate(run)\n",
    "\n",
    "    avg_metrics = {\n",
    "        metric: sum(query_scores[metric] for query_scores in results.values()) / len(results)\n",
    "        for metric in metrics\n",
    "    }\n",
    "\n",
    "    print(f\"\\nüìä Results for {name}\")\n",
    "    print(f\"  MAP:         {avg_metrics['map']:.4f}\")\n",
    "    print(f\"  MRR:         {avg_metrics['recip_rank']:.4f}\")\n",
    "    print(f\"  Recall@1000: {avg_metrics['recall_1000']:.4f}\")\n",
    "    print(f\"  Precision@10:{avg_metrics['P_10']:.4f}\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "fa8c5247-a0bd-4691-a027-539ca6e46186",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python [conda env:base] *",
   "language": "python",
   "name": "conda-base-py"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.12.7"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
